<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11335168</article-id><article-id pub-id-type="pmcid-ver">PMC11335168.1</article-id><article-id pub-id-type="pmcaid">11335168</article-id><article-id pub-id-type="pmcaiid">11335168</article-id><article-id pub-id-type="pmid">39163410</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0304960</article-id><article-id pub-id-type="publisher-id">PONE-D-23-21699</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Covid 19</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Nephrology</subject><subj-group><subject>Renal Diseases</subject><subj-group><subject>Chronic Kidney Disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Severe COVID-19 infection: An institutional review and literature overview</article-title><alt-title alt-title-type="running-head">Severe COVID-19 infection</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1730-1411</contrib-id><name name-style="western"><surname>Akpoviroro</surname><given-names initials="O">Ogheneyoma</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sauers</surname><given-names initials="NK">Nathan Kyle</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Uwandu</surname><given-names initials="Q">Queeneth</given-names></name><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Castagne</surname><given-names initials="M">Myriam</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akpoviroro</surname><given-names initials="OP">Oghenetejiro Princess</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Humayun</surname><given-names initials="S">Sara</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mirza</surname><given-names initials="W">Wasique</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Woodard</surname><given-names initials="J">Jameson</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Internal Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Engineering, Pennsylvania State University, State College, Pennsylvania, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Clinical &amp; Translational Science Institute, Boston University, Boston, Massachusetts, United States of America</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Medicine, Mater Dei Hospital, Msida, Malta</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Chen</surname><given-names initials="RJ">Robert Jeenchen</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Stanford University School of Medicine, UNITED STATES OF AMERICA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>o.akpoviroro@gmail.com</email>, <email>oakpoviroro@geisinger.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>19</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">467975</issue-id><elocation-id>e0304960</elocation-id><history><date date-type="received"><day>17</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>20</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-07 00:25:14.363"><day>07</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 Akpoviroro et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Akpoviroro et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0304960.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0304960.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" vol="19" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11379193"><article-title>Correction: Severe COVID-19 infection: An institutional review and literature overview</article-title><volume>19</volume><issue>9</issue><date><day>6</day><month>9</month><year>2024</year></date><elocation-id>e0310284</elocation-id><source>PLOS ONE</source><pub-id pub-id-type="doi">10.1371/journal.pone.0310284</pub-id><pub-id pub-id-type="pmcid">PMC11379193</pub-id><pub-id pub-id-type="pmid">39240868</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="39163410"><article-title>Severe COVID-19 infection: An institutional review and literature overview.</article-title><volume>19</volume><issue>8</issue><date><day>20</day><month>8</month><year>2024</year></date><fpage>e0304960</fpage><lpage>e0304960</lpage><source>PLoS One</source><pub-id pub-id-type="doi">10.1371/journal.pone.0304960</pub-id><pub-id pub-id-type="pmid">39163410</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="39163410"><article-title>Severe COVID-19 infection: An institutional review and literature overview.</article-title><volume>19</volume><issue>8</issue><date><day>20</day><month>8</month><year>2024</year></date><fpage>e0304960</fpage><lpage>e0304960</lpage><source>PLoS One</source><pub-id pub-id-type="doi">10.1371/journal.pone.0304960</pub-id><pub-id pub-id-type="pmid">39163410</pub-id></related-article><abstract><sec id="sec001"><title>Background</title><p>Our study aimed to describe the group of severe COVID-19 patients at an institutional level, and determine factors associated with different outcomes.</p></sec><sec id="sec002"><title>Methods</title><p>A retrospective chart review of patients admitted with severe acute hypoxic respiratory failure due to COVID-19 infection. Based on outcomes, we categorized 3 groups of severe COVID-19: (1) Favorable outcome: progressive care unit admission and discharge (2) Intermediate outcome: ICU care (3) Poor outcome: in-hospital mortality.</p></sec><sec id="sec003"><title>Results</title><p>Eighty-nine patients met our inclusion criteria; 42.7% were female. The average age was 59.7 (standard deviation (SD):13.7). Most of the population were Caucasian (95.5%) and non-Hispanic (91.0%). Age, sex, race, and ethnicity were similar between outcome groups. Medicare and Medicaid patients accounted for 62.9%. The average BMI was 33.5 (SD:8.2). Moderate comorbidity was observed, with an average Charlson Comorbidity index (CCI) of 3.8 (SD:2.6). There were no differences in the average CCI between groups(p = 0.291). Many patients (67.4%) had hypertension, diabetes (42.7%) and chronic lung disease (32.6%). A statistical difference was found when chronic lung disease was evaluated; p = 0.002. The prevalence of chronic lung disease was 19.6%, 27.8%, and 40% in the favorable, intermediate, and poor outcome groups, respectively. Smoking history was associated with poor outcomes (p = 0.04). Only 7.9% were fully vaccinated. Almost half (46.1%) were intubated and mechanically ventilated. Patients spent an average of 12.1 days ventilated (SD:8.5), with an average of 6.0 days from admission to ventilation (SD:5.1). The intermediate group had a shorter average interval from admission to ventilator (77.2 hours, SD:67.6), than the poor group (212.8 hours, SD:126.8); (p = 0.001). The presence of bacterial pneumonia was greatest in the intermediate group (72.2%), compared to the favorable group (17.4%), and the poor group (56%); this was significant (p&lt;0.0001). In-hospital mortality was seen in 28.1%.</p></sec><sec id="sec004"><title>Conclusion</title><p>Most patients were male, obese, had moderate-level comorbidity, a history of tobacco abuse, and government-funded insurance. Nearly 50% required mechanical ventilation, and about 28% died during hospitalization. Bacterial pneumonia was most prevalent in intubated groups. Patients who were intubated with a good outcome were intubated earlier during their hospital course, with an average difference of 135.6 hours. A history of cigarette smoking and chronic lung disease were associated with poor outcomes.</p></sec></abstract><funding-group><funding-statement>The author received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="5"/><page-count count="34"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The Data Availability Statement is under discussion and will be provided in a forthcoming update to this article.</meta-value></custom-meta><custom-meta id="outbreaks"><meta-name>Outbreaks</meta-name><meta-value>COVID-19</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The Data Availability Statement is under discussion and will be provided in a forthcoming update to this article.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>The worldwide COVID-19 pandemic significantly affected health systems, local communities and expected norms; this pandemic created a significant health resource scarcity in many geographic locations worldwide. Numerous descriptive studies have followed this pandemic as it continues, attempting to describe red flag patients that may require greater acuity of medical care.</p><p>Studies have shown that elevated inflammatory markers including inflammatory cytokines such as IL-6 [<xref rid="pone.0304960.ref001" ref-type="bibr">1</xref>], C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, markers of liver damage: alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), markers of kidney injury: blood urea nitrogen (BUN) and creatinine, amongst other markers of organ damage and inflammation, are associated with worse clinical course in COVID-19 infection [<xref rid="pone.0304960.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0304960.ref003" ref-type="bibr">3</xref>]. Some studies have also found that certain laboratory tests, such as high albumin levels [<xref rid="pone.0304960.ref004" ref-type="bibr">4</xref>], may be a marker of less severe infection, while others such as leukopenia, may be associated with worse outcomes [<xref rid="pone.0304960.ref001" ref-type="bibr">1</xref>].</p><p>Multiple studies have also shown an association between severe COVID-19 infection including mortality, and the variables of older age and certain comorbidities, including cardiovascular disease, chronic respiratory disease, metabolic disorders including obesity and diabetes, and malignancies [<xref rid="pone.0304960.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0304960.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0304960.ref005" ref-type="bibr">5</xref>&#8211;<xref rid="pone.0304960.ref009" ref-type="bibr">9</xref>].</p><p>To determine the factors associated with poor outcomes, including intubation and in-hospital mortality in patients admitted with acute hypoxic respiratory failure and requiring high flow supplemental oxygen at admission at our institution, we performed this study. We aimed to describe the group of patients with severe COVID-19 infection, not only to ascertain factors associated with the development of severe COVID-19 infection at an institutional level, but also to describe factors associated with different outcome groups within the group of severe infection. COVID-19 is a novel viral infection that continues to persist as a long uphill battle of continuous research development of treatments and preventive measures. Patient care management requires the understanding of disease process and the risks associated with the disease.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><sec id="sec007"><title>Design, setting, and patient population</title><p>A retrospective chart review study involving data collection from multiple Geisinger hospitals in Pennsylvania, USA. Geisinger Health System includes 10 major hospitals located in Central, South-Central, North-Central and Northeast regions of the state of Pennsylvania, USA. These hospitals serve over 3 million residents in these regions. Only Geisinger Health System&#8217;s data was used. We used the following inclusion criteria: admitted with acute hypoxic respiratory failure due to COVID-19 infection and requiring high flow nasal canula oxygen supplementation at admission, admission to the progressive care unit(PCU), age of 18&#8211;85 years, having received a 10-day course of high-dose dexamethasone (20mg for 5 days, followed by 10mg for a subsequent 5 days), and a 10-day course of remdesivir, and admission between 01/01/2021-12/31/2021. We defined severe COVID-19 infection as patients who required admission to the progressive care unit (PCU) of our institution. Based on outcomes, we categorized 3 groups of severe COVID-19: (1) Favorable outcome: this included patients who were admitted to the PCU, then discharged from the hospital, (2) Intermediate outcome: this group included patients who were initially admitted to the PCU but required escalation to an intensive cause unit (ICU) level of care and eventually discharged, and (3) Poor outcome: this group included patients with in-hospital mortality. ICU level of care was defined as requiring intubation and mechanical ventilation support. Some of the authors of this manuscript had access to identifiable patient information during data collection (<xref rid="pone.0304960.g001" ref-type="fig">Fig 1</xref>).</p><fig position="float" id="pone.0304960.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0304960.g001</object-id><label>Fig 1</label><caption><title>Inclusion and eligibility.</title><p>PCU, progressive care unit; ICU level of care equates requiring intubation and mechanical ventilation support.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0304960.g001.jpg"/></fig></sec><sec id="sec008"><title>Data collection and handling</title><p>Patients were identified using diagnosis on inpatient problem list between 01/01/2021-12/31/2021. Comorbidities were identified by ICD9 and ICD10 diagnosis codes, including tobacco use history, and required at least one reference to diagnosis on the inpatient problem list, or two outpatient diagnoses. Medication use was determined by orders within the Geisinger system and medication reconciliation during encounters. Charlson comorbidity index was calculated for each patient to determine comorbid burden.</p></sec><sec id="sec009"><title>Statistical methods</title><p>ANOVA test was used for comparison between the 3 groups. A post-hoc Tukey&#8217;s HSD test was conducted to compare the differences between 2 groups. IBM SPSS Statistics 26 was used for all analyses. Significance levels of &lt;0.05 and &lt;0.0167 were set for the ANOVA and Tukey&#8217;s HSD tests respectively.</p></sec><sec id="sec010"><title>Ethical approval</title><p>This study was approved by the institutional review board of Geisinger Northeast, Wilkes Barre, Pennsylvania as an exempt study, as defined by the U. S. Department of Health and Human Services Regulations for the Protection of Human Subjects [(45 CFR 46.104)]. This means that patient consent was not required for this retrospective study, with the requirement that only the investigators approved to participate in this study have access to identifiable patient data and information, and any data and results published that are associated with this study must be fully de-identified before publication. The institutional review board of Geisinger Northeast, Wilkes Barre, Pennsylvania, USA has approved the results of this study to be published.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Demographics</title><p>The study population included 89 patients; 42.7% were female and 57.3% were male. A favorable outcome occurred in 51.7% (46/89) of patients with severe COVID-19 infection, 20.2% (18/89) had an intermediate outcome, and 28.1% (25/89) had a poor outcome. The average age of the entire study population was 59.7 (standard deviation (SD):13.7). The average ages of the 3 outcome groups were 59.8(SD 13.1), 55.1(SD 14.6), and 62.8(SD 12.9) years in the favorable, intermediate, and poor groups, respectively.</p><p>Most of the entire study population were male (57.3%), with females constituting 42.7%. Female patients made up 39.1%, 61.1% and 36.0% of the favorable, intermediate, and poor outcome groups, respectively. Male patients made up 60.9%, 38.9% and 64.0% of the favorable, intermediate, and poor outcome groups, respectively.</p><p>Of the total study population, Caucasian patients were 95.5%, and 4.5% were Black or African American. Caucasian patients made up &gt;90% of each outcome group <xref rid="pone.0304960.t001" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="pone.0304960.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0304960.t001</object-id><label>Table 1</label><caption><title>Demographic data.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0304960.t001g" position="float" orientation="portrait" xlink:href="pone.0304960.t001.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Favorable<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Intermediate<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Poor<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Total<break/>n (%)</th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t001fn001" ref-type="table-fn">*</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t001fn002" ref-type="table-fn">**</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t001fn003" ref-type="table-fn">***</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t001fn004" ref-type="table-fn">*^</xref></th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">18 (39.1)</td><td align="left" rowspan="1" colspan="1">11 (61.1)</td><td align="left" rowspan="1" colspan="1">9 (36)</td><td align="left" rowspan="1" colspan="1">38 (42.7)</td><td align="left" rowspan="3" colspan="1">0.208</td><td align="left" rowspan="3" colspan="1">0.251</td><td align="left" rowspan="3" colspan="1">0.965</td><td align="left" rowspan="3" colspan="1">0.233</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">28 (60.9)</td><td align="left" rowspan="1" colspan="1">7 (38.9)</td><td align="left" rowspan="1" colspan="1">16 (64)</td><td align="left" rowspan="1" colspan="1">51 (57.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">86</td></tr><tr><td align="left" rowspan="3" colspan="1">Race</td><td align="left" rowspan="1" colspan="1">African American/Black</td><td align="left" rowspan="1" colspan="1">2 (4.3)</td><td align="left" rowspan="1" colspan="1">1 (5.6)</td><td align="left" rowspan="1" colspan="1">1 (4)</td><td align="left" rowspan="1" colspan="1">4 (4.5)</td><td align="left" rowspan="3" colspan="1">0.970</td><td align="left" rowspan="3" colspan="1">0.977</td><td align="left" rowspan="3" colspan="1">0.998</td><td align="left" rowspan="3" colspan="1">0.969</td></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">44 (95.7)</td><td align="left" rowspan="1" colspan="1">17 (94.4)</td><td align="left" rowspan="1" colspan="1">24 (96)</td><td align="left" rowspan="1" colspan="1">85 (95.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>46</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>18</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>25</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>89</bold>
</td></tr><tr><td align="left" rowspan="4" colspan="1">
<bold>Ethnicity</bold>
</td><td align="left" rowspan="1" colspan="1">Hispanic</td><td align="left" rowspan="1" colspan="1">1 (2.2)</td><td align="left" rowspan="1" colspan="1">3 (16.7)</td><td align="left" rowspan="1" colspan="1">1 (4)</td><td align="left" rowspan="1" colspan="1">5 (5.6)</td><td align="left" rowspan="4" colspan="1">
<bold>0.002</bold>
</td><td align="left" rowspan="4" colspan="1">0.002</td><td align="left" rowspan="4" colspan="1">0.945</td><td align="left" rowspan="4" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-Hispanic</td><td align="left" rowspan="1" colspan="1">45 (97.8)</td><td align="left" rowspan="1" colspan="1">12 (66.7)</td><td align="left" rowspan="1" colspan="1">24 (96.0)</td><td align="left" rowspan="1" colspan="1">81 (91.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3 (16.7)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3 (3.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>46</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>18</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>25</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>89</bold>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">59.8</td><td align="left" rowspan="1" colspan="1">55.1</td><td align="left" rowspan="1" colspan="1">62.8</td><td align="left" rowspan="1" colspan="1">59.7</td><td align="left" rowspan="3" colspan="1">0.189</td><td align="left" rowspan="3" colspan="1">0.431</td><td align="left" rowspan="3" colspan="1">0.642</td><td align="left" rowspan="3" colspan="1">0.162</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">13.1</td><td align="left" rowspan="1" colspan="1">14.6</td><td align="left" rowspan="1" colspan="1">12.9</td><td align="left" rowspan="1" colspan="1">13.7</td></tr><tr><td align="left" rowspan="1" colspan="1">IQR</td><td align="left" rowspan="1" colspan="1">19.3</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="4" colspan="1">Insurance</td><td align="left" rowspan="1" colspan="1">Commercial</td><td align="left" rowspan="1" colspan="1">18 (39.1)</td><td align="left" rowspan="1" colspan="1">6 (33.3)</td><td align="left" rowspan="1" colspan="1">9 (36)</td><td align="left" rowspan="1" colspan="1">33 (37.1)</td><td align="left" rowspan="4" colspan="1">0.906</td><td align="left" rowspan="4" colspan="1">0.905</td><td align="left" rowspan="4" colspan="1">0.964</td><td align="left" rowspan="4" colspan="1">0.983</td></tr><tr><td align="left" rowspan="1" colspan="1">Medicaid/Medicare</td><td align="left" rowspan="1" colspan="1">28 (60.9)</td><td align="left" rowspan="1" colspan="1">12 (66.7)</td><td align="left" rowspan="1" colspan="1">16 (64)</td><td align="left" rowspan="1" colspan="1">46 (62.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Self-paying</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">Vaccination</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">4(8.7)</td><td align="left" rowspan="1" colspan="1">1 (5.6)</td><td align="left" rowspan="1" colspan="1">2(8)</td><td align="left" rowspan="1" colspan="1">7(7.9)</td><td align="left" rowspan="3" colspan="1">0.806</td><td align="left" rowspan="3" colspan="1">0.793</td><td align="left" rowspan="3" colspan="1">0.994</td><td align="left" rowspan="3" colspan="1">0.870</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">42(91.3)</td><td align="left" rowspan="1" colspan="1">17(94.4)</td><td align="left" rowspan="1" colspan="1">23(92)</td><td align="left" rowspan="1" colspan="1">82(92.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>* Three-group comparison</p></fn><fn id="t001fn002"><p>** Favorable versus intermediate</p></fn><fn id="t001fn003"><p>*** Favorable versus poor</p></fn><fn id="t001fn004"><p>*^Intermediate versus poor; SD, standard deviation; IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap><p>Most of the total population were non-Hispanic at 91.0%; 5.6% were Hispanic and 3.4% had no ethnicity data available. Non-Hispanic patients made up 97.8%, 66.7%, and 96.0% of the favorable, intermediate, and poor outcome groups, respectively.</p><p>There were no statistical differences in sex, when all outcome groups were compared (p = 0.208), or between intergroup comparisons <xref rid="pone.0304960.t001" ref-type="table">Table 1</xref>. More Hispanic patients were present in the intermediate group (16.7%) than the favorable (2.2%), or poor (4%) outcome groups, and these differences were statistically significant(p = 0.002) <xref rid="pone.0304960.t001" ref-type="table">Table 1</xref>. Only 7.9% of the entire population were fully vaccinated. Of those vaccinated, 57.1% were in the favorable group, 14.3% in the intermediate group, and 28.6% in the poor group <xref rid="pone.0304960.t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec013"><title>Insurance</title><p>Medicare and Medicaid patients accounted for 62.9% of the study population, with private insurance in 37.1%. All outcome groups similarly had around 60% of Medicare/Medicaid insurance, and there were no differences between the outcome groups(p = 0.906) <xref rid="pone.0304960.t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec014"><title>Comorbidities</title><p>The average body mass index (BMI) was 33.5 (SD:8.2). Patients in all outcome groups were categorized as class I obese, with an average BMI in the favorable, intermediate, and poor outcome groups of 32.3 (SD 6.8), 34.9 (SD 10.7), and 34.7 (SD 8.0), respectively. No differences existed between outcome groups (p = 0.367) <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="pone.0304960.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0304960.t002</object-id><label>Table 2</label><caption><title>Comorbidities.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0304960.t002g" position="float" orientation="portrait" xlink:href="pone.0304960.t002.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Favorable<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Intermediate<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Poor<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Total<break/>n (%)</th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t002fn001" ref-type="table-fn">*</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t002fn002" ref-type="table-fn">**</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t002fn003" ref-type="table-fn">***</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t002fn004" ref-type="table-fn">*^</xref></th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">32.3</td><td align="left" rowspan="1" colspan="1">34.9</td><td align="left" rowspan="1" colspan="1">34.7</td><td align="left" rowspan="1" colspan="1">33.5</td><td align="left" rowspan="2" colspan="1">0.367<break/></td><td align="left" rowspan="2" colspan="1">0.499<break/></td><td align="left" rowspan="2" colspan="1">0.468<break/></td><td align="left" rowspan="2" colspan="1">0.998<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">6.8</td><td align="left" rowspan="1" colspan="1">10.7</td><td align="left" rowspan="1" colspan="1">8.0</td><td align="left" rowspan="1" colspan="1">8.2</td></tr><tr><td align="left" rowspan="2" colspan="1">CCI</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">3.8</td><td align="left" rowspan="2" colspan="1">0.291<break/></td><td align="left" rowspan="2" colspan="1">0.998<break/></td><td align="left" rowspan="2" colspan="1">0.304<break/></td><td align="left" rowspan="2" colspan="1">0.429<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" rowspan="3" colspan="1">CKD</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">4 (8.7)</td><td align="left" rowspan="1" colspan="1">2 (11.1)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">10 (11.2)</td><td align="left" rowspan="3" colspan="1">0.656<break/></td><td align="left" rowspan="3" colspan="1">0.960</td><td align="left" rowspan="3" colspan="1">0.630<break/></td><td align="left" rowspan="3" colspan="1">0.874<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">42 (91.3)</td><td align="left" rowspan="1" colspan="1">16 (88.9)</td><td align="left" rowspan="1" colspan="1">25 (100)</td><td align="left" rowspan="1" colspan="1">79 (88.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">DM2</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">20 (43.5)</td><td align="left" rowspan="1" colspan="1">10 (55.6)</td><td align="left" rowspan="1" colspan="1">8 (32.0)</td><td align="left" rowspan="1" colspan="1">38 (42.7)</td><td align="left" rowspan="3" colspan="1">0.309<break/></td><td align="left" rowspan="3" colspan="1">0.657<break/></td><td align="left" rowspan="3" colspan="1">0.622<break/></td><td align="left" rowspan="3" colspan="1">0.280<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">26 (56.5)</td><td align="left" rowspan="1" colspan="1">8 (44.4)</td><td align="left" rowspan="1" colspan="1">17 (68.0)</td><td align="left" rowspan="1" colspan="1">51 (57.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">HTN</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">30 (65.2)</td><td align="left" rowspan="1" colspan="1">14 (77.8)</td><td align="left" rowspan="1" colspan="1">16 (64.0)</td><td align="left" rowspan="1" colspan="1">60 (67.4)</td><td align="left" rowspan="3" colspan="1">0.582<break/></td><td align="left" rowspan="3" colspan="1">0.608<break/></td><td align="left" rowspan="3" colspan="1">0.994<break/></td><td align="left" rowspan="3" colspan="1">0.616<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">16 (34.8)</td><td align="left" rowspan="1" colspan="1">4 (22.2)</td><td align="left" rowspan="1" colspan="1">9 (36.0)</td><td align="left" rowspan="1" colspan="1">29 (32.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">CHF</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">8 (17.4)</td><td align="left" rowspan="1" colspan="1">2 (11.1)</td><td align="left" rowspan="1" colspan="1">4 (16.0)</td><td align="left" rowspan="1" colspan="1">14 (15.7)</td><td align="left" rowspan="3" colspan="1">0.829<break/></td><td align="left" rowspan="3" colspan="1">0.814<break/></td><td align="left" rowspan="3" colspan="1">0.987<break/></td><td align="left" rowspan="3" colspan="1">0.904<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">38 (82.6)</td><td align="left" rowspan="1" colspan="1">16 (88.9)</td><td align="left" rowspan="1" colspan="1">21 (84.0)</td><td align="left" rowspan="1" colspan="1">75 (84.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">
<bold>CLD</bold>
</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">9 (19.6)</td><td align="left" rowspan="1" colspan="1">5 (27.8)</td><td align="left" rowspan="1" colspan="1">10 (40.0)</td><td align="left" rowspan="1" colspan="1">29 (32.6)</td><td align="left" rowspan="3" colspan="1">
<bold>0.002</bold>
<break/>
</td><td align="left" rowspan="3" colspan="1">0.783<break/></td><td align="left" rowspan="3" colspan="1">0.001<break/></td><td align="left" rowspan="3" colspan="1">0.054<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">37 (80.4)</td><td align="left" rowspan="1" colspan="1">13 (72.2)</td><td align="left" rowspan="1" colspan="1">15 (60.0)</td><td align="left" rowspan="1" colspan="1">60 (67.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">COPD<break/></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">8 (17.4)</td><td align="left" rowspan="1" colspan="1">2 (11.1)</td><td align="left" rowspan="1" colspan="1">7 (28.0)</td><td align="left" rowspan="1" colspan="1">17 (19.1)</td><td align="left" rowspan="3" colspan="1">0.356<break/></td><td align="left" rowspan="3" colspan="1">0.836<break/></td><td align="left" rowspan="3" colspan="1">0.529<break/></td><td align="left" rowspan="3" colspan="1">0.354<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">38 (82.6)</td><td align="left" rowspan="1" colspan="1">16 (88.9)</td><td align="left" rowspan="1" colspan="1">18 (72.0)</td><td align="left" rowspan="1" colspan="1">72 (80.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">
<bold>OSA</bold>
</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">4 (8.7)</td><td align="left" rowspan="1" colspan="1">2 (11.1)</td><td align="left" rowspan="1" colspan="1">9 (36.0)</td><td align="left" rowspan="1" colspan="1">15 (16.9)</td><td align="left" rowspan="3" colspan="1">
<bold>0.009</bold>
<break/>
</td><td align="left" rowspan="3" colspan="1">0.969<break/></td><td align="left" rowspan="3" colspan="1">0.009<break/></td><td align="left" rowspan="3" colspan="1">0.354<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">42 (91.3)</td><td align="left" rowspan="1" colspan="1">16 (88.9)</td><td align="left" rowspan="1" colspan="1">16 (64.0)</td><td align="left" rowspan="1" colspan="1">74 (83.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">
<bold>Ever Smoker</bold>
</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">22 (47.8)</td><td align="left" rowspan="1" colspan="1">8 (44.4)</td><td align="left" rowspan="1" colspan="1">19 (76.0)</td><td align="left" rowspan="1" colspan="1">49 (55.1)</td><td align="left" rowspan="3" colspan="1">
<bold>0.044</bold>
<break/>
</td><td align="left" rowspan="3" colspan="1">0.966<break/></td><td align="left" rowspan="3" colspan="1">0.058<break/></td><td align="left" rowspan="3" colspan="1">0.098<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">24 (52.2)</td><td align="left" rowspan="1" colspan="1">10 (55.6)</td><td align="left" rowspan="1" colspan="1">6 (24.0)</td><td align="left" rowspan="1" colspan="1">40 (44.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">Former smoker</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">18(81.8)</td><td align="left" rowspan="1" colspan="1">8(100)</td><td align="left" rowspan="1" colspan="1">14(73.7)</td><td align="left" rowspan="1" colspan="1">40(81.6)</td><td align="left" rowspan="3" colspan="1">0.285<break/></td><td align="left" rowspan="3" colspan="1">0.499<break/></td><td align="left" rowspan="3" colspan="1">0.783<break/></td><td align="left" rowspan="3" colspan="1">0.254<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">4(18.2)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">5(26.3)</td><td align="left" rowspan="1" colspan="1">9(18.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">49</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>* Three-group comparison</p></fn><fn id="t002fn002"><p>** Favorable versus intermediate</p></fn><fn id="t002fn003"><p>*** Favorable versus poor</p></fn><fn id="t002fn004"><p>*^Intermediate versus poor; SD, standard deviation; IQR, interquartile range; BMI, body mass index; CCI, Charlson Comorbidity index; CKD, chronic kidney disease; DM2, type 2 diabetes mellitus; HTN, hypertension; CHF, congestive heart failure; CLD, chronic lung disease; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnea.</p></fn></table-wrap-foot></table-wrap><p>Moderate comorbidity was observed in the total population, with a mean Charlson Comorbidity index (CCI) of 3.8 (SD:2.6). The average CCI in the favorable, intermediate, and poor outcome groups were 3.5 (SD 2.6), 3.5 (SD 2.5), and 4.5 (SD 2.4), respectively(p = 0.291) <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>.</p><p>The prevalence of chronic kidney disease (CKD) in the entire study population was 11.2%; the prevalence was 8.7%, 11.1%, and 0% in the favorable, intermediate, and poor outcome groups, respectively(p = 0.656).</p><p>The overall prevalence of type 2 diabetes (DM2) was 42.7%, and this was similar in the favorable (43.5%), intermediate (55.6%), and poor (32.0%) outcome groups(p = 0.309). Hypertension(HTN) was prevalent in 67.4% of the entire population, and occurred in 65.2%, 77.8%, and 64.0% of the favorable, intermediate, and poor outcome groups, respectively(p = 0.582).</p><p>Congestive heart failure (CHF) was prevalent in 15.7% of the entire study population and occurred at a similar rate in all outcome groups(p = 0.829).</p><p>Although BMI, CCI, CKD, DM2, HTN, or CHF did not show any significant differences between outcome groups <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>, there was a noticeable difference between the outcome groups regarding chronic lung disease (CLD). The prevalence of CLD in the entire severe COVID-19 study population was 32.6%, with a stepwise increase in prevalence with increasing outcome severity. CLD was found in 19.6%, 27.8%, and 40% of the favorable, intermediate, and poor outcome groups, respectively. These findings were significant when all three groups were compared against each other (p = 0.002), and in all intergroup comparisons except favorable versus intermediate group <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>.</p><p>Chronic obstructive pulmonary disease (COPD) occurred in 19.1% of the entire study population, and in 17.4%, 11.1% and 28.0% of the favorable, intermediate, and poor outcome groups, respectively(p = 0.356) <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>. Obstructive sleep apnea (OSA) showed an upward trend with each subsequent outcome group (8.7%, 11.1%, 36.0%), and this was statistically significant(p = 0.009) in the 3-group comparison <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>.</p><p>A smoking history was found in 55.1% of the entire study population, and in 47.8%, 44.4%, and 76.0% of the favorable, intermediate, and poor outcome groups, respectively. These findings were significant(p = 0.044) <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>. We further evaluated the type of smoking history to determine if former smokers had a different outcome than current smokers. Former smokers were defined as those with a record of smoking cessation for at least 6 months per chart review; most patients who fell into this category had a record of having quit for greater than 1 year. Most smokers in all outcome groups were found to be former smokers, and there were no differences between the outcome groups(p = 0.285) <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec015"><title>Hospital course</title><p>Patients were on average admitted for 22.1 days. The mean length of stay was 17.1, 23.6 and 21.3 days in the favorable, intermediate, and poor outcome groups, respectively(p = 0.013) <xref rid="pone.0304960.t003" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="pone.0304960.t003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0304960.t003</object-id><label>Table 3</label><caption><title>Hospital course.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0304960.t003g" position="float" orientation="portrait" xlink:href="pone.0304960.t003.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Favorable<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Intermediate<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Poor<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Total<break/>n (%)</th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t003fn001" ref-type="table-fn">*</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t003fn002" ref-type="table-fn">**</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t003fn003" ref-type="table-fn">***</xref></th><th align="center" rowspan="1" colspan="1">P-value<xref rid="t003fn004" ref-type="table-fn">*^</xref></th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Length of stay (days)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">17.1</td><td align="left" rowspan="1" colspan="1">23.6</td><td align="left" rowspan="1" colspan="1">21.3</td><td align="left" rowspan="1" colspan="1">22.1<break/></td><td align="left" rowspan="2" colspan="1">0.013<break/></td><td align="left" rowspan="2" colspan="1">0.018<break/></td><td align="left" rowspan="2" colspan="1">0.117<break/></td><td align="left" rowspan="2" colspan="1">0.644<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">7.2</td><td align="left" rowspan="1" colspan="1">10.8</td><td align="left" rowspan="1" colspan="1">7.7</td><td align="left" rowspan="1" colspan="1">9.56<break/></td></tr><tr><td align="left" rowspan="3" colspan="1">Non-invasive ventilation</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">30(65.2)</td><td align="left" rowspan="1" colspan="1">16(88.9)</td><td align="left" rowspan="1" colspan="1">21(84)</td><td align="left" rowspan="1" colspan="1">67(75.3)</td><td align="left" rowspan="3" colspan="1">0.071</td><td align="left" rowspan="3" colspan="1">0.118</td><td align="left" rowspan="3" colspan="1">0.184</td><td align="left" rowspan="3" colspan="1">0.927</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">16(34.8)</td><td align="left" rowspan="1" colspan="1">2(11.1)</td><td align="left" rowspan="1" colspan="1">4(16)</td><td align="left" rowspan="1" colspan="1">22(24.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="3" colspan="1">Invasive ventilation</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">0(0)</td><td align="left" rowspan="1" colspan="1">18(100)</td><td align="left" rowspan="1" colspan="1">22(88.0)</td><td align="left" rowspan="1" colspan="1">40(44.9)</td><td align="left" rowspan="3" colspan="1">&lt;0.001</td><td align="left" rowspan="3" colspan="1">&lt;0.001</td><td align="left" rowspan="3" colspan="1">&lt;0.001</td><td align="left" rowspan="3" colspan="1">0.060</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">46(100)</td><td align="left" rowspan="1" colspan="1">0(0)</td><td align="left" rowspan="1" colspan="1">3(12.0)</td><td align="left" rowspan="1" colspan="1">49(55.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46(100)</td><td align="left" rowspan="1" colspan="1">18(100)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="2" colspan="1">Interval from admission to mechanical ventilation (hours)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">77.2</td><td align="left" rowspan="1" colspan="1">212.8</td><td align="left" rowspan="1" colspan="1">144.6</td><td align="left" rowspan="2" colspan="1">n/a</td><td align="left" rowspan="2" colspan="1">n/a</td><td align="left" rowspan="2" colspan="1">n/a</td><td align="left" rowspan="2" colspan="1">
<break/>
<bold>0.001</bold>
<break/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">67.6</td><td align="left" rowspan="1" colspan="1">126.8</td><td align="left" rowspan="1" colspan="1">122.0</td></tr><tr><td align="left" rowspan="2" colspan="1">Number of days on mechanical ventilator</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">13.2<break/></td><td align="left" rowspan="1" colspan="1">10.6<break/></td><td align="left" rowspan="1" colspan="1">12.1<break/></td><td align="left" rowspan="2" colspan="1">n/a</td><td align="left" rowspan="2" colspan="1">n/a</td><td align="left" rowspan="2" colspan="1">n/a</td><td align="left" rowspan="2" colspan="1">0.474<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">9.7<break/></td><td align="left" rowspan="1" colspan="1">7.2<break/></td><td align="left" rowspan="1" colspan="1">8.5<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">Bacterial pneumonia</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">8(17.4)</td><td align="left" rowspan="1" colspan="1">13(72.2)</td><td align="left" rowspan="1" colspan="1">14(56.0)</td><td align="left" rowspan="1" colspan="1">35(39.3)</td><td align="left" rowspan="3" colspan="1">&lt;0.001</td><td align="left" rowspan="3" colspan="1">&lt;0.001</td><td align="left" rowspan="3" colspan="1">0.002</td><td align="left" rowspan="3" colspan="1">0.455</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">38(82.6)</td><td align="left" rowspan="1" colspan="1">5(27.8)</td><td align="left" rowspan="1" colspan="1">11(44.0)</td><td align="left" rowspan="1" colspan="1">54(60.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="1" colspan="1">In-hospital mortality</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">0(0)</td><td align="left" rowspan="1" colspan="1">0(0)</td><td align="left" rowspan="1" colspan="1">23(92.0)</td><td align="left" rowspan="1" colspan="1">23(25.8)</td><td align="left" rowspan="3" colspan="1">n/a</td><td align="left" rowspan="3" colspan="1">n/a</td><td align="left" rowspan="3" colspan="1">n/a</td><td align="left" rowspan="3" colspan="1">n/a</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">46(100)</td><td align="left" rowspan="1" colspan="1">18(100)</td><td align="left" rowspan="1" colspan="1">2(8.0)</td><td align="left" rowspan="1" colspan="1">66(74.2)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>* Three-group comparison</p></fn><fn id="t003fn002"><p>** Favorable versus intermediate</p></fn><fn id="t003fn003"><p>*** Favorable versus poor</p></fn><fn id="t003fn004"><p>*^Intermediate versus poor.</p></fn></table-wrap-foot></table-wrap><p>Most patients(75.3%) needed non-invasive ventilation(NIV), and while more patients in the intermediate(88.9%) and poor(84.0%) groups needed NIV than the favorable group(65.2%), these differences were not statistically significant(p = 0.071) <xref rid="pone.0304960.t003" ref-type="table">Table 3</xref>.</p><p>Almost half (44.9%) of the severe COVID-19 population were intubated and mechanically ventilated. All patients in the intermediate group where intubated and mechanically ventilation per definition, and no patients in the favorable group were intubated and mechanically ventilated. All but 3 patients in the poor group were intubated(88.0%) <xref rid="pone.0304960.t003" ref-type="table">Table 3</xref>. The average interval to intubation was 144.6 hours (SD 122.0). Of those who were intubated, the interval from admission to intubation was 77.2 hours(SD 67.6) and 212.8 hours(SD 126.8) in the intermediate and poor groups, respectively(p = 0.001) <xref rid="pone.0304960.t003" ref-type="table">Table 3</xref>. The average number of days intubated was 12.1 days, and this was similar between the intermediate(13.2, SD 9.7) and poor (10.6, SD 7.2) groups.</p><p>The prevalence of bacterial pneumonia was greatest in the intermediate group (72.2%) than the favorable (17.4%), or poor (56%) groups(p&lt;0.0001). These differences were significant in all intergroup comparisons except between intermediate and poor (p = 0.455).</p><p>In-hospital mortality occurred in 28.1% (25/89), and these patients belonged to the poor outcome group <xref rid="pone.0304960.t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec016"><title>Laboratory values</title><sec id="sec017"><title>Liver function panel</title><p>The average albumin in the entire study population was 3.0(SD 0.4); the favorable outcome group had the lowest average albumin levels during admission (2.8, SD: 0.3), compared with the intermediate (3.2, SD:0.3) and the poor (3.0, SD: 0.7) outcome groups(p = 0.001) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>. The average population AST was 56.1(SD 53.7) and trended up with each subsequent outcome group. Average AST was 43.4 (SD 16.1), 49.0(SD 20.7), and 84.7(SD 90.7) in the favorable, intermediate, and poor outcome groups, respectively(p = 0.006) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>. The average ALT in the total population was 68.5 (SD 127.0) and was not statistically different between outcome groups, even though it trended up with each subsequent outcome group(p = 0.197) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>. The average total population bilirubin was 0.5(SD 0.2), and this was highest in the poor outcome group (0.5, SD:0.2) than the favorable (0.4, SD:0.2), or the intermediate (0.4, SD:0.2) groups(p = 0.042) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>.</p><table-wrap position="float" id="pone.0304960.t004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0304960.t004</object-id><label>Table 4</label><caption><title>Laboratory tests.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0304960.t004g" position="float" orientation="portrait" xlink:href="pone.0304960.t004.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Favorable<break/>n (%)</th><th align="left" rowspan="1" colspan="1">Intermediate<break/>n (%)</th><th align="left" rowspan="1" colspan="1">Poor<break/>n (%)</th><th align="left" rowspan="1" colspan="1">Total<break/>n (%)</th><th align="left" rowspan="1" colspan="1">P-value<xref rid="t004fn001" ref-type="table-fn">*</xref></th><th align="left" rowspan="1" colspan="1">P-value<xref rid="t004fn002" ref-type="table-fn">**</xref></th><th align="left" rowspan="1" colspan="1">P-value<xref rid="t004fn003" ref-type="table-fn">***</xref></th><th align="left" rowspan="1" colspan="1">P-value<xref rid="t004fn004" ref-type="table-fn">*^</xref></th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Average albumin (g/dL)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">2.8</td><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="2" colspan="1">
<bold>0.001</bold>
<break/>
</td><td align="left" rowspan="2" colspan="1">0.001<break/></td><td align="left" rowspan="2" colspan="1">0.144<break/></td><td align="left" rowspan="2" colspan="1">0.131<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="2" colspan="1">Average AST (U/L)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">43.4</td><td align="left" rowspan="1" colspan="1">49.0</td><td align="left" rowspan="1" colspan="1">84.7</td><td align="left" rowspan="1" colspan="1">56.1</td><td align="left" rowspan="2" colspan="1">
<bold>0.006</bold>
</td><td align="left" rowspan="2" colspan="1">0.918</td><td align="left" rowspan="2" colspan="1">0.005</td><td align="left" rowspan="2" colspan="1">0.068</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">16.1</td><td align="left" rowspan="1" colspan="1">20.7</td><td align="left" rowspan="1" colspan="1">90.7</td><td align="left" rowspan="1" colspan="1">53.7</td></tr><tr><td align="left" rowspan="2" colspan="1">Average ALT (U/L)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">54.5</td><td align="left" rowspan="1" colspan="1">50.4</td><td align="left" rowspan="1" colspan="1">107.3</td><td align="left" rowspan="1" colspan="1">68.5</td><td align="left" rowspan="2" colspan="1">0.197</td><td align="left" rowspan="2" colspan="1">0.992</td><td align="left" rowspan="2" colspan="1">0.216</td><td align="left" rowspan="2" colspan="1">0.397</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">34.8</td><td align="left" rowspan="1" colspan="1">33.6</td><td align="left" rowspan="1" colspan="1">227.2</td><td align="left" rowspan="1" colspan="1">127.0</td></tr><tr><td align="left" rowspan="2" colspan="1">Average bilirubin (mg/dL)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="2" colspan="1">0.042</td><td align="left" rowspan="2" colspan="1">0.616</td><td align="left" rowspan="2" colspan="1">0.127</td><td align="left" rowspan="2" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="2" colspan="1">Average CRP (mg/L)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">56.0<break/></td><td align="left" rowspan="1" colspan="1">111.5<break/></td><td align="left" rowspan="1" colspan="1">65.7<break/></td><td align="left" rowspan="1" colspan="1">69.5<break/></td><td align="left" rowspan="2" colspan="1">
<bold>&lt;0.001</bold>
</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.678</td><td align="left" rowspan="2" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">39.6</td><td align="left" rowspan="1" colspan="1">69.8</td><td align="left" rowspan="1" colspan="1">31.9</td><td align="left" rowspan="1" colspan="1">50.2</td></tr><tr><td align="left" rowspan="2" colspan="1">Average Ferritin (ng/mL)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">1398.6</td><td align="left" rowspan="1" colspan="1">917.3</td><td align="left" rowspan="1" colspan="1">1241.1</td><td align="left" rowspan="1" colspan="1">1259.3</td><td align="left" rowspan="2" colspan="1">0.356</td><td align="left" rowspan="2" colspan="1">0.324</td><td align="left" rowspan="2" colspan="1">0.853</td><td align="left" rowspan="2" colspan="1">0.655</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">1349.5</td><td align="left" rowspan="1" colspan="1">704.0</td><td align="left" rowspan="1" colspan="1">1020.3</td><td align="left" rowspan="1" colspan="1">1172.5</td></tr><tr><td align="left" rowspan="2" colspan="1">Average lactate (mmol/L)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="2" colspan="1">
<bold>0.02</bold>
</td><td align="left" rowspan="2" colspan="1">0.94</td><td align="left" rowspan="2" colspan="1">0.033</td><td align="left" rowspan="2" colspan="1">0.046</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">3.8</td><td align="left" rowspan="1" colspan="1">2.3</td></tr><tr><td align="left" rowspan="2" colspan="1">Average lymphocyte(K/uL)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="2" colspan="1">0.381</td><td align="left" rowspan="2" colspan="1">0.680</td><td align="left" rowspan="2" colspan="1">0.713</td><td align="left" rowspan="2" colspan="1">0.347</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="2" colspan="1">Average WBC (K/uL)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">11.8</td><td align="left" rowspan="1" colspan="1">13.4</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">12.8</td><td align="left" rowspan="2" colspan="1">0.029</td><td align="left" rowspan="2" colspan="1">0.314</td><td align="left" rowspan="2" colspan="1">0.027</td><td align="left" rowspan="2" colspan="1">0.704</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">3.6</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1">4.0</td></tr><tr><td align="left" rowspan="2" colspan="1">Average procalcitonin (ng/mL)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="2" colspan="1">0.173</td><td align="left" rowspan="2" colspan="1">0.167</td><td align="left" rowspan="2" colspan="1">0.994</td><td align="left" rowspan="2" colspan="1">0.262</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">1.9</td></tr><tr><td align="left" rowspan="3" colspan="1">AKI</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">2 (4.3)</td><td align="left" rowspan="1" colspan="1">1 (5.6)</td><td align="left" rowspan="1" colspan="1">5 (20)</td><td align="left" rowspan="1" colspan="1">8 (9)</td><td align="left" rowspan="3" colspan="1">0.076</td><td align="left" rowspan="3" colspan="1">0.987</td><td align="left" rowspan="3" colspan="1">0.072</td><td align="left" rowspan="3" colspan="1">0.229</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">44 (95.7)</td><td align="left" rowspan="1" colspan="1">17 (94.4)</td><td align="left" rowspan="1" colspan="1">20 (80)</td><td align="left" rowspan="1" colspan="1">81 (91)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">89</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>* Three-group comparison</p></fn><fn id="t004fn002"><p>** Favorable versus intermediate</p></fn><fn id="t004fn003"><p>*** Favorable versus poor</p></fn><fn id="t004fn004"><p>*^Intermediate versus poor.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec018"><title>Markers of inflammation</title><p>Average CRP in the total study population was 69.5 (SD 50.2), and was greater in the intermediate (111.5, SD 69.8) and poor (65.7, SD 31.9) groups than the favorable (56.0, SD 39.6) group(p&lt;0.001) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>.</p><p>The total population average lactate was 2.2(SD 2.3). Average lactate was significantly elevated in the poor outcome group (3.4, SD 3.8), than the favorable (1.8, SD 0.6), or intermediate (1.6, SD 0.3) groups(p = 0.02) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>. The average total population lymphocyte count was 0.9K/uL(SD 0.5) and was similar between outcome groups(p = 0.381) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>. Although there were no outcome differences in the average lymphocyte count, there was an uptrend in the total WBC count, and the poor group had a significantly higher average white blood cell count(WBC)(14.3, SD 4.4) than either the favorable (11.8, SD 3.7), or the intermediate (13.4, SD 3.6) groups(p = 0.029) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>.</p><p>As expected, the average procalcitonin level was elevated in the total study population(0.5, SD 1.9); however, there were no differences between the outcome groups(p = 0.173) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>.</p></sec><sec id="sec019"><title>Renal function</title><p>We further evaluated the presence of acute kidney injury (AKI). There was an insignificant upward trend in the prevalence of AKI in the outcome groups. While 4.3% in the favorable outcome group had AKI, 5.6% and 20% in the intermediate and poor outcome groups, respectively, had AKI(p = 0.076) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>.</p></sec></sec><sec id="sec020"><title>Respiratory parameters</title><sec id="sec021"><title>Patrial pressure of carbon dioxide and oxygen</title><p>The average total population partial pressure of arterial carbon dioxide (PaCO2) was 41.4, and PaCO2 showed an uptrend with each subsequent outcome group(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. Similarly, the maximum PaCO2 was above the upper limit of normal in the intermediate and poor groups, being greatest in the poor group(64.8, SD:30.0), than the intermediate (52.5, SD 12.2) or favorable (36.5, SD 7.4) groups(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>.</p><table-wrap position="float" id="pone.0304960.t005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0304960.t005</object-id><label>Table 5</label><caption><title>Respiratory parameters.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0304960.t005g" position="float" orientation="portrait" xlink:href="pone.0304960.t005.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Favorable<break/>n (%)</th><th align="left" rowspan="1" colspan="1">Intermediate<break/>n (%)</th><th align="left" rowspan="1" colspan="1">Poor<break/>n (%)</th><th align="left" rowspan="1" colspan="1">Total<break/>n (%)</th><th align="left" rowspan="1" colspan="1">P-value<xref rid="t005fn001" ref-type="table-fn">*</xref></th><th align="left" rowspan="1" colspan="1">P-value<xref rid="t005fn002" ref-type="table-fn">**</xref></th><th align="left" rowspan="1" colspan="1">P-value<xref rid="t005fn003" ref-type="table-fn">***</xref></th><th align="left" rowspan="1" colspan="1">P-value<xref rid="t005fn004" ref-type="table-fn">*^</xref></th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Average PaCO2(mmHg)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">35.4</td><td align="center" rowspan="1" colspan="1">39.9</td><td align="center" rowspan="1" colspan="1">46.4</td><td align="center" rowspan="1" colspan="1">41.4</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.313</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">6.4</td><td align="center" rowspan="1" colspan="1">8.5</td><td align="center" rowspan="1" colspan="1">14.4</td><td align="center" rowspan="1" colspan="1">11.6</td></tr><tr><td align="left" rowspan="2" colspan="1">Maximum PaCO2(mmHg)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">36.5</td><td align="center" rowspan="1" colspan="1">52.5</td><td align="center" rowspan="1" colspan="1">64.8</td><td align="center" rowspan="1" colspan="1">52.3</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.015</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">7.4</td><td align="center" rowspan="1" colspan="1">12.2</td><td align="center" rowspan="1" colspan="1">30.0</td><td align="center" rowspan="1" colspan="1">23.2</td></tr><tr><td align="left" rowspan="2" colspan="1">Minimum PaCO2(mmHg)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">34.3</td><td align="center" rowspan="1" colspan="1">25.2</td><td align="center" rowspan="1" colspan="1">32.0</td><td align="center" rowspan="1" colspan="1">31.5</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.758</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">6.0</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">7.7</td><td align="center" rowspan="1" colspan="1">6.9</td></tr><tr><td align="left" rowspan="2" colspan="1">Average PaO2(mmHg)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">76.0</td><td align="center" rowspan="1" colspan="1">111.8</td><td align="center" rowspan="1" colspan="1">83.0</td><td align="center" rowspan="1" colspan="1">88.7</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.23</td><td align="left" rowspan="2" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">19.4</td><td align="center" rowspan="1" colspan="1">24.5</td><td align="center" rowspan="1" colspan="1">18.3</td><td align="center" rowspan="1" colspan="1">24.7</td></tr><tr><td align="left" rowspan="2" colspan="1">Maximum PaO2(mmHg)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">83.9</td><td align="center" rowspan="1" colspan="1">227.6</td><td align="center" rowspan="1" colspan="1">132.8</td><td align="center" rowspan="1" colspan="1">141.7</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.001</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">27.4</td><td align="center" rowspan="1" colspan="1">71.8</td><td align="center" rowspan="1" colspan="1">55.5</td><td align="center" rowspan="1" colspan="1">77.5</td></tr><tr><td align="left" rowspan="2" colspan="1">Minimum PaO2(mmHg)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">69.1</td><td align="center" rowspan="1" colspan="1">60.4</td><td align="center" rowspan="1" colspan="1">52.5</td><td align="center" rowspan="1" colspan="1">61.0</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.128</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.143</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">190</td><td align="center" rowspan="1" colspan="1">9.5</td><td align="center" rowspan="1" colspan="1">11.4</td><td align="center" rowspan="1" colspan="1">15.8</td></tr><tr><td align="left" rowspan="2" colspan="1">Average pH</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">7.45</td><td align="center" rowspan="1" colspan="1">7.40</td><td align="center" rowspan="1" colspan="1">7.36</td><td align="center" rowspan="1" colspan="1">7.40</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.001</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">0.042</td><td align="center" rowspan="1" colspan="1">0.035</td><td align="center" rowspan="1" colspan="1">0.061</td><td align="center" rowspan="1" colspan="1">0.060</td></tr><tr><td align="left" rowspan="2" colspan="1">Maximum pH</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">7.46<break/></td><td align="center" rowspan="1" colspan="1">7.51<break/></td><td align="center" rowspan="1" colspan="1">7.46<break/></td><td align="center" rowspan="1" colspan="1">7.47<break/></td><td align="left" rowspan="2" colspan="1">0.001<break/></td><td align="left" rowspan="2" colspan="1">0.002<break/></td><td align="left" rowspan="2" colspan="1">0.998<break/></td><td align="left" rowspan="2" colspan="1">0.004<break/></td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">0.043<break/></td><td align="center" rowspan="1" colspan="1">0.038<break/></td><td align="center" rowspan="1" colspan="1">0.043<break/></td><td align="center" rowspan="1" colspan="1">0.04<break/></td></tr><tr><td align="left" rowspan="2" colspan="1">Minimum pH</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">7.44</td><td align="center" rowspan="1" colspan="1">7.27</td><td align="center" rowspan="1" colspan="1">7.25</td><td align="center" rowspan="1" colspan="1">7.33</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.205</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">0.047</td><td align="center" rowspan="1" colspan="1">0.076</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="2" colspan="1">Respiratory rate on admission(bpm)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">23.8</td><td align="center" rowspan="1" colspan="1">27.8</td><td align="center" rowspan="1" colspan="1">23.3</td><td align="center" rowspan="1" colspan="1">24.5</td><td align="left" rowspan="2" colspan="1">0.049</td><td align="left" rowspan="2" colspan="1">0.069</td><td align="left" rowspan="2" colspan="1">0.944</td><td align="left" rowspan="2" colspan="1">0.064</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">5.9</td><td align="center" rowspan="1" colspan="1">7.9</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">6.5</td></tr><tr><td align="left" rowspan="2" colspan="1">Average respiratory rate(bpm)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">22.2</td><td align="center" rowspan="1" colspan="1">21.2</td><td align="center" rowspan="1" colspan="1">24.0</td><td align="center" rowspan="1" colspan="1">22.5</td><td align="left" rowspan="2" colspan="1">0.008</td><td align="left" rowspan="2" colspan="1">0.478</td><td align="left" rowspan="2" colspan="1">0.044</td><td align="left" rowspan="2" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" rowspan="2" colspan="1">SpO2 on admission(%)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">89.0</td><td align="center" rowspan="1" colspan="1">86.0</td><td align="center" rowspan="1" colspan="1">89.1</td><td align="center" rowspan="1" colspan="1">88.4</td><td align="left" rowspan="1" colspan="1">0.402</td><td align="left" rowspan="1" colspan="1">0.409</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">0.476</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">7.9</td><td align="center" rowspan="1" colspan="1">10.1</td><td align="center" rowspan="1" colspan="1">8.0</td><td align="center" rowspan="1" colspan="1">8.5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Minimum SpO2(%)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">76.5</td><td align="center" rowspan="1" colspan="1">70.8</td><td align="center" rowspan="1" colspan="1">57.0</td><td align="center" rowspan="1" colspan="1">69.9</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.451</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">13.2</td><td align="center" rowspan="1" colspan="1">18.6</td><td align="center" rowspan="1" colspan="1">19.8</td><td align="center" rowspan="1" colspan="1">18.5</td></tr><tr><td align="left" rowspan="2" colspan="1">Average SpO2(%)</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">93.5</td><td align="center" rowspan="1" colspan="1">94.6</td><td align="center" rowspan="1" colspan="1">92.2</td><td align="center" rowspan="1" colspan="1">93.4</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td><td align="left" rowspan="2" colspan="1">0.009</td><td align="left" rowspan="2" colspan="1">0.004</td><td align="left" rowspan="2" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">1.6</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>* Three-group comparison</p></fn><fn id="t005fn002"><p>** Favorable versus intermediate</p></fn><fn id="t005fn003"><p>*** Favorable versus poor</p></fn><fn id="t005fn004"><p>*^Intermediate versus poor; mmHg, millimeters of mercury; bmp, breaths per minute.</p></fn></table-wrap-foot></table-wrap><p>The minimum PaCO2 was lowest in the intermediate, followed by the poor, and then the favorable groups(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>.</p><p>The average partial pressure of arterial oxygen (PaO2) of the entire population was 88.7mmHg(SD24.7). Average PaO2 was highest in the intermediate group(111.8, SD 24.5) than the favorable (76.0, SD 19.4) or poor (83.0, SD 18.3) groups(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. Similarly, the maximum PaO2 was greatest in the intermediate group, followed by the poor and then the favorable groups(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. The minimum PaO2 was lowest in the poor group and highest in the favorable group(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>.</p></sec><sec id="sec022"><title>pH</title><p>Average total population pH was 7.40(SD 0.06). The average pH of each outcome group was within normal limits. While the favorable outcome group had a more alkalotic average pH (7.45, SD 0.042), the intermediate (7.40, SD:0.035) and poor (7.36, SD:0.061) groups had slightly more acidic average pH(p&lt;0.001) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>. The average minimum pH was 7.33, and it was most acidotic in the poor group(7.25, SD 0.14) than the intermediate(7.27, SD 0.076) or favorable(7.44, SD:0.047) groups(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. The average maximum pH was greatest in the intermediate group than the other groups(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>.</p></sec><sec id="sec023"><title>Respiratory rate and oxygen saturation</title><p>The respiratory rate (RR) on admission was greatest in the intermediate group (27.8, SD 7.9), compared to the favorable (23.8, SD 5.9) and poor (23.3, SD 5.2) outcome groups(p = 0.049). The average RR of the entire study population was 22.5(SD 3.7). The average RR was greatest in the poor(24.0, SD 3.7), than the favorable (22.2, SD 2.7) or intermediate (21.2, SD 2.4) groups(p = 0.008) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. The average oxygen saturation(SpO2) on admission was 88.4% and the average values were similar across all outcome groups(p = 0.402) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. The average SpO2 of the entire study population during admission was 93.4%(SD 1.6); the poor outcome group had the lowest average(92.2% SD 1.9) and minimum(57.0% SD 19.8) SpO2 values than the other outcome groups(p&lt;0.001) <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. The average maximum SpO2 of the entire population was 99.9%, and no differences existed between the favorable(99.9% SD 0.4), intermediate(100% SD 0.0) and poor(99.8% SD 0.7) outcome groups(p = 0.308).</p></sec><sec id="sec024"><title>Medications during admission</title><p>Approximately 4&#8211;5% of patients in each outcome group received hydroxychloroquine during admission(p = 0.970) Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. Similarly, approximately 30% of patients in each subgroup received tocilizumab(p = 0.960) Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. More patients in the poor outcome group received baricitinib(28%) than in the intermediate(5.6%) or poor(4.3%) groups(p = 0.007) Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. There were no differences in the exposure to azithromycin in the three outcome groups(p = 0.268); all patients in all outcome groups received remdesivir for 10 days during admission. Similarly, all patients received dexamethasone during admission, and there were no differences in prior-to-admission receipt of dexamethasone between groups(p = 0.562) Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. Patients in the poor outcome group had a longer average number of days on dexamethasone(16.6 days SD 4.3), than the intermediate(12.9 days SD 4.0) or the favorable (13.3 days SD 3.5) outcome groups(p = 0.002). Although the poor outcome group had the lowest proportion of patients on angiotensin receptor blockers(ARBs)(4%) and angiotensin converting enzyme inhibitors(ACEi)(12%) during admission, compared with the intermediate group(11.1% and 27.8%, respectively) and the favorable(8,7% and 23.9%, respectively) groups, these differences were not significant for either ARB exposure(p = 0.971), or ACEi exposure(p = 0.631) Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. Thirty percent of the study population were on statin medications during admission, and more patients in the poor(48%) than the intermediate(27.8%) or favorable(28.3%) outcome groups were on statin medications during admission(p = 0.209) Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>.</p></sec></sec></sec><sec sec-type="conclusions" id="sec025"><title>Discussion</title><sec id="sec026"><title>Severe COVID-19 and sex</title><p>Our study showed that several factors were associated with poor outcomes in severe COVID-19 infection, including intubation and in-hospital mortality. Similar to other studies [<xref rid="pone.0304960.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0304960.ref010" ref-type="bibr">10</xref>&#8211;<xref rid="pone.0304960.ref014" ref-type="bibr">14</xref>], men were overrepresented in our study population, making up close to 60%. Similarly, a greater proportion of male patients experienced in-hospital mortality than did female patients. Studies have suggested that the overrepresentation of COVID-19 infection and poor outcomes in male patients may be associated with biological factors, and gender-specific behaviors such as poorer baseline health that might be associated with poor lifestyle choices that permit a greater comorbid burden [<xref rid="pone.0304960.ref015" ref-type="bibr">15</xref>]. Such a theory is supported by studies that have shown a greater incidence of alcohol-attributable deaths and disease burden in men [<xref rid="pone.0304960.ref016" ref-type="bibr">16</xref>], greater participation in illicit drug use than females [<xref rid="pone.0304960.ref017" ref-type="bibr">17</xref>], and greater tobacco consumption [<xref rid="pone.0304960.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0304960.ref018" ref-type="bibr">18</xref>]; in the resultant comorbidities such as chronic lung disease and cardiovascular disease have been linked to worse outcomes in COVID-19 [<xref rid="pone.0304960.ref015" ref-type="bibr">15</xref>]. Biological mechanisms that have been proposed to explain the worse prevalence and outcomes in male patients relate to how the SARS-CoV-2 virus enters the respiratory epithelium via transmembrane angiotensin converting enzyme-2(ACE2) also known as ACE2 receptor (ACE2r) [<xref rid="pone.0304960.ref019" ref-type="bibr">19</xref>]. Males have been shown to have increased androgen receptor expression compared to women [<xref rid="pone.0304960.ref020" ref-type="bibr">20</xref>]. Androgen receptors have been shown to have a positive correlation with ACE2 [<xref rid="pone.0304960.ref021" ref-type="bibr">21</xref>]. Increased ACE2 expression may increase susceptibility to SARS-CoV-2; it therefore follows that male patients may have a heightened risk of COVID-19 infection and more invasive disease than females [<xref rid="pone.0304960.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0304960.ref021" ref-type="bibr">21</xref>]. Additionally, behavioral factors that increase ACE2 expression, specifically smoking [<xref rid="pone.0304960.ref015" ref-type="bibr">15</xref>], may also increase susceptibility to COVID-19 infection in male patients in an additive manner. Other biological mechanisms proposed to predispose males to worse outcomes include increased inflammatory marker production in males compared to females [<xref rid="pone.0304960.ref022" ref-type="bibr">22</xref>], increasing the probability of cytokine storm, linked to the pathogenesis of poor outcomes in COVID-19 infection [<xref rid="pone.0304960.ref023" ref-type="bibr">23</xref>]. The relative biological lack of estrogen and its anti-inflammatory effects in men compared with women, further predisposes male patients to developing cytokine storm with resulting poor outcomes [<xref rid="pone.0304960.ref024" ref-type="bibr">24</xref>].</p></sec><sec id="sec027"><title>Severe COVID-19 and race and ethnicity</title><p>Most of our study population were non-Hispanic and Caucasian, and within this homogenous population, there were no differences in outcome when race was taken into consideration. Greater than 90% within each outcome group were Caucasian, and the remaining patients were Black. However, our study showed that a greater proportion of Hispanics were intubated than had a favorable outcome, or underwent in-hospital mortality, and this was a significant finding. Multiple studies have shown a racial and ethnic disparity in COVID 19 deaths, with Black and Hispanic patients experiencing greater mortality than other racial and ethnic groups [<xref rid="pone.0304960.ref025" ref-type="bibr">25</xref>&#8211;<xref rid="pone.0304960.ref028" ref-type="bibr">28</xref>]. The possible contributing factors to poorer outcomes in Black and Hispanic patients are likely multifactorial and include factors such as an increased prevalence of comorbidities and behavioral variables that predispose to worse outcomes in COVID-19 infection, such as hypertension, congestive heart failure, chronic lung diseases, and smoking [<xref rid="pone.0304960.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0304960.ref029" ref-type="bibr">29</xref>]. It has also been suggested that socioeconomic disparities limiting access to healthcare and impacting living conditions may also play a part in the disproportionate mortality rate from COVID-19 infection in minorities [<xref rid="pone.0304960.ref026" ref-type="bibr">26</xref>]. Vitamin D deficiency has been postulated as a possible contributing factor to poor outcomes in Black patients. Blacks have been shown to have the highest rate of vitamin D deficiency compared to other racial groups. In a study by Liu et al, the prevalence of vitamin D deficiency was 71.9% in non-Hispanic Black adults in the US, compared to 18.6% in non-Hispanic Caucasians, and 42.8% in Hispanics [<xref rid="pone.0304960.ref030" ref-type="bibr">30</xref>]. Chiodini et al showed that vitamin D deficiency was associated with a 2-times greater odd for ICU admission and mortality in COVID-19 patients [<xref rid="pone.0304960.ref031" ref-type="bibr">31</xref>]. The significance of vitamin D in COVID-19 infection is highlighted by studies that have elaborated the roles played by vitamin D in antiviral immunity and anti-inflammation [<xref rid="pone.0304960.ref032" ref-type="bibr">32</xref>]. These studies highlight the need for targeted primary care and preventative efforts towards minorities who are at increased risk of poor outcomes from COVID-19 infection.</p></sec><sec id="sec028"><title>Severe COVID-19 and age</title><p>Although our study highlights a trend for older patients to have worse outcomes, this was not statistically significant, unlike findings from other studies. A Belgian study by Molenberghs et al shows a stepwise increase in COVID-19 deaths with age, with the greatest number of deaths occurring in patients in their 90s [<xref rid="pone.0304960.ref033" ref-type="bibr">33</xref>]. Another study shows a steep exponential relationship between increasing age and severe, critical COVID-19 infection. For example, around the age of 25 years, fatal disease occurs in about 0.01% of their study population, compared with almost 10% of fatal disease in those aged 75 [<xref rid="pone.0304960.ref034" ref-type="bibr">34</xref>]. Other studies have also had similar findings [<xref rid="pone.0304960.ref035" ref-type="bibr">35</xref>&#8211;<xref rid="pone.0304960.ref037" ref-type="bibr">37</xref>]. The increased risk of severe illness in older individuals might be related to factors such as a generally diminished immune system [<xref rid="pone.0304960.ref038" ref-type="bibr">38</xref>], and a specific age-related decline in lung-associated immune function and accumulation of inhaled particulate matter within pulmonary macrophages, leading to weakened phagocytosis [<xref rid="pone.0304960.ref039" ref-type="bibr">39</xref>].</p></sec><sec id="sec029"><title>Severe COVID-19 and vaccination status</title><p>In our population of patients with severe COVID-19 infection, the rate of full vaccination was very poor (7.9%), and there was no difference in vaccination rates between outcome groups. Multiple studies have shown a link between a lack of vaccination and severity of COVID-19 infection [<xref rid="pone.0304960.ref040" ref-type="bibr">40</xref>], including hospitalization [<xref rid="pone.0304960.ref041" ref-type="bibr">41</xref>], requirement for invasive ventilation [<xref rid="pone.0304960.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0304960.ref043" ref-type="bibr">43</xref>], and mortality [<xref rid="pone.0304960.ref042" ref-type="bibr">42</xref>]. Our study describes a poor rate of vaccination in a population with severe COVID-19 but does not show a difference between outcome categories.</p></sec><sec id="sec030"><title>Severe COVID-19 and comorbidities</title><sec id="sec031"><title>Body mass index</title><p>Numerous studies have linked greater BMIs to increased severity of COVID-19 infection, including requirement for invasive ventilation and mortality from disease [<xref rid="pone.0304960.ref044" ref-type="bibr">44</xref>,<xref rid="pone.0304960.ref045" ref-type="bibr">45</xref>], although our study revealed no association with BMI. Some of the suggested pathophysiologic mechanisms underlying the severity of COVID-19 infection in obese individuals include the association of obesity with chronic inflammation, known to hinder immunologic responses to pathogens [<xref rid="pone.0304960.ref046" ref-type="bibr">46</xref>]. Furthermore, it has been suggested that the innate and adaptive immune responses differ in overweight and obese individuals than normal weight individuals; an outcome due to leptin and lower adiponectin concentrations, resulting in a dysregulated immune response [<xref rid="pone.0304960.ref047" ref-type="bibr">47</xref>,<xref rid="pone.0304960.ref048" ref-type="bibr">48</xref>].</p><p>Obesity has also been shown to decrease lung function, including decreasing the forced vital capacity, forced expiratory volume, and the overall respiratory system&#8217;s capacity to function, with a resultant poor baseline respiratory status [<xref rid="pone.0304960.ref049" ref-type="bibr">49</xref>]. Such decreased baseline respiratory status could be exacerbated by COVID-19 infection, resulting in a need for supportive ventilation [<xref rid="pone.0304960.ref050" ref-type="bibr">50</xref>]. Approximately 42.4% of individuals suffer from obesity in the United States [<xref rid="pone.0304960.ref051" ref-type="bibr">51</xref>], indicating that a substantial proportion of our population is at increased risk of severe COVID-19 infection based on BMI alone. Additionally, studies have shown a strong association between high BMIs and an increased risk for developing other chronic illnesses, such as heart disease, type 2 diabetes [<xref rid="pone.0304960.ref052" ref-type="bibr">52</xref>], chronic kidney disease, hypertension, and dyslipidemia [<xref rid="pone.0304960.ref053" ref-type="bibr">53</xref>], further increasing the risk of disease severity by other pathophysiologic mechanisms. Although statistically insignificant, our study reveals a trend between increasing BMI and disease severity. Moreover, some other studies did not find any associations between COVID-19 and BMI [<xref rid="pone.0304960.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0304960.ref055" ref-type="bibr">55</xref>]. Ultimately, obese patients should be continuously monitored to properly manage potential escalation of respiratory support needs.</p></sec><sec id="sec032"><title>Chronic kidney disease</title><p>One of the most frequent risk factors for severe COVID-19 was CKD, globally [<xref rid="pone.0304960.ref056" ref-type="bibr">56</xref>]. While CKD was prevalent in both the favorable and intermediate groups, it was not in the poor outcome group. This finding differs from other studies, that have shown CKD to be a major risk factor for both severe disease and mortality in COVID-19 infection [<xref rid="pone.0304960.ref057" ref-type="bibr">57</xref>&#8211;<xref rid="pone.0304960.ref059" ref-type="bibr">59</xref>].</p><p>CKD has emerged as the comorbidity that not only carries the highest risk for severe COVID-19 but also the most common comorbidity, despite the fact this was not initially noted in medical publications pertaining to risk factors for severe COVID-19 [<xref rid="pone.0304960.ref057" ref-type="bibr">57</xref>]. The poor outcomes seen in CKD patients with COVID-19 is likely multifactorial. Patients with CKD following renal transplants are likely on immunosuppressive medications that dampens their immune response to the virus, predisposing them to more invasive and poorly controlled infections [<xref rid="pone.0304960.ref060" ref-type="bibr">60</xref>]. Furthermore, it has been suggested that worse outcomes in CKD patients may be related to worsened pulmonary inflammation, due to a baseline pro-inflammatory state in CKD, and impaired innate and adaptive immune systems [<xref rid="pone.0304960.ref061" ref-type="bibr">61</xref>,<xref rid="pone.0304960.ref062" ref-type="bibr">62</xref>]. Moreover, other researchers have suggested that CKD, especially at the end-stage renal disease phase, is an acquired immunodeficiency state that predisposes to upper respiratory tract infections, greater than the risks faced by the non-CKD general population [<xref rid="pone.0304960.ref063" ref-type="bibr">63</xref>].</p></sec><sec id="sec033"><title>Type 2 diabetes mellitus</title><p>Our study revealed no statistical association between COVID-19 severity and DM2. While some studies suggest that DM2 does not necessarily increase the risk of getting COVID-19 infection, their findings do indicate that DM2 predisposes to severe COVID-19 infection [<xref rid="pone.0304960.ref064" ref-type="bibr">64</xref>]. More studies have supported the notion that both type 1 and type 2 DM are associated with an increased odds for mortality compared to non-diabetic patients [<xref rid="pone.0304960.ref064" ref-type="bibr">64</xref>&#8211;<xref rid="pone.0304960.ref066" ref-type="bibr">66</xref>]. Furthermore, COVID-19 in DM and uncontrolled hyperglycemia has been associated with an increased risk for respiratory and cardiac compromise, and increased risk for ICU admission [<xref rid="pone.0304960.ref066" ref-type="bibr">66</xref>,<xref rid="pone.0304960.ref067" ref-type="bibr">67</xref>]. In non-diabetic patients, elevated blood glucose on hospital admission has been linked with increased mortality risk [<xref rid="pone.0304960.ref068" ref-type="bibr">68</xref>]. COVID-19 infection not only leads to worsening of baseline DM but could also lead to new-onset DM and poor glycemic control [<xref rid="pone.0304960.ref069" ref-type="bibr">69</xref>]. The poor outcomes that have been associated with DM are likely driven by multiple pathophysiologic mechanisms, including insulin resistance resulting from the proinflammatory state caused by COVID-19 infection [<xref rid="pone.0304960.ref070" ref-type="bibr">70</xref>], and impaired immunity including impaired neutrophil chemotaxis and phagocytosis [<xref rid="pone.0304960.ref071" ref-type="bibr">71</xref>]. Both increased ACE2 and increased furin (a type-1-membrane-bound protease) have been associated with DM; both proteins are associated with entry of the SARS-CoV-2 virus and coronaviruses, respectively, into cells [<xref rid="pone.0304960.ref072" ref-type="bibr">72</xref>,<xref rid="pone.0304960.ref073" ref-type="bibr">73</xref>]. It could therefore be deducted that DM predisposes to increased invasion of the respiratory system and worse respiratory outcomes [<xref rid="pone.0304960.ref071" ref-type="bibr">71</xref>]. Furthermore, ACE2 is not only found in the respiratory epithelium, but also in other organs, such as the renal cortex, liver, and the pancreas [<xref rid="pone.0304960.ref072" ref-type="bibr">72</xref>&#8211;<xref rid="pone.0304960.ref074" ref-type="bibr">74</xref>]. Invasion of the virus into cells leads to inflammation that could ultimately damage cells. In the case of diabetic patients, damage to the beta cells in the pancreas could further exacerbate underlying DM, and in those without DM, cause uncontrolled hyperglycemia, that further perpetuates a proinflammatory state that contributes to the cytokine storm which is associated with severe infections. These mechanisms would also account for hyperglycemia seen in non-diabetic COVID-19 patients [<xref rid="pone.0304960.ref070" ref-type="bibr">70</xref>,<xref rid="pone.0304960.ref072" ref-type="bibr">72</xref>].</p></sec><sec id="sec034"><title>Hypertension</title><p>According to an analysis of adults hospitalized with COVID-19 between December 2021 and April 2022, hypertension more than doubled the risk for hospitalization from the Omicron-variant of COVID-19 infection, even in the presence of full vaccination, including a booster dose of the COVID-19 vaccines. Our study had a population prevalence of hypertension of 67.4%, and the intermediate group had the greatest prevalence at 77.8%, although this was not statistically different from the favorable or poor groups. Studies have also found that hypertension has the greatest risk for hospitalization when compared with other comorbidities [<xref rid="pone.0304960.ref075" ref-type="bibr">75</xref>]. Another study showed that hypertension, along with diabetes and cardiovascular disease were the most common comorbidities in their COVID-19 population, and hypertension trended in association with disease severity(p = 0.085) [<xref rid="pone.0304960.ref076" ref-type="bibr">76</xref>]. Other studies have shown that hypertension was associated with greater infection severity, and that hypertensive compared with normotensive patients had a greater incidence of ICU admissions, necessity for mechanical ventilation, and mortality [<xref rid="pone.0304960.ref010" ref-type="bibr">10</xref>]. One of the major pathophysiological mechanisms suggested for the association of hypertension with worse outcomes in COVID-19, is based on the renin-angiotensin-aldosterone system(RAS). This system ultimately leads to elevated blood pressure, increased fibrosis, increased inflammation, and increased production of reactive oxygen species [<xref rid="pone.0304960.ref077" ref-type="bibr">77</xref>]. Renin is produced by the juxtaglomerular cells of the kidneys; renin converts angiotensinogen to angiotensin I(Ang I), which is cleaved into Angiotensin II (Ang II) by angiotensin converting enzyme (ACE) in the lungs. Ang II is the main effector of the RAS system and leads to the effects previously mentioned after binding angiotensin II type 1 receptors (AT<sub>1</sub>R) [<xref rid="pone.0304960.ref078" ref-type="bibr">78</xref>]. The enzyme, angiotensin converting enzyme 2(ACE2) acts as a counter regulator of the RAS system [<xref rid="pone.0304960.ref079" ref-type="bibr">79</xref>]. This enzyme cleaves Ang II into angiotensin 1&#8211;7, which binds to the Mas receptor and results in increased activity of nitric oxide synthase, vasodilation, anti-inflammatory activity, and anti-fibrosis activity. These effects result in vasodilation, decreased blood pressure, and are ultimately cardioprotective [<xref rid="pone.0304960.ref080" ref-type="bibr">80</xref>]. ACE2 also cleaves a precursor of the RAS system, Ang I, into angiotensin 1&#8211;9, which binds to angiotensin II type 2 receptors (AT<sub>2</sub>R) and results in similar cardioprotective and vasodilatory effects like angiotensin 1&#8211;7 [<xref rid="pone.0304960.ref081" ref-type="bibr">81</xref>]. However, AT<sub>2</sub>R is sparse in adult human tissues, including cells of the cardiovascular system, which means that the major counter-regulatory mechanism against the RAS pathway within the pathway itself, is via ACE2 [<xref rid="pone.0304960.ref082" ref-type="bibr">82</xref>]. The significance of ACE2 within the pathophysiologic mechanism by which the severity of COVID-19 infection is elucidated in hypertensive patients, is seen by understanding how the SARS-CoV-2 virus enters cells via ACE2 [<xref rid="pone.0304960.ref019" ref-type="bibr">19</xref>]. After the binding of the SARS-CoV-2 virus via its spike protein to ACE2, the virus is internalized into the cells. This is followed by shedding of ACE2 from cell surface membranes, which ultimately results in decreased expression of ACE2 in tissues affected by SARS-CoV-2 virus [<xref rid="pone.0304960.ref083" ref-type="bibr">83</xref>,<xref rid="pone.0304960.ref084" ref-type="bibr">84</xref>]. The lack of a major component (i.e., ACE2) of the counter-regulatory mechanism of the RAS system, leads to poorly controlled blood pressures and pulmonary hypertension. These outcomes contribute to endothelial dysfunction and pulmonary oedema formation, with subsequent worsened pulmonary function and possible ARDS. These mechanisms can result in worse outcomes in COVID-19 infection [<xref rid="pone.0304960.ref085" ref-type="bibr">85</xref>].</p></sec><sec id="sec035"><title>Congestive heart failure</title><p>The prevalence of CHF in our study population was 15.7%. Patients who experienced in-hospital mortality had a greater prevalence(16%) of CHF than those who were intubated but did not experience in-hospital mortality (11.1%); however, neither this finding nor any of the intergroup comparisons were significant <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>. A metanalysis involving over 150,000 COVID-19 patients from 198 papers showed that CHF was associated with a &gt;11 times odds for mortality; this was greater than the odds associated with hypertension and other cardiovascular diseases [<xref rid="pone.0304960.ref086" ref-type="bibr">86</xref>]. Another metanalysis showed that the relative risk of death in COVID-19 patients with CHF was 3.38(95% confidence interval (CI) 1.80&#8211;6.32), indicating an association with severe COVID-19 infection and CHF [<xref rid="pone.0304960.ref087" ref-type="bibr">87</xref>]. Other studies have also shown CHF to be a strong risk for hospital admission, critical illness [<xref rid="pone.0304960.ref014" ref-type="bibr">14</xref>], mechanical ventilation, and mortality [<xref rid="pone.0304960.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0304960.ref088" ref-type="bibr">88</xref>&#8211;<xref rid="pone.0304960.ref090" ref-type="bibr">90</xref>]. Several pathophysiologic mechanisms have been suggested to explain poor outcomes seen in CHF patients with COVID-19 infection. One possible mechanism suggested is via myocardial damage, either directly or indirectly. These mechanisms culminate in exacerbation of underlying heart failure, worsening baseline oxygenation status, which in combination with the mechanisms by which the COVID-19 infection worsens oxygenation (i.e., ARDS), increases the requirement for respiratory support [<xref rid="pone.0304960.ref088" ref-type="bibr">88</xref>]. Fever from the infection may result in tachycardia that if sustained, could lead to decreased diastolic filling and stroke volumes, pushing a heart with underlying congestive problems into an acute exacerbation [<xref rid="pone.0304960.ref091" ref-type="bibr">91</xref>]. This resulting tachycardia can also lead to worsening of functional parameters in a failing heart, or to the development of new-onset heart failure via tachyarrhythmia-induced cardiomyopathy [<xref rid="pone.0304960.ref092" ref-type="bibr">92</xref>]. Examples of indirect mechanisms that have been suggested include the inflammatory milieu resulting from COVID-19 infection, which favors endothelial dysfunction, with resulting thrombotic manifestations, which may also include the pulmonary and coronary vasculature [<xref rid="pone.0304960.ref093" ref-type="bibr">93</xref>&#8211;<xref rid="pone.0304960.ref095" ref-type="bibr">95</xref>]. Such pathological mechanisms could lead to poor oxygenation of the myocardium, with resulting myocardial dysfunction that could subsequently push a congestive heart into acute exacerbation, worsening the baseline respiratory status, necessitating respiratory support.</p></sec><sec id="sec036"><title>Chronic lung disease, COPD, OSA</title><p>At the beginning of the COVID-19 pandemic, it was quickly hypothesized and supported by real-world data that patients with underlying lung disease were at increased risk for severe infection [<xref rid="pone.0304960.ref096" ref-type="bibr">96</xref>]. Our study shows a stepwise increase in the proportion of patients with CLD within each subsequent outcome group (19.6%, 27.8%, and 40.0%, respectively) (p = 0.002) <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>. These findings indicate a statistical association between the severity of COVID-19 infection and underlying CLD. Furthermore, although our study showed that the poor outcome group had the greatest prevalence of COPD(28.0%) compared with the intermediate(11.1%) or favorable (17.4%) groups, this finding was not significant. However, similar to the compiled group of CLD, OSA showed a stepwise increase in prevalence with each subsequent outcome group <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>. Other studies support our findings, and have specifically shown an increased risk for severe forms of COVID-19 infection in the presence of baseline CLD. Studies have shown that chronic lung disease was associated with an increased odds for requiring hospitalization, intensive care unit level of care, and in-hospital mortality [<xref rid="pone.0304960.ref097" ref-type="bibr">97</xref>&#8211;<xref rid="pone.0304960.ref100" ref-type="bibr">100</xref>]. Cade et al. showed an increased all-cause mortality in COVID-19 patients with OSA compared with controls without OSA (OR: 1.79, 95% CI 1.31&#8211;2.45; p&lt;0.001) [<xref rid="pone.0304960.ref101" ref-type="bibr">101</xref>]. Similar mortality trends in COVID-19 patients with OSA [<xref rid="pone.0304960.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0304960.ref102" ref-type="bibr">102</xref>], and COPD [<xref rid="pone.0304960.ref103" ref-type="bibr">103</xref>,<xref rid="pone.0304960.ref104" ref-type="bibr">104</xref>] have been shown by other studies. Poor outcomes in patients with OSA and COPD may been attributed to a baseline heightened inflammatory state [<xref rid="pone.0304960.ref105" ref-type="bibr">105</xref>], which is associated with increased oxidative stress and impaired immunity [<xref rid="pone.0304960.ref106" ref-type="bibr">106</xref>]. When this background of inflammation and impaired immunity is combined with the COVID-19 infection, an additive or synergistic effect may result, amplifying the cytokine storm associated with worse respiratory outcomes [<xref rid="pone.0304960.ref107" ref-type="bibr">107</xref>,<xref rid="pone.0304960.ref108" ref-type="bibr">108</xref>]. Another possible mechanism for poor outcomes in OSA patients with COVID-19 infection, is via vitamin D deficiency [<xref rid="pone.0304960.ref108" ref-type="bibr">108</xref>]. One study has shown that vitamin D levels are lower in patients with OSA [<xref rid="pone.0304960.ref109" ref-type="bibr">109</xref>]. Vitamin D is associated with reducing oxidative stress, has anti-inflammatory activities, and is involved in regulating cellular immunity including antiviral immunity [<xref rid="pone.0304960.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0304960.ref110" ref-type="bibr">110</xref>]. A deficiency of vitamin D may predispose to worse outcomes; this is supported by studies in which vitamin D deficiency was associated with ICU admission and mortality in COVID-19 infection [<xref rid="pone.0304960.ref031" ref-type="bibr">31</xref>]. OSA is also associated with elevated levels of angiotensin II and aldosterone [<xref rid="pone.0304960.ref111" ref-type="bibr">111</xref>]. As previously elaborated earlier in this manuscript, ACE2, the membrane-bound enzyme by which the SARS-CoV-2 virus enters cells, is also a counter-regulator of the RAS system. ACE2 cleaves Ang II into angiotensin 1&#8211;7, a molecule which results in vasodilation and has anti-inflammatory, antifibrosis and cardioprotective effects [<xref rid="pone.0304960.ref079" ref-type="bibr">79</xref>,<xref rid="pone.0304960.ref080" ref-type="bibr">80</xref>]. It may be suggested that an elevation of Ang II in a setting where ACE2 becomes diminished due to shedding from the cell surface after binding the SARS-CoV-2 virus [<xref rid="pone.0304960.ref083" ref-type="bibr">83</xref>,<xref rid="pone.0304960.ref084" ref-type="bibr">84</xref>], leads to an imbalance of the RAS system, veered towards the Ang II pathway, which may exacerbate systemic and pulmonary hypertension, with resulting cardiotoxic effects and respiratory compromise [<xref rid="pone.0304960.ref085" ref-type="bibr">85</xref>]. There is no single pathophysiological pathway by which chronic lung diseases increase the risks of poor outcomes in COVID-19 infection, but rather multiple mechanisms working in concert.</p></sec><sec id="sec037"><title>Smoking history</title><p>Our study reveals a notable trend in which the poor outcome group had the greatest prevalence of a smoking history; however, there were no differences in outcomes when current versus former smokers were compared <xref rid="pone.0304960.t002" ref-type="table">Table 2</xref>. Other studies show greater mortality in smokers than non-smokers [<xref rid="pone.0304960.ref112" ref-type="bibr">112</xref>&#8211;<xref rid="pone.0304960.ref114" ref-type="bibr">114</xref>], and a higher risk of severe disease and mortality in current smokers than in former smokers, unlike our study [<xref rid="pone.0304960.ref115" ref-type="bibr">115</xref>]. The mechanisms suggested to explain this increased risk of poor outcomes, include an increased baseline inflammatory state in smokers, which increases oxidative stress with resulting immune dysfunction. This combination of increased inflammatory cytokine and immune dysfunction creates a fertile background for poorly controlled invasion and proliferation of the SAR-CoV2 virus [<xref rid="pone.0304960.ref116" ref-type="bibr">116</xref>,<xref rid="pone.0304960.ref117" ref-type="bibr">117</xref>]. In addition to the poor respiratory reserve found in patients with a smoking history, the elaborated pro-inflammatory state created by the COVID-19 infection may lead to ARDS, necessitating respiratory support, and may eventually lead to death [<xref rid="pone.0304960.ref112" ref-type="bibr">112</xref>].</p></sec></sec><sec id="sec038"><title>Hospital course in severe COVID-10</title><sec id="sec039"><title>Markers of liver injury</title><p>Aminotransferases were most greatly elevated in the poor outcome group in our study. While these findings were significant for aspartate amino transferase(AST), they only trended for alanine aminotransferase(ALT) <xref rid="pone.0304960.t004" ref-type="table">Table 4</xref>. Bloom et al showed that patients who underwent intubation had on average, greater peak AST and ALT values than those who were not intubated [<xref rid="pone.0304960.ref118" ref-type="bibr">118</xref>]. Similar to other studies [<xref rid="pone.0304960.ref118" ref-type="bibr">118</xref>], the pattern of enzyme elevation in our study was consistent with hepatocellular injury. Another study showed that a greater proportion of patients with AST and ALT values greater than the upper limit of normal experienced the primary composite outcomes of ICU admission, mechanical ventilation, and death, than those with normal values [<xref rid="pone.0304960.ref119" ref-type="bibr">119</xref>]. Liu et al., further support the findings that those with severe COVID-19 infection have greater elevations in their AST and ALT levels, compared with those with non-severe disease; however, stratification was not done within the severe group, unlike our study [<xref rid="pone.0304960.ref120" ref-type="bibr">120</xref>]. Another study stratifies patients based ICU hospitalization versus non-ICU hospitalization, and show a greater median ALT in the former than the latter (49.0 U/L vs 27.0 U/L, p = 0.038), with similar findings for AST. (44.0 U/L vs34.0 U/L, p = 0.10). When the proportion of patients with AST&lt;40 was considered, there were more patients in the non-ICU group(75%) than the ICU group(38%), and this was significant(p = 0.025) [<xref rid="pone.0304960.ref121" ref-type="bibr">121</xref>].</p><p>These studies indicate a relationship between COVID-19 severity and markers of liver injury, specifically that more severe COVID-19 infection appears to be associated with greater increases in markers of liver injury. One plausible mechanism of liver injury in COVID-19 infection is direct invasion of liver cells by the virus via the ACE2 receptor (ACE2r), similar to invasion in the respiratory epithelium. RNA sequencing studies have shown that hepatocytes express ACE2rs [<xref rid="pone.0304960.ref122" ref-type="bibr">122</xref>], however poorly so (about 3% expression), compared to cholangiocytes with almost 60% expression [<xref rid="pone.0304960.ref123" ref-type="bibr">123</xref>]. While Chai et al have suggested that liver injury may occur via cholangiocyte injury, a specific mechanism was not suggested [<xref rid="pone.0304960.ref123" ref-type="bibr">123</xref>]. Both murine studies and human tissue studies have depicted an increase in ACE2r expression following liver injury and cirrhosis [<xref rid="pone.0304960.ref124" ref-type="bibr">124</xref>,<xref rid="pone.0304960.ref125" ref-type="bibr">125</xref>]. Findings suggest that the upregulation of ACE2r was secondary to compensatory proliferation of hepatocytes that were derived from bile duct epithelial cells [<xref rid="pone.0304960.ref126" ref-type="bibr">126</xref>]. It could be deducted that an initial liver insult results in upregulation of ACE2r, which may subsequently create an environment that supports greater invasion and pronounced hepatocyte injury by the SARVS-CoV2 virus, although such a hypothesis has not been proven. Nonetheless, given the low expression of ACE2rs in liver cells, the origin of the initial insult in COVID-19 infection, if such a hypothesis is to be considered, must be postulated.</p><p>Besides the ACE2r, it has been shown that the SARS-CoV-2 virus is also able to invade cells via different receptors, specifically the dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin(DC-SIGN), which is a transmembrane adhesion molecule found on dendritic cells [<xref rid="pone.0304960.ref127" ref-type="bibr">127</xref>,<xref rid="pone.0304960.ref128" ref-type="bibr">128</xref>]. SARS-CoV-2 along with other viruses including HIV-1 and CMV can enter dendritic cells via this molecule. The virus is subsequently hypothesized to avoid antigen processing within dendritic cells, but instead uses these cells as a transportation route to tissues where they can invade and institute an infection [<xref rid="pone.0304960.ref127" ref-type="bibr">127</xref>,<xref rid="pone.0304960.ref128" ref-type="bibr">128</xref>]. Similar transmembrane molecules have been described in human liver cells and are known as liver/lymph node-specific intercellular adhesion molecule-grabbing nonintegrin(L-SIGN). These liver transmembrane molecules can equally facilitate the entry of the virus into hepatocytes [<xref rid="pone.0304960.ref128" ref-type="bibr">128</xref>,<xref rid="pone.0304960.ref129" ref-type="bibr">129</xref>]. Although it has not been shown that the virus can replicate after entry via L-SIGN, it is reasonable to assume that an initial injury may occur to hepatocytes via this route, with subsequent ACE2r upregulation that exacerbates liver injury. The differential response in liver injury in patients may be associated with genetic differences and polymorphisms in the aforementioned receptors. Studies have suggested that liver injury occurring in the presence of COVID-19 infection may likely be caused by cytokine storm syndrome(CSS) and drug-induced liver injury. CSS is a state in which an infectious or non-infectious insult leads to the proliferation of immune cells of the innate and adaptive systems, with subsequent elaboration of cytokines that mediate increased inflammation with associated organ dysfunction. It has been suggested that slight genetic polymorphisms in receptors involved in cytokine function and effect may be responsible for differential manifestations of CSS, or the lack thereof, in patients exposed to similar insulting stimuli [<xref rid="pone.0304960.ref130" ref-type="bibr">130</xref>]. In CSS, the resulting immune cells attack tissue cells leading to apoptosis and necrosis, with resulting organ dysfunction and an exacerbated inflammatory process [<xref rid="pone.0304960.ref131" ref-type="bibr">131</xref>]. Hypoxia-induced liver injury is also one of the mechanisms that has been postulated, given as COVID-19, especially severe disease, leads to acute hypoxic respiratory failure. Hepatocyte hypoxia further exacerbates inflammation that perpetuates liver damage [<xref rid="pone.0304960.ref131" ref-type="bibr">131</xref>,<xref rid="pone.0304960.ref132" ref-type="bibr">132</xref>]. The mechanisms of liver injury in COVID-19 infection appear to be multifactorial, and more severe disease appears to be associated with greater elevations in liver enzymes.</p></sec><sec id="sec040"><title>AKI</title><p>Our study shows a progressive increase in the prevalence of AKI in each subsequent outcome group, with a general population incidence of 9%. AKI occurred in 4.3%, 5.6% and 20.0% of each subsequent outcome group respectively, although these findings were not significant. Cheng et al also showed an association between AKI and in-hospital mortality [<xref rid="pone.0304960.ref062" ref-type="bibr">62</xref>], as did Richardson et al [<xref rid="pone.0304960.ref007" ref-type="bibr">7</xref>]. Other studies have shown that AKI was more prevalent in patients who required ICU care than those who did not [<xref rid="pone.0304960.ref002" ref-type="bibr">2</xref>]. One possible mechanism suggested for the occurrence of AKI in COVID-19 infection involves the attenuation of the ACE2 receptors (ACE2rs) in the kidneys. Studies have shown that ACE2rs are present in the kidneys [<xref rid="pone.0304960.ref133" ref-type="bibr">133</xref>], and that SARS-CoV-2 is capable of invading renal cells [<xref rid="pone.0304960.ref134" ref-type="bibr">134</xref>&#8211;<xref rid="pone.0304960.ref138" ref-type="bibr">138</xref>]. As previously explained in this manuscript, SARS-CoV-2 enters cells via ACE2rs; binding to this receptor by the viral spike protein leads to endocytosis of the ACE2r with resultant decreased expression on cell surfaces. ACE2 cleaves Ag II into angiotensin 1&#8211;7, acting as a counter-regulator of the pro-inflammatory and pro-thrombotic effects of Ang II. It may be proposed that an attenuation of ACE2 after binding the virus in the kidneys may also institute similar inflammation and thrombotic complications similar to what occurs in the lungs, due to uninhibited Ang II, leading to kidney injury [<xref rid="pone.0304960.ref139" ref-type="bibr">139</xref>,<xref rid="pone.0304960.ref140" ref-type="bibr">140</xref>]. In addition to cleaving Ang II into angiotensin 1&#8211;7, ACE2 is also involved in cleaving an active product of the kinin-kallikrein system(KKS) [<xref rid="pone.0304960.ref141" ref-type="bibr">141</xref>]. The KKS involves the cleavage of high molecular weight kininogen into bradykinin and des-arg-973-bradykinin(DABK). Bradykinin is involved in causing vasodilation and decreasing blood pressure. DABK has been shown to be involved in promoting inflammation, including increasing capillary permeability, vasodilation, and leukocyte recruitment [<xref rid="pone.0304960.ref142" ref-type="bibr">142</xref>]. ACE2 breaks down DABK and therefore acts as a counter regulator of the DABK pathway [<xref rid="pone.0304960.ref143" ref-type="bibr">143</xref>]. In a situation when ACE2 is diminished, DABK can promote inflammation in a less inhibited manner. It can therefore be inferred that increased DABK in the pre-renal vasculature may lead to decreased renal perfusion and subsequent ischemic renal injury, which could lead to AKI. Similarly, within the renal vasculature, increased DABK may promote inflammation within the kidneys, which could also lead to AKI [<xref rid="pone.0304960.ref139" ref-type="bibr">139</xref>].</p><p>It has also been suggested that direct invasion of renal cells by the virus may lead to tubular cell damage with resulting acute tubular necrosis and AKI [<xref rid="pone.0304960.ref139" ref-type="bibr">139</xref>]. Other hypothesized mechanisms of renal injury in COVID-19 infection include the cytokine storm-mediated septic shock, with resultant renal hypoperfusion and hypoxia, which could lead to AKI [<xref rid="pone.0304960.ref139" ref-type="bibr">139</xref>]. Furthermore, hypoxia resulting from shock may also lead to non-traumatic rhabdomyolysis, as could direct invasion of skeletal muscles by the virus; these mechanisms could cause acute tubular necrosis [<xref rid="pone.0304960.ref139" ref-type="bibr">139</xref>]. Similar to other pathological consequences of COVID-19 infection, the mechanisms by which the virus is proposed to cause kidney injury are myriad.</p></sec><sec id="sec041"><title>Severe COVID-19 infection and respiratory parameters</title><p>Arterial blood gases and respiratory indices are important to monitor patient status, determine need for assisted ventilation, and predict outcomes in COVID-19. Our results show that differences in average PaCO2, PaO2 and pH are associated with prognostic outcomes.</p><p>The average PaCO2 for the entire study population was within normal limits at 41.4mmHg; however, only the poor outcome group had an average PaCO2 level that was greater than the upper limit of normal (46.4mmHg). In a similar manner, the poor outcome group had the highest maximum PaCO2 compared to the other outcome groups. The inflammation resulting from COVID-19 infection leads to increased vascular permeability in the pulmonary vasculature, increasing the alveolar-capillary membrane, resulting in decreased gas diffusion across this membrane and subsequent CO2 retention and poor oxygen uptake [<xref rid="pone.0304960.ref144" ref-type="bibr">144</xref>]. It follows that more severe infection would lead to greater extravasation from the pulmonary vasculature, greater pulmonary edema, and a greater barrier to diffusion of gases [<xref rid="pone.0304960.ref144" ref-type="bibr">144</xref>]. Studies have also shown abnormal shunting of pulmonary perfusion to poorly ventilated lung areas, exacerbating hypoxia in the already inflamed lungs [<xref rid="pone.0304960.ref145" ref-type="bibr">145</xref>]. Studies have indicated that hypercapnia early in the course of admission might be indicative of severe ARDS, requiring ICU care [<xref rid="pone.0304960.ref146" ref-type="bibr">146</xref>]. Other studies have linked hypercapnia to the occurrence of thromboembolic events, longer mechanical ventilation, ICU stay, and longer length of hospital stay. Furthermore, hypercapnia has been associated with comorbidities including COPD and increased BMI above normal limits; however, mortality was not increased in hypercapnic, compared with normocapnic patients [<xref rid="pone.0304960.ref146" ref-type="bibr">146</xref>,<xref rid="pone.0304960.ref147" ref-type="bibr">147</xref>]. These results differ from our study regarding mortality, in that the group that experienced in-hospital mortality had the greatest average and maximum PaCO2 than the other outcome groups, and this was a significant finding. The comorbidities associated with hypercapnia, including COPD and obesity, have been discussed earlier in this manuscript. It has been suggested that hypercapnia has both beneficial effects, such as reduction of oxidative stress and promoting oxygenation, and also deleterious effects; the net result effect depends on the balance of effects [<xref rid="pone.0304960.ref148" ref-type="bibr">148</xref>]. Such a hypothesis may explain why certain studies show a net non-mortality effect, while others like ours show a statistical association with mortality [<xref rid="pone.0304960.ref149" ref-type="bibr">149</xref>,<xref rid="pone.0304960.ref150" ref-type="bibr">150</xref>]. Nonetheless, it is unclear which factors drive the balance in either direction.</p><p>Moreover, our results show a statistically significant association between lower blood pH and worse outcomes <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. These findings agree with previous studies [<xref rid="pone.0304960.ref151" ref-type="bibr">151</xref>]. Lower recorded pH values may be secondary to carbon dioxide accumulation, which is also shown to be greatest in the poor outcome/in-hospital mortality group in our study <xref rid="pone.0304960.t005" ref-type="table">Table 5</xref>. Acidosis may also be associated with worse inflammation with resulting tissue hypoxia and lactic acidosis, all of which are associated with poorer outcomes in severe COVID-19 infection [<xref rid="pone.0304960.ref152" ref-type="bibr">152</xref>]. Although our study shows no statistical association between average oxygen saturation on admission and outcome groups, other studies have associated lower admission oxygen saturation with poor outcomes which include increased mortality [<xref rid="pone.0304960.ref153" ref-type="bibr">153</xref>], and increased requirement for ICU care [<xref rid="pone.0304960.ref154" ref-type="bibr">154</xref>]. These findings suggest that admission oxygen saturation may be a predictor of ICU level care during admission, although our study did not make such a distinction [<xref rid="pone.0304960.ref154" ref-type="bibr">154</xref>].</p></sec></sec><sec id="sec042"><title>Medications</title><sec id="sec043"><title>Hydroxychloroquine</title><p>Approximately 4&#8211;5% of patients in each outcome group received hydroxychloroquine during admission, and there were no significant differences between the outcome groups and hydroxychloroquine exposure in our study. In a randomized trial of 491 patients, at 14 days, there were no differences in symptoms experienced by patients in the hydroxychloroquine group versus the placebo group. While 24% of participants receiving hydroxychloroquine had ongoing symptoms, 30% receiving placebo experienced symptoms(p = 0.21). This trial concluded that hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19 [<xref rid="pone.0304960.ref155" ref-type="bibr">155</xref>]. Another retrospective study involving data collected from 6 continents including North and South America, Europe, Africa, Asia, and Australia, showed that hydroxychloroquine was administered more often in the group that experienced in-hospital mortality(5.1%), than in the survival group(2.9%); hazard ratio(HR):1.335, 95% CI 1.223&#8211;1.457 [<xref rid="pone.0304960.ref156" ref-type="bibr">156</xref>]. Multiple studies have provided contradicting results regarding the efficacy of hydroxychloroquine in COVID-19 infection and outcomes, with some studies supporting efficacy [<xref rid="pone.0304960.ref157" ref-type="bibr">157</xref>,<xref rid="pone.0304960.ref158" ref-type="bibr">158</xref>], and others showing a lack of efficacy and increased adverse effects with hydroxychloroquine regimens [<xref rid="pone.0304960.ref159" ref-type="bibr">159</xref>&#8211;<xref rid="pone.0304960.ref162" ref-type="bibr">162</xref>]. The mechanisms suggested to be involved in the antiviral activities of hydroxychloroquine include its ability to decrease the elaboration of pro-inflammatory cytokines, by inhibiting antigen presentation by antigen presenting cells, including B cells. Another mechanism involves the glycosylation of the ACE2 receptors, which inhibits the binding of the viral spike protein to the receptor, thereby inhibiting viral invasion [<xref rid="pone.0304960.ref163" ref-type="bibr">163</xref>,<xref rid="pone.0304960.ref164" ref-type="bibr">164</xref>]. There is currently not enough evidence to support, or definitively refute the efficacy of hydroxychloroquine in COVID-19 infection.</p></sec><sec id="sec044"><title>Tocilizumab</title><p>In our study, approximately 30% of patients in each subgroup received tocilizumab, and there were no statistical differences between subgroups. Another retrospective study of 1,938 patients with confirmed SARS-CoV-2 pneumonia found that patients who received tocilizumab experienced more inpatient mortality(26.1% vs 13.2%), higher ICU admission rates(56.4% vs. 20.7%), and increased rate of mechanical ventilation (33.6% vs. 11.4%), compared with the patient population that did not receive tocilizumab treatment. This study concluded that tocilizumab did not improve inpatient mortality rate for COVID-19 patients [<xref rid="pone.0304960.ref165" ref-type="bibr">165</xref>]. Martinez-Sanz et al., showed similar results, in that ICU admission (19% vs 3%), overall mortality (23% vs 12%), and ICU mortality (32% vs 19%) was greater in the group that received tocilizumab. Tocilizumab was associated with a higher risk of death in the initial analysis (HR 1.53, 95% CI 1.20&#8211;1.96, p = 0.001). However, when their study cohort was stratified by CRP levels (&lt;150 vs &gt;150), tocilizumab was associated with a decreased rate of death than in the population who did not receive tocilizumab (HR 0.34, 95% CI 0.17&#8211;0.71, p = 0.005) [<xref rid="pone.0304960.ref166" ref-type="bibr">166</xref>]. Studies showing a positive association between tocilizumab and ICU admission or mortality, may indicate that a high-risk group of patients were being selected; specifically, these patients had severe disease that was not responding to standard of care treatment, necessitating the addition of supplemental therapy. Other studies have shown tocilizumab to be associated with improved survival [<xref rid="pone.0304960.ref167" ref-type="bibr">167</xref>&#8211;<xref rid="pone.0304960.ref170" ref-type="bibr">170</xref>]. The most up to date consensus appears to suggest that tocilizumab is beneficial in reducing mortality; however, in our study that selected severe COVID-19 patients, tocilizumab was similarly administered in all outcome groups, and there was no statistical association with mortality.</p></sec><sec id="sec045"><title>Baricitinib</title><p>In our study, baricitinib was statistically associated with the poor outcome group Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. According to a meta-analysis of 52 studies of which 4 studies were randomized controlled trials, baricitinib significantly reduced mortality and disease progression in the patient population treated with a dosage of 2&#8201;mg or 4&#8201;mg, for a maximum duration of 14 days of baricitinib [<xref rid="pone.0304960.ref171" ref-type="bibr">171</xref>]. These findings are supported by another meta-analysis in which a pooled analysis showed a statistically significant reduction in 28-day mortality in the baricitinib arm, compared to the standard of care arm (OR 0.69, 95% CI 0.50&#8211;0.95, p = 0.04) [<xref rid="pone.0304960.ref172" ref-type="bibr">172</xref>]. Despite this portrayed improved mortality, progression to respiratory failure requiring positive pressure ventilation, and progression to invasive ventilation or extracorporeal membrane oxygenation appeared to be greater in the baricitinib group than the standard of care group [<xref rid="pone.0304960.ref172" ref-type="bibr">172</xref>]. In another non-controlled retrospective cohort study on moderate-to-severe infection, baricitinib was temporally associated with clinical improvement and recovery [<xref rid="pone.0304960.ref173" ref-type="bibr">173</xref>]. The mechanism of action behind the improved outcomes with baricitinib administration is associated with the reduction of the cytokine storm associated with severe cases of COVID-19 infection [<xref rid="pone.0304960.ref174" ref-type="bibr">174</xref>,<xref rid="pone.0304960.ref175" ref-type="bibr">175</xref>]. Although our study showed a statistical association between baricitinib and poor outcomes, specifically in-hospital mortality, this might be an effect of late administration in patients in whom outcomes would have been poor regardless of the drug administered, although we have not explored such an effect in this study.</p></sec><sec id="sec046"><title>Azithromycin</title><p>Although a greater proportion of patients in each subsequent outcome group was administered azithromycin, there were no statistical differences(p = 0.268), Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. Azithromycin is a broad-spectrum macrolide antibiotic with anti-inflammatory properties, which appear to be the basis for consideration in COVID-19 treatment [<xref rid="pone.0304960.ref176" ref-type="bibr">176</xref>,<xref rid="pone.0304960.ref177" ref-type="bibr">177</xref>]. Some studies have also indicated in-vitro antiviral activity [<xref rid="pone.0304960.ref178" ref-type="bibr">178</xref>], including against RNA viruses such as Zika, rhinovirus and SARS-CoV-2 [<xref rid="pone.0304960.ref179" ref-type="bibr">179</xref>,<xref rid="pone.0304960.ref180" ref-type="bibr">180</xref>]. Despite these proposed beneficial effects of azithromycin in-vitro, real life studies have not shown such effects. A randomize trial by Furtado et al concluded that azithromycin added to standard of care treatment did not have any beneficial effects including on mortality, need for ventilation, or other clinical status [<xref rid="pone.0304960.ref181" ref-type="bibr">181</xref>]. Similarly, Cavalcanti et al did not show any improved outcomes when azithromycin was added to hydroxychloroquine and compared against standard of care. Rather, adverse events appeared to be more prevalent in the azithromycin group [<xref rid="pone.0304960.ref162" ref-type="bibr">162</xref>]. Other studies also support the notion that azithromycin neither results in clinical improvement nor reduce the risk of poor outcomes [<xref rid="pone.0304960.ref182" ref-type="bibr">182</xref>&#8211;<xref rid="pone.0304960.ref184" ref-type="bibr">184</xref>], similar to the findings in our study.</p></sec><sec id="sec047"><title>Dexamethasone</title><p>Patients in the poor outcome group had a significantly longer average number of days on dexamethasone than the other outcome groups (p = 0.002) Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. Although during the early phases of the pandemic the use of glucocorticoids was controversial [<xref rid="pone.0304960.ref185" ref-type="bibr">185</xref>], dexamethasone has now become a staple in the standard of care treatment for COVID-19 infection, especially in moderate-to-severe infections, owing to multiple studies supporting improved mortality and clinical outcomes when glucocorticoids are administered [<xref rid="pone.0304960.ref186" ref-type="bibr">186</xref>&#8211;<xref rid="pone.0304960.ref192" ref-type="bibr">192</xref>].</p><p>Although Chaudhuri et al have suggested that longer duration of low-dose glucocorticoids is associated with improved survival [<xref rid="pone.0304960.ref193" ref-type="bibr">193</xref>], our study shows a clear and statistically significant pattern in which a greater number of days on high-dose dexamethasone was associated with worse outcomes. Whether this finding might have arisen due to the inherent detrimental effects of prolonged glucocorticoid exposure, or prolongation of treatment in very sick patients that showed no signs of improvement, is unclear and not explored by our study. However, studies have indicated that prolonged glucocorticoid therapy [<xref rid="pone.0304960.ref194" ref-type="bibr">194</xref>], and late administration during the course of severe COVID-19 infection [<xref rid="pone.0304960.ref195" ref-type="bibr">195</xref>] may be associated with increased mortality. Autopsy findings have confirmed the prothrombotic state involved in COVID-19 infection; specifically, autopsy studies have shown large vessel thrombi and microthrombi in infected patients [<xref rid="pone.0304960.ref196" ref-type="bibr">196</xref>]. Glucocorticoids have also been shown to have prothrombotic effects by increasing clotting factors and fibrinogen concentration [<xref rid="pone.0304960.ref197" ref-type="bibr">197</xref>,<xref rid="pone.0304960.ref198" ref-type="bibr">198</xref>]. The combination of a prothrombotic inflammatory state created by COVID-19 infection, and prolonged exposure to prothrombotic glucocorticoids, may exacerbated microthrombi and large vessel thrombi leading to worse outcomes [<xref rid="pone.0304960.ref199" ref-type="bibr">199</xref>]. Therefore, the duration of glucocorticoid treatment in severe COVID-19 infection may be relevant to outcomes, as has been indicated by our study.</p></sec><sec id="sec048"><title>Angiotensin converting enzyme inhibitors(ACEi)/Angiotensin receptor blockers(ARB)</title><p>While patients who experienced in-hospital mortality had the smallest prevalence of ARB and ACEi use during admission, this finding was not statistically significant Table 6 in <xref rid="pone.0304960.s001" ref-type="supplementary-material">S1 Table</xref>. Some studies have suggested that ACE inhibition leads to a lack of Ang II, which in turn upregulates ACE2 receptors (ACE2r), which ultimately promotes anti-inflammation and anti-fibrinolysis via Angiotensin 1&#8211;7, as previously discussed in this manuscript [<xref rid="pone.0304960.ref200" ref-type="bibr">200</xref>]. Other authors have suggested disruption of the RAS pathway by ACEi, or ARBs leads to a disruption of the ACE2/Angiotensin 1-7/MAS pathway, with resultant decreased ACE2, and subsequently decreased viral entry into cells [<xref rid="pone.0304960.ref201" ref-type="bibr">201</xref>]. Such a hypothesis is supported by murine models which showed that ACE2 knockout mice had significantly lower viral replication and less lung injury after infection with SARS-CoV-1, compared with wild type mice [<xref rid="pone.0304960.ref085" ref-type="bibr">85</xref>]. Feng et al showed that administration of ACEi/ARBs as antihypertensives was more prevalent in moderate disease than severe and critical disease [<xref rid="pone.0304960.ref202" ref-type="bibr">202</xref>]. Other studies also support the greater prevalence of ACEi/ARBs administration in less severe disease including less inflammation and lower mortality [<xref rid="pone.0304960.ref203" ref-type="bibr">203</xref>&#8211;<xref rid="pone.0304960.ref206" ref-type="bibr">206</xref>]. In contrast, a meta-analysis of 53 studies showed no association between mortality and COVID-19 severity, and ACEi/ARB use [<xref rid="pone.0304960.ref207" ref-type="bibr">207</xref>]. There appears to be no general consensus regarding the use of ACEi/ARB in setting of COVID-19; it is therefore the job of the clinician to weigh the risks and benefits while taking into consideration underlying comorbidities, acute organ dysfunctions, and hemodynamic status, to determine whether or not the use of ACEi/ARBs during admission for severe COVID-19 disease is imperative.</p></sec></sec></sec><sec id="sec049"><title>Study limitations</title><p>Our study was limited by several factors. First, our population was very homogenous with regard to race and ethnicity. While other studies have shown a racial and ethnic distribution regarding COVID outcomes, we were not able to test similar findings in our population, owing to a greater than 90% Caucasian make-up of our population. Furthermore, our study was limited to a specific geographic location within the Geisinger health system; COVID-19 outcomes might differ based on geography within the US and this is an aspect of the infection that we were unable to test. Our sample size was small, especially after stratifying patients into 3 separate outcome groups. Some trends according to outcome groups were shown by our study but a level of statistical significance was not reached for some variables.</p><sec sec-type="conclusions" id="sec050"><title>Conclusion</title><p>Our study showed statistical associations between specific outcome groups in severe COVID-19 infection and clinical variables. In a homogenous study population with severe COVID-19 infection, in-hospital mortality was more prevalent in males than females. Chronic lung disease, obstructive sleep apnea and a history of smoking were associated with in-hospital mortality. Bacterial pneumonia was associated with invasive mechanical ventilation. Average albumin was lowest in patients who were never invasively ventilated. Average AST was greatest in patients who experienced in-hospital mortality. Although average ALT was also greatest in the in-hospital mortality group, this finding was statistically insignificant. Average bilirubin, average lactate, average PaCO2 and maximum PaCO2 were greatest in the in-hospital mortality group. Average CRP was greatest in the combined group of patients who underwent invasive mechanical ventilation and in-hospital mortality. Although AKI was more prevalent in the in-hospital mortality group, this was not a significant finding. The in-hospital mortality group had the most acidotic average pH compared to the other 2 outcome groups. Baricitinib administration was most prevalent in the in-hospital mortality group, and the average number of days on dexamethasone was greatest in this group. Patients who were intubated with a good (i.e., non-mortality) outcome were intubated earlier during their hospital course, with an average difference of 135.6 hours, when compared with intubated patients with poor outcomes.</p></sec></sec><sec id="sec051" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0304960.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 Table</label><caption><title>Post-hoc statistical power analysis.</title><p>(XLSX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0304960.s001.xlsx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACE2</term><def><p>angiotensin converting enzyme 2</p></def></def-item><def-item><term>ACEi</term><def><p>angiotensin converting enzyme inhibitor</p></def></def-item><def-item><term>AKI</term><def><p>acute kidney injury</p></def></def-item><def-item><term>ALP</term><def><p>alkaline phosphatase</p></def></def-item><def-item><term>ALT</term><def><p>alanine aminotransferase</p></def></def-item><def-item><term>Ang I</term><def><p>angiotensin I</p></def></def-item><def-item><term>Ang II</term><def><p>angiotensin II</p></def></def-item><def-item><term>ARB</term><def><p>angiotensin receptor blocker</p></def></def-item><def-item><term>ARDS</term><def><p>acute respiratory distress syndrome</p></def></def-item><def-item><term>AST</term><def><p>aspartate aminotransferase</p></def></def-item><def-item><term>AT<sub>1</sub>R</term><def><p>angiotensin II type 1 receptors</p></def></def-item><def-item><term>AT<sub>2</sub>R</term><def><p>angiotensin II type 2 receptors</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>BUN</term><def><p>blood urea nitrogen</p></def></def-item><def-item><term>CCI</term><def><p>Charlson comorbidity index</p></def></def-item><def-item><term>CHF</term><def><p>congestive heart failure</p></def></def-item><def-item><term>CKD</term><def><p>chronic kidney disease</p></def></def-item><def-item><term>CLD</term><def><p>chronic lung disease</p></def></def-item><def-item><term>COPD</term><def><p>chronic obstructive pulmonary disease</p></def></def-item><def-item><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term>CSS</term><def><p>cytokine storm syndrome</p></def></def-item><def-item><term>DABK</term><def><p>des-arg-973-bradykinin</p></def></def-item><def-item><term>DM2</term><def><p>diabetes mellitus type 2</p></def></def-item><def-item><term>ESR</term><def><p>erythrocyte sedimentation rate</p></def></def-item><def-item><term>HTN</term><def><p>hypertension</p></def></def-item><def-item><term>KKS</term><def><p>kinin-kallikrein system</p></def></def-item><def-item><term>OSA</term><def><p>obstructive sleep apnea</p></def></def-item><def-item><term>PCU</term><def><p>progressive care unit</p></def></def-item><def-item><term>RAS</term><def><p>renin-angiotensin-aldosterone system</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0304960.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Characteristics of lymphocyte subsets and cytokine profiles of patients with COVID-19.</article-title><source><italic toggle="yes">Virol J</italic>.</source><year>2022</year>;<volume>19</volume>(<issue>1</issue>):<fpage>57</fpage>. Published 2022 Mar 28. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12985-022-01786-2</pub-id><pub-id pub-id-type="pmid">35346253</pub-id><pub-id pub-id-type="pmcid">PMC8960102</pub-id></mixed-citation></ref><ref id="pone.0304960.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published correction appears in JAMA. 2021 Mar 16;325(11):1113].</article-title><source><italic toggle="yes">JAMA</italic></source>. <year>2020</year>;<volume>323</volume>(<issue>11</issue>):<fpage>1061</fpage>&#8211;<lpage>1069</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><pub-id pub-id-type="pmid">32031570</pub-id><pub-id pub-id-type="pmcid">PMC7042881</pub-id></mixed-citation></ref><ref id="pone.0304960.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ejaz</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Alsrhani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zafar</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 and comorbidities: Deleterious impact on infected patients.</article-title><source><italic toggle="yes">J Infect Public Health</italic></source>. <year>2020</year>;<volume>13</volume>(<issue>12</issue>):<fpage>1833</fpage>&#8211;<lpage>1839</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jiph.2020.07.014</pub-id><pub-id pub-id-type="pmid">32788073</pub-id><pub-id pub-id-type="pmcid">PMC7402107</pub-id></mixed-citation></ref><ref id="pone.0304960.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hariyanto</surname><given-names>TI</given-names></name>, <name name-style="western"><surname>Japar</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Kwenandar</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis.</article-title><source><italic toggle="yes">Am J Emerg Med</italic></source>. <year>2021</year>;<volume>41</volume>:<fpage>110</fpage>&#8211;<lpage>119</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajem.2020.12.076</pub-id><pub-id pub-id-type="pmid">33418211</pub-id><pub-id pub-id-type="pmcid">PMC7831442</pub-id></mixed-citation></ref><ref id="pone.0304960.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Guan</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2020</year>;<volume>55</volume>(<issue>5</issue>):<fpage>2000547</fpage>. Published 2020 May 14. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/13993003.00547-2020</pub-id><pub-id pub-id-type="pmid">32217650</pub-id><pub-id pub-id-type="pmcid">PMC7098485</pub-id></mixed-citation></ref><ref id="pone.0304960.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>507</fpage>&#8211;<lpage>513</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id><pub-id pub-id-type="pmcid">PMC7135076</pub-id></mixed-citation></ref><ref id="pone.0304960.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Richardson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hirsch</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Narasimhan</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [published correction appears in JAMA. 2020 May 26;323(20):2098].</article-title><source><italic toggle="yes">JAMA</italic></source>. <year>2020</year>;<volume>323</volume>(<issue>20</issue>):<fpage>2052</fpage>&#8211;<lpage>2059</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2020.6775</pub-id><pub-id pub-id-type="pmid">32320003</pub-id><pub-id pub-id-type="pmcid">PMC7177629</pub-id></mixed-citation></ref><ref id="pone.0304960.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zuin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rigatelli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zuliani</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Rigatelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mazza</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Roncon</surname><given-names>L</given-names></name>. <article-title>Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis.</article-title><source><italic toggle="yes">J Infect</italic>.</source><year>2020</year>;<volume>81</volume>(<issue>1</issue>):<fpage>e84</fpage>&#8211;<lpage>e86</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.059</pub-id><pub-id pub-id-type="pmid">32283158</pub-id><pub-id pub-id-type="pmcid">PMC7151373</pub-id></mixed-citation></ref><ref id="pone.0304960.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cariou</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Hadjadj</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wargny</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pichelin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Al-Salameh</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Allix</surname><given-names>I.</given-names></name>, <etal>et al</etal> (<year>2020</year>). <article-title>Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study</article-title>. <source><italic toggle="yes">Diabetologia</italic></source>, <volume>63</volume>(<issue>8</issue>), <fpage>1500</fpage>&#8211;<lpage>1515</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00125-020-05180-x</pub-id><pub-id pub-id-type="pmid">32472191</pub-id><pub-id pub-id-type="pmcid">PMC7256180</pub-id></mixed-citation></ref><ref id="pone.0304960.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Guan</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>ZY</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2020</year>;<volume>382</volume>(<issue>18</issue>):<fpage>1708</fpage>&#8211;<lpage>1720</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id><pub-id pub-id-type="pmcid">PMC7092819</pub-id></mixed-citation></ref><ref id="pone.0304960.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital.</article-title><source><italic toggle="yes">Clin Microbiol Infect</italic></source>. <year>2020</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1063</fpage>&#8211;<lpage>1068</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cmi.2020.03.032</pub-id><pub-id pub-id-type="pmid">32251842</pub-id><pub-id pub-id-type="pmcid">PMC7195539</pub-id></mixed-citation></ref><ref id="pone.0304960.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Simonnet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chetboun</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Poissy</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation [published correction appears in Obesity (Silver Spring). 2020 Oct;28(10):1994]</article-title>. <source><italic toggle="yes">Obesity (Silver Spring)</italic>.</source><year>2020</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1195</fpage>&#8211;<lpage>1199</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/oby.22831</pub-id><pub-id pub-id-type="pmid">32271993</pub-id><pub-id pub-id-type="pmcid">PMC7262326</pub-id></mixed-citation></ref><ref id="pone.0304960.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Grasselli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zangrillo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zanella</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy [published correction appears in JAMA. 2021 May 25;325(20):2120].</article-title><source><italic toggle="yes">JAMA</italic></source>. <year>2020</year>;<volume>323</volume>(<issue>16</issue>):<fpage>1574</fpage>&#8211;<lpage>1581</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2020.5394</pub-id><pub-id pub-id-type="pmid">32250385</pub-id><pub-id pub-id-type="pmcid">PMC7136855</pub-id></mixed-citation></ref><ref id="pone.0304960.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Petrilli</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2020</year>;<volume>369</volume>:<fpage>m1966</fpage>. Published 2020 May 22. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.m1966</pub-id><pub-id pub-id-type="pmid">32444366</pub-id><pub-id pub-id-type="pmcid">PMC7243801</pub-id></mixed-citation></ref><ref id="pone.0304960.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Haitao</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Vermunt</surname><given-names>JV</given-names></name>, <name name-style="western"><surname>Abeykoon</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 and Sex Differences: Mechanisms and Biomarkers</article-title>. <source><italic toggle="yes">Mayo Clin Proc</italic></source>. <year>2020</year>;<volume>95</volume>(<issue>10</issue>):<fpage>2189</fpage>&#8211;<lpage>2203</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.mayocp.2020.07.024</pub-id><pub-id pub-id-type="pmid">33012349</pub-id><pub-id pub-id-type="pmcid">PMC7402208</pub-id></mixed-citation></ref><ref id="pone.0304960.ref016"><label>16</label><mixed-citation publication-type="journal"><collab>GBD 2016 Alcohol Collaborators</collab>. <article-title>Alcohol use and burden for 195 countries and territories, 1990&#8211;2016: a systematic analysis for the Global Burden of Disease Study 2016 [published correction appears in Lancet.</article-title><source>2018 Sep 29;392(10153):1116] [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]. <italic toggle="yes">Lancet</italic>.</source><year>2018</year>;<volume>392</volume>(<issue>10152</issue>):<fpage>1015</fpage>&#8211;<lpage>1035</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31310-2</pub-id><pub-id pub-id-type="pmid">30146330</pub-id><pub-id pub-id-type="pmcid">PMC6148333</pub-id></mixed-citation></ref><ref id="pone.0304960.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Minutillo</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pacifici</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Scaravelli</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>De Luca</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Palmi</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Mortali</surname><given-names>C.</given-names></name>, <etal>et al</etal>. (<year>2016</year>). <article-title>Gender disparity in addiction: an Italian epidemiological sketch</article-title>. <source><italic toggle="yes">Annali dell&#8217;Istituto superiore di sanita</italic></source>, <volume>52</volume>(<issue>2</issue>), <fpage>176</fpage>&#8211;<lpage>183</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4415/ANN_16_02_08</pub-id><pub-id pub-id-type="pmid">27364391</pub-id></mixed-citation></ref><ref id="pone.0304960.ref018"><label>18</label><mixed-citation publication-type="journal"><collab>GBD 2015 Tobacco Collaborators</collab>. <article-title>Smoking prevalence and attributable disease burden in 195 countries and territories, 1990&#8211;2015: a systematic analysis from the Global Burden of Disease Study 2015 [published correction appears in Lancet. 2017 Oct 7;390(10103):1644].</article-title><source><italic toggle="yes">Lancet</italic></source>. <year>2017</year>;<volume>389</volume>(<issue>10082</issue>):<fpage>1885</fpage>&#8211;<lpage>1906</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(17)30819-X</pub-id><pub-id pub-id-type="pmid">28390697</pub-id><pub-id pub-id-type="pmcid">PMC5439023</pub-id></mixed-citation></ref><ref id="pone.0304960.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Vasilieva</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2003</year>;<volume>426</volume>(<issue>6965</issue>):<fpage>450</fpage>&#8211;<lpage>454</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id><pub-id pub-id-type="pmcid">PMC7095016</pub-id></mixed-citation></ref><ref id="pone.0304960.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Death</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>McGrath</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Sader</surname><given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway</article-title>. <source><italic toggle="yes">Endocrinology</italic></source>. <year>2004</year>;<volume>145</volume>(<issue>4</issue>):<fpage>1889</fpage>&#8211;<lpage>1897</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1210/en.2003-0789</pub-id><pub-id pub-id-type="pmid">14684616</pub-id></mixed-citation></ref><ref id="pone.0304960.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ghazizadeh</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Majd</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Richter</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men. Preprint</article-title>. <source><italic toggle="yes">bioRxiv</italic>.</source><year>2020</year>;<fpage>2020</fpage>.05.12.091082. Published 2020 May 15. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2020.05.12.091082</pub-id><pub-id pub-id-type="pmid">33232663</pub-id><pub-id pub-id-type="pmcid">PMC7670929</pub-id></mixed-citation></ref><ref id="pone.0304960.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Qin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan</article-title>. <source><italic toggle="yes">J Med Virol</italic></source>. <year>2020</year>;<volume>92</volume>(<issue>11</issue>):<fpage>2684</fpage>&#8211;<lpage>2692</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jmv.26137</pub-id><pub-id pub-id-type="pmid">32497297</pub-id><pub-id pub-id-type="pmcid">PMC7300463</pub-id></mixed-citation></ref><ref id="pone.0304960.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zeng</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Association of inflammatory markers with the severity of COVID-19: A meta-analysis</article-title>. <source><italic toggle="yes">Int J Infect Dis</italic></source>. <year>2020</year>;<volume>96</volume>:<fpage>467</fpage>&#8211;<lpage>474</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijid.2020.05.055</pub-id><pub-id pub-id-type="pmid">32425643</pub-id><pub-id pub-id-type="pmcid">PMC7233226</pub-id></mixed-citation></ref><ref id="pone.0304960.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Straub</surname><given-names>RH</given-names></name>. <article-title>The complex role of estrogens in inflammation</article-title>. <source><italic toggle="yes">Endocr Rev</italic></source>. <year>2007</year>;<volume>28</volume>(<issue>5</issue>):<fpage>521</fpage>&#8211;<lpage>574</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1210/er.2007-0001</pub-id><pub-id pub-id-type="pmid">17640948</pub-id></mixed-citation></ref><ref id="pone.0304960.ref025"><label>25</label><mixed-citation publication-type="journal"><collab><italic toggle="yes">Covid-19 provisional counts&#8212;health disparities</italic></collab> (<year>2022</year>) <source><italic toggle="yes">Centers for Disease Control and Prevention</italic>. Centers for Disease Control and Prevention.</source> Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/nvss/vsrr/covid19/health_disparities.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nvss/vsrr/covid19/health_disparities.htm</ext-link> (Accessed: December 11, 2022).</mixed-citation></ref><ref id="pone.0304960.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yancy</surname><given-names>CW</given-names></name>. <article-title>COVID-19 and African Americans</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>2020</year>;<volume>323</volume>(<issue>19</issue>):<fpage>1891</fpage>&#8211;<lpage>1892</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2020.6548</pub-id><pub-id pub-id-type="pmid">32293639</pub-id></mixed-citation></ref><ref id="pone.0304960.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Hannah</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Durbin</surname><given-names>JR</given-names></name>, <etal>et al</etal>. <article-title>Multivariate Analysis of Black Race and Environmental Temperature on COVID-19 in the US</article-title>. <source><italic toggle="yes">Am J Med Sci</italic></source>. <year>2020</year>;<volume>360</volume>(<issue>4</issue>):<fpage>348</fpage>&#8211;<lpage>356</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.amjms.2020.06.015</pub-id><pub-id pub-id-type="pmid">32709397</pub-id><pub-id pub-id-type="pmcid">PMC7305735</pub-id></mixed-citation></ref><ref id="pone.0304960.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mackey</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ayers</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>KK</given-names></name>, <etal>et al</etal>. <article-title>Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review</article-title>. <source><italic toggle="yes">Ann Intern Med</italic></source>. <year>2021</year>;<volume>174</volume>(<issue>3</issue>):<fpage>362</fpage>&#8211;<lpage>373</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7326/M20-6306</pub-id><pub-id pub-id-type="pmid">33253040</pub-id><pub-id pub-id-type="pmcid">PMC7772883</pub-id></mixed-citation></ref><ref id="pone.0304960.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038].</article-title><source><italic toggle="yes">Lancet</italic></source>. <year>2020</year>;<volume>395</volume>(<issue>10229</issue>):<fpage>1054</fpage>&#8211;<lpage>1062</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id><pub-id pub-id-type="pmcid">PMC7270627</pub-id></mixed-citation></ref><ref id="pone.0304960.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Baylin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>PD</given-names></name>. <article-title>Vitamin D deficiency and insufficiency among US adults: prevalence, predictors and clinical implications</article-title>. <source><italic toggle="yes">Br J Nutr</italic></source>. <year>2018</year>;<volume>119</volume>(<issue>8</issue>):<fpage>928</fpage>&#8211;<lpage>936</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1017/S0007114518000491</pub-id><pub-id pub-id-type="pmid">29644951</pub-id></mixed-citation></ref><ref id="pone.0304960.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chiodini</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Gatti</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Soranna</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes.</article-title><source><italic toggle="yes">Front Public Health</italic>.</source><year>2021</year>;<volume>9</volume>:<fpage>736665</fpage>. Published 2021 Dec 22. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fpubh.2021.736665</pub-id><pub-id pub-id-type="pmid">35004568</pub-id><pub-id pub-id-type="pmcid">PMC8727532</pub-id></mixed-citation></ref><ref id="pone.0304960.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chiu</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>CC</given-names></name>, <etal>et al</etal>. <article-title>Putative Role of Vitamin D for COVID-19 Vaccination.</article-title><source><italic toggle="yes">Int J Mol Sci</italic>.</source><year>2021</year>;<volume>22</volume>(<issue>16</issue>):<fpage>8988</fpage>. Published 2021 Aug 20. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms22168988</pub-id><pub-id pub-id-type="pmid">34445700</pub-id><pub-id pub-id-type="pmcid">PMC8396570</pub-id></mixed-citation></ref><ref id="pone.0304960.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Molenberghs</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Faes</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Verbeeck</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 mortality, excess mortality, deaths per million and infection fatality ratio, Belgium, 9 March 2020 to 28 June 2020.</article-title><source><italic toggle="yes">Euro Surveill</italic></source>. <year>2022</year>;<volume>27</volume>(<issue>7</issue>):<fpage>2002060</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2022.27.7.2002060</pub-id><pub-id pub-id-type="pmid">35177167</pub-id><pub-id pub-id-type="pmcid">PMC8855510</pub-id></mixed-citation></ref><ref id="pone.0304960.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Herrera-Esposito</surname><given-names>D</given-names></name>, <name name-style="western"><surname>de Los Campos</surname><given-names>G</given-names></name>. <article-title>Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies.</article-title><source><italic toggle="yes">BMC Infect Dis</italic>.</source><year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>311</fpage>. Published 2022 Mar 29. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12879-022-07262-0</pub-id><pub-id pub-id-type="pmid">35351016</pub-id><pub-id pub-id-type="pmcid">PMC8962942</pub-id></mixed-citation></ref><ref id="pone.0304960.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>O&#8217;Driscoll</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ribeiro Dos Santos</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Cummings</surname><given-names>D. A. T.</given-names></name>, <name name-style="western"><surname>Azman</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Paireau</surname><given-names>J.</given-names></name>, <etal>et al</etal>. (<year>2021</year>). <article-title>Age-specific mortality and immunity patterns of SARS-CoV-2</article-title>. <source><italic toggle="yes">Nature</italic></source>, <volume>590</volume>(<issue>7844</issue>), <fpage>140</fpage>&#8211;<lpage>145</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2918-0</pub-id><pub-id pub-id-type="pmid">33137809</pub-id></mixed-citation></ref><ref id="pone.0304960.ref036"><label>36</label><mixed-citation publication-type="other"><italic toggle="yes">Statement&#8211;older people are at highest risk from COVID-19</italic>, <italic toggle="yes">but all must act to prevent community spread</italic> (no date) <italic toggle="yes">World Health Organization</italic>. World Health Organization. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/europe/news/item/03-04-2020-statement-older-people-are-at-highest-risk-from-covid-19-but-all-must-act-to-prevent-community-spread" ext-link-type="uri">https://www.who.int/europe/news/item/03-04-2020-statement-older-people-are-at-highest-risk-from-covid-19-but-all-must-act-to-prevent-community-spread</ext-link> (Accessed: December 12, 2022).</mixed-citation></ref><ref id="pone.0304960.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Reilev</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kristensen</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Potteg&#229;rd</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort.</article-title><source><italic toggle="yes">Int J Epidemiol</italic></source>. <year>2020</year>;<volume>49</volume>(<issue>5</issue>):<fpage>1468</fpage>&#8211;<lpage>1481</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/ije/dyaa140</pub-id><pub-id pub-id-type="pmid">32887982</pub-id><pub-id pub-id-type="pmcid">PMC7499657</pub-id></mixed-citation></ref><ref id="pone.0304960.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sadighi Akha</surname><given-names>AA</given-names></name>. <article-title>Aging and the immune system: An overview</article-title>. <source><italic toggle="yes">J Immunol Methods</italic></source>. <year>2018</year>;<volume>463</volume>:<fpage>21</fpage>&#8211;<lpage>26</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jim.2018.08.005</pub-id><pub-id pub-id-type="pmid">30114401</pub-id></mixed-citation></ref><ref id="pone.0304960.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ural</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Caron</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Dogra</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Inhaled particulate accumulation with age impairs immune function and architecture in human lung lymph nodes [published online ahead of print, 2022 Nov 21]</article-title>. <source><italic toggle="yes">Nat Med</italic></source>. <year>2022</year>;<fpage>10</fpage>.1038/s41591-022-02073-x. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41591-022-02073-x</pub-id><pub-id pub-id-type="pmid">36411343</pub-id><pub-id pub-id-type="pmcid">PMC9835154</pub-id></mixed-citation></ref><ref id="pone.0304960.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wada</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hino</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 Vaccination reduced pneumonia severity.</article-title><source><italic toggle="yes">Eur J Radiol Open</italic></source>. <year>2022</year>;<volume>9</volume>:<fpage>100456</fpage>. Published 2022 Nov 11. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejro.2022.100456</pub-id><pub-id pub-id-type="pmid">36386765</pub-id><pub-id pub-id-type="pmcid">PMC9650570</pub-id></mixed-citation></ref><ref id="pone.0304960.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tenforde</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Self</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>2021</year>;<volume>326</volume>(<issue>20</issue>):<fpage>2043</fpage>&#8211;<lpage>2054</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2021.19499</pub-id><pub-id pub-id-type="pmid">34734975</pub-id><pub-id pub-id-type="pmcid">PMC8569602</pub-id></mixed-citation></ref><ref id="pone.0304960.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tenforde</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Self</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Gaglani</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death&#8212;United States, March 2021-January 2022.</article-title><source><italic toggle="yes">MMWR Morb Mortal Wkly Rep</italic>.</source><year>2022</year>;<volume>71</volume>(<issue>12</issue>):<fpage>459</fpage>&#8211;<lpage>465</lpage>. Published 2022 Mar 25. <comment>doi: </comment><pub-id pub-id-type="doi">10.15585/mmwr.mm7112e1</pub-id><pub-id pub-id-type="pmid">35324878</pub-id><pub-id pub-id-type="pmcid">PMC8956334</pub-id></mixed-citation></ref><ref id="pone.0304960.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Grasselli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zanella</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Carlesso</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy</article-title>, <source>Italy. <italic toggle="yes">JAMA Netw Open</italic></source>. <year>2022</year>;<volume>5</volume>(<issue>10</issue>):<fpage>e2238871</fpage>. Published 2022 Oct 3. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.38871</pub-id><pub-id pub-id-type="pmid">36301541</pub-id><pub-id pub-id-type="pmcid">PMC9614574</pub-id></mixed-citation></ref><ref id="pone.0304960.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Peng</surname><given-names>YD</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>HQ</given-names></name>, <etal>et al</etal>. <article-title>Clinical features and outcomes of 112 patients with cardiovascular disease infected with novel coronavirus pneumonia.</article-title><source><italic toggle="yes">Zhonghua Xin Xue Guan Bing Za Zhi</italic></source>. <year>2020</year>;<volume>2</volume>(<issue>48</issue>):<fpage>E0048</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3760/cma.j.cn112148-20200220-00105</pub-id><pub-id pub-id-type="pmid">32120458</pub-id></mixed-citation></ref><ref id="pone.0304960.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>F&#246;ldi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Farkas</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kiss</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis.</article-title><source><italic toggle="yes">Obes Rev</italic></source>. <year>2020</year>;<volume>21</volume>(<issue>10</issue>):<fpage>e13095</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/obr.13095</pub-id><pub-id pub-id-type="pmid">32686331</pub-id><pub-id pub-id-type="pmcid">PMC7404429</pub-id></mixed-citation></ref><ref id="pone.0304960.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Popkin</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>WD</given-names></name>, <etal>et al</etal>. <article-title>Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships [published correction appears in Obes Rev. 2021 Oct;22(10):e13305]</article-title>. <source><italic toggle="yes">Obes Rev</italic>.</source><year>2020</year>;<volume>21</volume>(<issue>11</issue>):<fpage>e13128</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/obr.13128</pub-id><pub-id pub-id-type="pmid">32845580</pub-id><pub-id pub-id-type="pmcid">PMC7461480</pub-id></mixed-citation></ref><ref id="pone.0304960.ref047"><label>47</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Andersen</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>ML</given-names></name>. <article-title>Impact of Obesity and Metabolic Syndrome on Immunity.</article-title><source><italic toggle="yes">Adv Nutr</italic></source>. <year>2016</year>;<volume>7</volume>(<issue>1</issue>):<fpage>66</fpage>&#8211;<lpage>75</lpage>. Published 2016 Jan 15. <comment>doi: </comment><pub-id pub-id-type="doi">10.3945/an.115.010207</pub-id><pub-id pub-id-type="pmid">26773015</pub-id><pub-id pub-id-type="pmcid">PMC4717890</pub-id></mixed-citation></ref><ref id="pone.0304960.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chowdhury</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Alam</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Rabbi</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Reza</surname><given-names>S</given-names></name>. <article-title>Does higher body mass index increase COVID-19 severity? A systematic review and meta-analysis.</article-title><source><italic toggle="yes">Obes Med</italic></source>. <year>2021</year>;<volume>23</volume>:<fpage>100340</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.obmed.2021.100340</pub-id><pub-id pub-id-type="pmid">33875972</pub-id><pub-id pub-id-type="pmcid">PMC8046705</pub-id></mixed-citation></ref><ref id="pone.0304960.ref049"><label>49</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dixon</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>U</given-names></name>. <article-title>The effect of obesity on lung function</article-title>. <source><italic toggle="yes">Expert Rev Respir Med</italic></source>. <year>2018</year>;<volume>12</volume>(<issue>9</issue>):<fpage>755</fpage>&#8211;<lpage>767</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/17476348.2018.1506331</pub-id><pub-id pub-id-type="pmid">30056777</pub-id><pub-id pub-id-type="pmcid">PMC6311385</pub-id></mixed-citation></ref><ref id="pone.0304960.ref050"><label>50</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sattar</surname><given-names>N</given-names></name>, <name name-style="western"><surname>McInnes</surname><given-names>IB</given-names></name>, <name name-style="western"><surname>McMurray</surname><given-names>JJV</given-names></name>. <article-title>Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms</article-title>. <source><italic toggle="yes">Circulation</italic></source>. <year>2020</year>;<volume>142</volume>(<issue>1</issue>):<fpage>4</fpage>&#8211;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047659</pub-id><pub-id pub-id-type="pmid">32320270</pub-id></mixed-citation></ref><ref id="pone.0304960.ref051"><label>51</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kompaniyets</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Belay</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death&#8212;United States, March-December 2020.</article-title><source><italic toggle="yes">MMWR Morb Mortal Wkly Rep</italic>.</source><year>2021</year>;<volume>70</volume>(<issue>10</issue>):<fpage>355</fpage>&#8211;<lpage>361</lpage>. Published 2021 Mar 12. <comment>doi: </comment><pub-id pub-id-type="doi">10.15585/mmwr.mm7010e4</pub-id><pub-id pub-id-type="pmid">33705371</pub-id><pub-id pub-id-type="pmcid">PMC7951819</pub-id></mixed-citation></ref><ref id="pone.0304960.ref052"><label>52</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hales</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Fryar</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Ogden</surname><given-names>CL</given-names></name>. <article-title>Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017&#8211;2018.</article-title><source><italic toggle="yes">NCHS Data Brief</italic>.</source><year>2020</year>;(360):<fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="pmid">32487284</pub-id></mixed-citation></ref><ref id="pone.0304960.ref053"><label>53</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stefan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Birkenfeld</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Schulze</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Ludwig</surname><given-names>DS</given-names></name>. <article-title>Obesity and impaired metabolic health in patients with COVID-19.</article-title><source><italic toggle="yes">Nat Rev Endocrinol</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>7</issue>):<fpage>341</fpage>&#8211;<lpage>342</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41574-020-0364-6</pub-id><pub-id pub-id-type="pmid">32327737</pub-id><pub-id pub-id-type="pmcid">PMC7187148</pub-id></mixed-citation></ref><ref id="pone.0304960.ref054"><label>54</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Deng</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China.</article-title><source><italic toggle="yes">Int J Cardiol</italic></source>. <year>2020</year>;<volume>311</volume>:<fpage>116</fpage>&#8211;<lpage>121</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijcard.2020.03.087</pub-id><pub-id pub-id-type="pmid">32291207</pub-id><pub-id pub-id-type="pmcid">PMC7141178</pub-id></mixed-citation></ref><ref id="pone.0304960.ref055"><label>55</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Risk Factors Associated With Clinical Outcomes in 323 Coronavirus Disease 2019 (COVID-19) Hospitalized Patients in Wuhan, China.</article-title><source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2020</year>;<volume>71</volume>(<issue>16</issue>):<fpage>2089</fpage>&#8211;<lpage>2098</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cid/ciaa539</pub-id><pub-id pub-id-type="pmid">32361738</pub-id><pub-id pub-id-type="pmcid">PMC7197620</pub-id></mixed-citation></ref><ref id="pone.0304960.ref056"><label>56</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Williamson</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Bhaskaran</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Factors associated with COVID-19-related death using OpenSAFELY</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2020</year>;<volume>584</volume>(<issue>7821</issue>):<fpage>430</fpage>&#8211;<lpage>436</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2521-4</pub-id><pub-id pub-id-type="pmid">32640463</pub-id><pub-id pub-id-type="pmcid">PMC7611074</pub-id></mixed-citation></ref><ref id="pone.0304960.ref057"><label>57</label><mixed-citation publication-type="book"><collab>ERA-EDTA Council, and ERACODA Working Group</collab>. <part-title>&#8220;Chronic Kidney Disease Is a Key Risk Factor for Severe COVID-19: A Call to Action by the Era-EDTA.&#8221;</part-title><source>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association&#8212;European Renal Association.</source> U.<publisher-name>S. National Library of Medicine</publisher-name>, <month>January</month><day>1</day>, <year>2021</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771976/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771976/</ext-link>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfaa314</pub-id><pub-id pub-id-type="pmcid">PMC7771976</pub-id><pub-id pub-id-type="pmid">33340043</pub-id></mixed-citation></ref><ref id="pone.0304960.ref058"><label>58</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Docherty</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Harrison</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>CA</given-names></name>, <etal>et al</etal>. <article-title>Features of 20&#8201;133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2020</year>;<volume>369</volume>:<fpage>m1985</fpage>. Published 2020 May 22. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.m1985</pub-id><pub-id pub-id-type="pmid">32444460</pub-id><pub-id pub-id-type="pmcid">PMC7243036</pub-id></mixed-citation></ref><ref id="pone.0304960.ref059"><label>59</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chung</surname><given-names>EYM</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Natale</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis</article-title>. <source><italic toggle="yes">Am J Kidney Dis</italic></source>. <year>2021</year>;<volume>78</volume>(<issue>6</issue>):<fpage>804</fpage>&#8211;<lpage>815</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1053/j.ajkd.2021.07.003</pub-id><pub-id pub-id-type="pmid">34364906</pub-id><pub-id pub-id-type="pmcid">PMC8339603</pub-id></mixed-citation></ref><ref id="pone.0304960.ref060"><label>60</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Caillard</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chavarot</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Francois</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Is COVID-19 infection more severe in kidney transplant recipients?.</article-title><source><italic toggle="yes">Am J Transplant</italic></source>. <year>2021</year>;<volume>21</volume>(<issue>3</issue>):<fpage>1295</fpage>&#8211;<lpage>1303</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/ajt.16424</pub-id><pub-id pub-id-type="pmid">33259686</pub-id><pub-id pub-id-type="pmcid">PMC7753418</pub-id></mixed-citation></ref><ref id="pone.0304960.ref061"><label>61</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Betjes</surname><given-names>MG</given-names></name>. <article-title>Immune cell dysfunction and inflammation in end-stage renal disease</article-title>. <source><italic toggle="yes">Nat Rev Nephrol</italic></source>. <year>2013</year>;<volume>9</volume>(<issue>5</issue>):<fpage>255</fpage>&#8211;<lpage>265</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrneph.2013.44</pub-id><pub-id pub-id-type="pmid">23507826</pub-id></mixed-citation></ref><ref id="pone.0304960.ref062"><label>62</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Kidney disease is associated with in-hospital death of patients with COVID-19</article-title>. <source><italic toggle="yes">Kidney Int</italic></source>. <year>2020</year>;<volume>97</volume>(<issue>5</issue>):<fpage>829</fpage>&#8211;<lpage>838</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.kint.2020.03.005</pub-id><pub-id pub-id-type="pmid">32247631</pub-id><pub-id pub-id-type="pmcid">PMC7110296</pub-id></mixed-citation></ref><ref id="pone.0304960.ref063"><label>63</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cohen-Hagai</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rozenberg</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Korzets</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zitman-Gal</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Einbinder</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Benchetrit</surname><given-names>S</given-names></name>. <article-title>Upper Respiratory Tract Infection among Dialysis Patients.</article-title><source><italic toggle="yes">Isr Med Assoc J</italic>.</source><year>2016</year>;<volume>18</volume>(<issue>9</issue>):<fpage>557</fpage>&#8211;<lpage>560</lpage>. <pub-id pub-id-type="pmid">28471606</pub-id></mixed-citation></ref><ref id="pone.0304960.ref064"><label>64</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fadini</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Morieri</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Longato</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Avogaro</surname><given-names>A</given-names></name>. <article-title>Prevalence and impact of diabetes among people infected with SARS-CoV-2</article-title>. <source><italic toggle="yes">J Endocrinol Invest</italic></source>. <year>2020</year>;<volume>43</volume>(<issue>6</issue>):<fpage>867</fpage>&#8211;<lpage>869</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s40618-020-01236-2</pub-id><pub-id pub-id-type="pmid">32222956</pub-id><pub-id pub-id-type="pmcid">PMC7103097</pub-id></mixed-citation></ref><ref id="pone.0304960.ref065"><label>65</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Barron</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bakhai</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kar</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.</article-title><source><italic toggle="yes">Lancet Diabetes Endocrinol</italic>.</source><year>2020</year>;<volume>8</volume>(<issue>10</issue>):<fpage>813</fpage>&#8211;<lpage>822</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2213-8587(20)30272-2</pub-id><pub-id pub-id-type="pmid">32798472</pub-id><pub-id pub-id-type="pmcid">PMC7426088</pub-id></mixed-citation></ref><ref id="pone.0304960.ref066"><label>66</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Pranata</surname><given-names>R</given-names></name>. <article-title>Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia&#8212;A systematic review, meta-analysis, and meta-regression.</article-title><source><italic toggle="yes">Diabetes Metab Syndr</italic>.</source><year>2020</year>;<volume>14</volume>(<issue>4</issue>):<fpage>395</fpage>&#8211;<lpage>403</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.dsx.2020.04.018</pub-id><pub-id pub-id-type="pmid">32334395</pub-id><pub-id pub-id-type="pmcid">PMC7162793</pub-id></mixed-citation></ref><ref id="pone.0304960.ref067"><label>67</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Roncon</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zuin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rigatelli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zuliani</surname><given-names>G</given-names></name>. <article-title>Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome.</article-title><source><italic toggle="yes">J Clin Virol</italic></source>. <year>2020</year>;<volume>127</volume>:<fpage>104354</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jcv.2020.104354</pub-id><pub-id pub-id-type="pmid">32305882</pub-id><pub-id pub-id-type="pmcid">PMC7195018</pub-id></mixed-citation></ref><ref id="pone.0304960.ref068"><label>68</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lim</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Nauck</surname><given-names>MA</given-names></name>. <article-title>COVID-19 and diabetes mellitus: from pathophysiology to clinical management</article-title>. <source><italic toggle="yes">Nat Rev Endocrinol</italic></source>. <year>2021</year>;<volume>17</volume>(<issue>1</issue>):<fpage>11</fpage>&#8211;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41574-020-00435-4</pub-id><pub-id pub-id-type="pmid">33188364</pub-id><pub-id pub-id-type="pmcid">PMC7664589</pub-id></mixed-citation></ref><ref id="pone.0304960.ref069"><label>69</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Klonoff</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Messler</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Umpierrez</surname><given-names>GE</given-names></name>, <etal>et al</etal>. <article-title>Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis.</article-title><source><italic toggle="yes">Diabetes Care</italic></source>. <year>2021</year>;<volume>44</volume>(<issue>2</issue>):<fpage>578</fpage>&#8211;<lpage>585</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2337/dc20-1857</pub-id><pub-id pub-id-type="pmid">33323475</pub-id><pub-id pub-id-type="pmcid">PMC7818335</pub-id></mixed-citation></ref><ref id="pone.0304960.ref070"><label>70</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bellido</surname><given-names>V</given-names></name>, <name name-style="western"><surname>P&#233;rez</surname><given-names>A</given-names></name>. <article-title>COVID-19 and Diabetes.</article-title><source><italic toggle="yes">J Clin Med</italic></source>. <year>2021</year>;<volume>10</volume>(<issue>22</issue>):<fpage>5341</fpage>. Published 2021 Nov 16. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/jcm10225341</pub-id><pub-id pub-id-type="pmid">34830623</pub-id><pub-id pub-id-type="pmcid">PMC8618368</pub-id></mixed-citation></ref><ref id="pone.0304960.ref071"><label>71</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Misra</surname><given-names>A</given-names></name>. <article-title>Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations.</article-title><source><italic toggle="yes">Diabetes Metab Syndr</italic>.</source><year>2020</year>;<volume>14</volume>(<issue>4</issue>):<fpage>303</fpage>&#8211;<lpage>310</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.dsx.2020.04.004</pub-id><pub-id pub-id-type="pmid">32298981</pub-id><pub-id pub-id-type="pmcid">PMC7195120</pub-id></mixed-citation></ref><ref id="pone.0304960.ref072"><label>72</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>A</given-names></name>, <name name-style="western"><surname>So</surname><given-names>HC</given-names></name>. <article-title>Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits</article-title>. <source><italic toggle="yes">Diabetes Care</italic></source>. <year>2020</year>;<volume>43</volume>(<issue>7</issue>):<fpage>1416</fpage>&#8211;<lpage>1426</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2337/dc20-0643</pub-id><pub-id pub-id-type="pmid">32430459</pub-id></mixed-citation></ref><ref id="pone.0304960.ref073"><label>73</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>XJ</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>LM</given-names></name>. <article-title>Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes</article-title>. <source><italic toggle="yes">Acta Diabetol</italic></source>. <year>2010</year>;<volume>47</volume>(<issue>3</issue>):<fpage>193</fpage>&#8211;<lpage>199</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00592-009-0109-4</pub-id><pub-id pub-id-type="pmid">19333547</pub-id><pub-id pub-id-type="pmcid">PMC7088164</pub-id></mixed-citation></ref><ref id="pone.0304960.ref074"><label>74</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fernandez</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rys&#228;</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Almgren</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality</article-title>. <source><italic toggle="yes">J Intern Med</italic></source>. <year>2018</year>;<volume>284</volume>(<issue>4</issue>):<fpage>377</fpage>&#8211;<lpage>387</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/joim.12783</pub-id><pub-id pub-id-type="pmid">29888466</pub-id><pub-id pub-id-type="pmcid">PMC6175079</pub-id></mixed-citation></ref><ref id="pone.0304960.ref075"><label>75</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ebinger</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Driver</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Joung</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Hypertension and Excess Risk for Severe COVID-19 Illness Despite Booster Vaccination</article-title>. <source><italic toggle="yes">Hypertension</italic></source>. <year>2022</year>;<volume>79</volume>(<issue>10</issue>):<fpage>e132</fpage>&#8211;<lpage>e134</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.122.19694</pub-id><pub-id pub-id-type="pmid">35862106</pub-id><pub-id pub-id-type="pmcid">PMC9444256</pub-id></mixed-citation></ref><ref id="pone.0304960.ref076"><label>76</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>YY</given-names></name>, <etal>et al</etal>. <article-title>Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan</article-title>, <source>China. <italic toggle="yes">Allergy</italic></source>. <year>2020</year>;<volume>75</volume>(<issue>7</issue>):<fpage>1730</fpage>&#8211;<lpage>1741</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/all.14238</pub-id><pub-id pub-id-type="pmid">32077115</pub-id></mixed-citation></ref><ref id="pone.0304960.ref077"><label>77</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mori</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Oudit</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Lopaschuk</surname><given-names>GD</given-names></name>. <article-title>SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism</article-title>. <source><italic toggle="yes">Am J Physiol Endocrinol Metab</italic></source>. <year>2020</year>;<volume>319</volume>(<issue>1</issue>):<fpage>E43</fpage>&#8211;<lpage>E47</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1152/ajpendo.00219.2020</pub-id><pub-id pub-id-type="pmid">32469255</pub-id><pub-id pub-id-type="pmcid">PMC7322507</pub-id></mixed-citation></ref><ref id="pone.0304960.ref078"><label>78</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mu&#241;oz-Durango</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Fuentes</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Castillo</surname><given-names>AE</given-names></name>, <etal>et al</etal>. <article-title>Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2016</year>;<volume>17</volume>(<issue>7</issue>):<fpage>797</fpage>. Published 2016 Jun 23. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms17070797</pub-id><pub-id pub-id-type="pmid">27347925</pub-id><pub-id pub-id-type="pmcid">PMC4964362</pub-id></mixed-citation></ref><ref id="pone.0304960.ref079"><label>79</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mordwinkin</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Meeks</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Jadhav</surname><given-names>SS</given-names></name>, <etal>et al</etal>. <article-title>Angiotensin-(1&#8211;7) administration reduces oxidative stress in diabetic bone marrow.</article-title><source><italic toggle="yes">Endocrinology</italic></source>. <year>2012</year>;<volume>153</volume>(<issue>5</issue>):<fpage>2189</fpage>&#8211;<lpage>2197</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1210/en.2011-2031</pub-id><pub-id pub-id-type="pmid">22434085</pub-id><pub-id pub-id-type="pmcid">PMC3339643</pub-id></mixed-citation></ref><ref id="pone.0304960.ref080"><label>80</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ingelfinger</surname><given-names>JR</given-names></name>. <article-title>Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease.</article-title><source><italic toggle="yes">Curr Opin Nephrol Hypertens</italic>.</source><year>2009</year>;<volume>18</volume>(<issue>1</issue>):<fpage>79</fpage>&#8211;<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MNH.0b013e32831b70ad</pub-id><pub-id pub-id-type="pmid">19077694</pub-id></mixed-citation></ref><ref id="pone.0304960.ref081"><label>81</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ocaranza</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Michea</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chiong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lagos</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Lavandero</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jalil</surname><given-names>JE</given-names></name>. <article-title>Recent insights and therapeutic perspectives of angiotensin-(1&#8211;9) in the cardiovascular system.</article-title><source><italic toggle="yes">Clin Sci (Lond)</italic>.</source><year>2014</year>;<volume>127</volume>(<issue>9</issue>):<fpage>549</fpage>&#8211;<lpage>557</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1042/CS20130449</pub-id><pub-id pub-id-type="pmid">25029123</pub-id></mixed-citation></ref><ref id="pone.0304960.ref082"><label>82</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Steckelings</surname><given-names>UM</given-names></name>, <name name-style="western"><surname>Kaschina</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Unger</surname><given-names>T</given-names></name>. <article-title>The AT2 receptor&#8212;a matter of love and hate</article-title>. <source><italic toggle="yes">Peptides</italic></source>. <year>2005</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1401</fpage>&#8211;<lpage>1409</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.peptides.2005.03.010</pub-id><pub-id pub-id-type="pmid">16042980</pub-id></mixed-citation></ref><ref id="pone.0304960.ref083"><label>83</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Structure</surname><given-names>Li F.</given-names></name>, <article-title>Function, and Evolution of Coronavirus Spike Proteins</article-title>. <source><italic toggle="yes">Annu Rev Virol</italic></source>. <year>2016</year>;<volume>3</volume>(<issue>1</issue>):<fpage>237</fpage>&#8211;<lpage>261</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev-virology-110615-042301</pub-id><pub-id pub-id-type="pmid">27578435</pub-id><pub-id pub-id-type="pmcid">PMC5457962</pub-id></mixed-citation></ref><ref id="pone.0304960.ref084"><label>84</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kleine-Weber</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Schroeder</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>. <source><italic toggle="yes">Cell</italic></source>. <year>2020</year>;<volume>181</volume>(<issue>2</issue>):<fpage>271</fpage>&#8211;<lpage>280</lpage>.e8. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></mixed-citation></ref><ref id="pone.0304960.ref085"><label>85</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kuba</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Imai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.</article-title><source><italic toggle="yes">Nat Med</italic></source>. <year>2005</year>;<volume>11</volume>(<issue>8</issue>):<fpage>875</fpage>&#8211;<lpage>879</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nm1267</pub-id><pub-id pub-id-type="pmid">16007097</pub-id><pub-id pub-id-type="pmcid">PMC7095783</pub-id></mixed-citation></ref><ref id="pone.0304960.ref086"><label>86</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shamshirian</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Heydari</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Alizadeh-Navaei</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Moosazadeh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Abrotan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hessami</surname><given-names>A</given-names></name>. <year>2020</year>. <source>Cardiovascular Diseases and COVID-19 Mortality and Intensive Care Unit Admission: A Systematic Review and Meta-Analysis</source>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2020.10.022</pub-id><pub-id pub-id-type="pmcid">PMC7561581</pub-id><pub-id pub-id-type="pmid">33268238</pub-id></mixed-citation></ref><ref id="pone.0304960.ref087"><label>87</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dalia</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lahan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ranka</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Impact of congestive heart failure and role of cardiac biomarkers in COVID-19 patients: A systematic review and meta-analysis.</article-title><source><italic toggle="yes">Indian Heart J</italic>.</source><year>2021</year>;<volume>73</volume>(<issue>1</issue>):<fpage>91</fpage>&#8211;<lpage>98</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ihj.2020.12.002</pub-id><pub-id pub-id-type="pmid">33714416</pub-id><pub-id pub-id-type="pmcid">PMC7719198</pub-id></mixed-citation></ref><ref id="pone.0304960.ref088"><label>88</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Italia</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tomasoni</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bisegna</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae.</article-title><source><italic toggle="yes">Front Cardiovasc Med</italic>.</source><year>2021</year>;<volume>8</volume>:<fpage>713560</fpage>. Published 2021 Aug 10. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fcvm.2021.713560</pub-id><pub-id pub-id-type="pmid">34447795</pub-id><pub-id pub-id-type="pmcid">PMC8382715</pub-id></mixed-citation></ref><ref id="pone.0304960.ref089"><label>89</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Alvarez-Garcia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19</article-title>. <source><italic toggle="yes">J Am Coll Cardiol</italic></source>. <year>2020</year>;<volume>76</volume>(<issue>20</issue>):<fpage>2334</fpage>&#8211;<lpage>2348</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jacc.2020.09.549</pub-id><pub-id pub-id-type="pmid">33129663</pub-id><pub-id pub-id-type="pmcid">PMC7598769</pub-id></mixed-citation></ref><ref id="pone.0304960.ref090"><label>90</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tomasoni</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Inciardi</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Lombardi</surname><given-names>CM</given-names></name>, <etal>et al</etal>. <article-title>Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19.</article-title><source>Results of the Cardio-COVID-Italy multicentre study. <italic toggle="yes">Eur J Heart Fail</italic>.</source><year>2020</year>;<volume>22</volume>(<issue>12</issue>):<fpage>2238</fpage>&#8211;<lpage>2247</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ejhf.2052</pub-id><pub-id pub-id-type="pmid">33179839</pub-id></mixed-citation></ref><ref id="pone.0304960.ref091"><label>91</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fujino</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy</article-title>. <source><italic toggle="yes">Circ J</italic></source>. <year>2007</year>;<volume>71</volume>(<issue>6</issue>):<fpage>936</fpage>&#8211;<lpage>940</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1253/circj.71.936</pub-id><pub-id pub-id-type="pmid">17526993</pub-id></mixed-citation></ref><ref id="pone.0304960.ref092"><label>92</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Umana</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Solares</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Alpert</surname><given-names>MA</given-names></name>. <article-title>Tachycardia-induced cardiomyopathy.</article-title><source><italic toggle="yes">Am J Med</italic></source>. <year>2003</year>;<volume>114</volume>(<issue>1</issue>):<fpage>51</fpage>&#8211;<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0002-9343(02)01472-9</pub-id><pub-id pub-id-type="pmid">12543289</pub-id></mixed-citation></ref><ref id="pone.0304960.ref093"><label>93</label><mixed-citation publication-type="journal"><name name-style="western"><surname>de Roquetaillade</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chousterman</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Tomasoni</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Unusual arterial thrombotic events in Covid-19 patients.</article-title><source><italic toggle="yes">Int J Cardiol</italic></source>. <year>2021</year>;<volume>323</volume>:<fpage>281</fpage>&#8211;<lpage>284</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijcard.2020.08.103</pub-id><pub-id pub-id-type="pmid">32918938</pub-id><pub-id pub-id-type="pmcid">PMC7481127</pub-id></mixed-citation></ref><ref id="pone.0304960.ref094"><label>94</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Klok</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Kruip</surname><given-names>MJHA</given-names></name>, <name name-style="western"><surname>van der Meer</surname><given-names>NJM</given-names></name>, <etal>et al</etal>. <article-title>Incidence of thrombotic complications in critically ill ICU patients with COVID-19</article-title>. <source><italic toggle="yes">Thromb Res</italic></source>. <year>2020</year>;<volume>191</volume>:<fpage>145</fpage>&#8211;<lpage>147</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.013</pub-id><pub-id pub-id-type="pmid">32291094</pub-id><pub-id pub-id-type="pmcid">PMC7146714</pub-id></mixed-citation></ref><ref id="pone.0304960.ref095"><label>95</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Luft</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wendtner</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Kosely</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.</article-title><source><italic toggle="yes">Front Immunol</italic>.</source><year>2021</year>;<volume>12</volume>:<fpage>634416</fpage>. Published 2021 Jun 23. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2021.634416</pub-id><pub-id pub-id-type="pmid">34248931</pub-id><pub-id pub-id-type="pmcid">PMC8261154</pub-id></mixed-citation></ref><ref id="pone.0304960.ref096"><label>96</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schultze</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>MacKenna</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2020</year>;<volume>8</volume>(<issue>11</issue>):<fpage>1106</fpage>&#8211;<lpage>1120</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30415-X</pub-id><pub-id pub-id-type="pmid">32979987</pub-id><pub-id pub-id-type="pmcid">PMC7515601</pub-id></mixed-citation></ref><ref id="pone.0304960.ref097"><label>97</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Beltramo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cottenet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mariet</surname><given-names>AS</given-names></name>, <etal>et al</etal>. <article-title>Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2021</year>;<volume>58</volume>(<issue>6</issue>):<fpage>2004474</fpage>. Published 2021 Dec 9. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/13993003.04474-2020</pub-id><pub-id pub-id-type="pmid">34016619</pub-id><pub-id pub-id-type="pmcid">PMC8135927</pub-id></mixed-citation></ref><ref id="pone.0304960.ref098"><label>98</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Aveyard</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lindson</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2021</year>;<volume>9</volume>(<issue>8</issue>):<fpage>909</fpage>&#8211;<lpage>923</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00095-3</pub-id><pub-id pub-id-type="pmid">33812494</pub-id><pub-id pub-id-type="pmcid">PMC8016404</pub-id></mixed-citation></ref><ref id="pone.0304960.ref099"><label>99</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bloom</surname><given-names>CI</given-names></name>, <name name-style="western"><surname>Drake</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Docherty</surname><given-names>AB</given-names></name>, <etal>et al</etal>. <article-title>Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2021</year>;<volume>9</volume>(<issue>7</issue>):<fpage>699</fpage>&#8211;<lpage>711</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00013-8</pub-id><pub-id pub-id-type="pmid">33676593</pub-id><pub-id pub-id-type="pmcid">PMC8241313</pub-id></mixed-citation></ref><ref id="pone.0304960.ref100"><label>100</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vardavas</surname><given-names>CI</given-names></name>, <name name-style="western"><surname>Mathioudakis</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Nikitara</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe.</article-title><source><italic toggle="yes">Eur Respir Rev</italic></source>. <year>2022</year>;<volume>31</volume>(<issue>166</issue>):<fpage>220098</fpage>. Published 2022 Nov 2. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/16000617.0098-2022</pub-id><pub-id pub-id-type="pmid">36323422</pub-id><pub-id pub-id-type="pmcid">PMC9724816</pub-id></mixed-citation></ref><ref id="pone.0304960.ref101"><label>101</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cade</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Dashti</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Redline</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Karlson</surname><given-names>EW</given-names></name>. <article-title>Sleep Apnea and COVID-19 Mortality and Hospitalization</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med</italic></source>. <year>2020</year>;<volume>202</volume>(<issue>10</issue>):<fpage>1462</fpage>&#8211;<lpage>1464</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1164/rccm.202006-2252LE</pub-id><pub-id pub-id-type="pmid">32946275</pub-id><pub-id pub-id-type="pmcid">PMC7667903</pub-id></mixed-citation></ref><ref id="pone.0304960.ref102"><label>102</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pena Orbea</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System</article-title>. <source><italic toggle="yes">JAMA Netw Open</italic></source>. <year>2021</year>;<volume>4</volume>(<issue>11</issue>):<fpage>e2134241</fpage>. Published 2021 Nov 1. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.34241</pub-id><pub-id pub-id-type="pmid">34757409</pub-id><pub-id pub-id-type="pmcid">PMC8581726</pub-id></mixed-citation></ref><ref id="pone.0304960.ref103"><label>103</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meza</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Khuder</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bailey</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Kalhan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Reyfman</surname><given-names>PA</given-names></name>. <article-title>Mortality from COVID-19 in Patients with COPD: A US Study in the N3C Data Enclave.</article-title><source><italic toggle="yes">Int J Chron Obstruct Pulmon Dis</italic>.</source><year>2021</year>;<volume>16</volume>:<fpage>2323</fpage>&#8211;<lpage>2326</lpage>. Published 2021 Aug 13. <comment>doi: </comment><pub-id pub-id-type="doi">10.2147/COPD.S318000</pub-id><pub-id pub-id-type="pmid">34413640</pub-id><pub-id pub-id-type="pmcid">PMC8370846</pub-id></mixed-citation></ref><ref id="pone.0304960.ref104"><label>104</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gerayeli</surname><given-names>FV</given-names></name>, <name name-style="western"><surname>Milne</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cheung</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis.</article-title><source><italic toggle="yes">EClinicalMedicine</italic></source>. <year>2021</year>;<volume>33</volume>:<fpage>100789</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100789</pub-id><pub-id pub-id-type="pmid">33758801</pub-id><pub-id pub-id-type="pmcid">PMC7971471</pub-id></mixed-citation></ref><ref id="pone.0304960.ref105"><label>105</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rovina</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Koutsoukou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koulouris</surname><given-names>NG</given-names></name>. <article-title>Inflammation and immune response in COPD: where do we stand?.</article-title><source><italic toggle="yes">Mediators Inflamm</italic>.</source><year>2013</year>;<volume>2013</volume>:<fpage>413735</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2013/413735</pub-id><pub-id pub-id-type="pmid">23956502</pub-id><pub-id pub-id-type="pmcid">PMC3728539</pub-id></mixed-citation></ref><ref id="pone.0304960.ref106"><label>106</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Unnikrishnan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jun</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Polotsky</surname><given-names>V</given-names></name>. <article-title>Inflammation in sleep apnea: an update</article-title>. <source><italic toggle="yes">Rev Endocr Metab Disord</italic></source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>25</fpage>&#8211;<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11154-014-9304-x</pub-id><pub-id pub-id-type="pmid">25502450</pub-id><pub-id pub-id-type="pmcid">PMC4346503</pub-id></mixed-citation></ref><ref id="pone.0304960.ref107"><label>107</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jose</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Manuel</surname><given-names>A</given-names></name>. <article-title>COVID-19 cytokine storm: the interplay between inflammation and coagulation</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2020</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e46</fpage>&#8211;<lpage>e47</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30216-2</pub-id><pub-id pub-id-type="pmid">32353251</pub-id><pub-id pub-id-type="pmcid">PMC7185942</pub-id></mixed-citation></ref><ref id="pone.0304960.ref108"><label>108</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Miller</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Cappuccio</surname><given-names>FP</given-names></name>. <article-title>A systematic review of COVID-19 and obstructive sleep apnoea.</article-title><source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2021</year>;<volume>55</volume>:<fpage>101382</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.smrv.2020.101382</pub-id><pub-id pub-id-type="pmid">32980614</pub-id><pub-id pub-id-type="pmcid">PMC7833740</pub-id></mixed-citation></ref><ref id="pone.0304960.ref109"><label>109</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kheirandish-Gozal</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Peris</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gozal</surname><given-names>D</given-names></name>. <article-title>Vitamin D levels and obstructive sleep apnoea in children.</article-title><source><italic toggle="yes">Sleep Med</italic>.</source><year>2014</year>;<volume>15</volume>(<issue>4</issue>):<fpage>459</fpage>&#8211;<lpage>463</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.sleep.2013.12.009</pub-id><pub-id pub-id-type="pmid">24684979</pub-id><pub-id pub-id-type="pmcid">PMC4247539</pub-id></mixed-citation></ref><ref id="pone.0304960.ref110"><label>110</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Grant</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Lahore</surname><given-names>H</given-names></name>, <name name-style="western"><surname>McDonnell</surname><given-names>SL</given-names></name>, <etal>et al</etal>. <article-title>Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths.</article-title><source><italic toggle="yes">Nutrients</italic>.</source><year>2020</year>;<volume>12</volume>(<issue>4</issue>):<fpage>988</fpage>. Published 2020 Apr 2. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/nu12040988</pub-id><pub-id pub-id-type="pmid">32492787</pub-id><pub-id pub-id-type="pmcid">PMC7352449</pub-id></mixed-citation></ref><ref id="pone.0304960.ref111"><label>111</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jin</surname><given-names>ZN</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>YX</given-names></name>. <article-title>Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system.</article-title><source><italic toggle="yes">J Geriatr Cardiol</italic></source>. <year>2016</year>;<volume>13</volume>(<issue>4</issue>):<fpage>333</fpage>&#8211;<lpage>343</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.11909/j.issn.1671-5411.2016.03.020</pub-id><pub-id pub-id-type="pmid">27403143</pub-id><pub-id pub-id-type="pmcid">PMC4921546</pub-id></mixed-citation></ref><ref id="pone.0304960.ref112"><label>112</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Salah</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mehta</surname><given-names>J</given-names></name>. <article-title>Smoking Doubles the Mortality Risk in COVID-19: A Meta-Analysis of Recent Reports and Potential Mechanisms.</article-title><source><italic toggle="yes">Cureus</italic></source>. <year>2020</year>;<volume>12</volume>(<issue>10</issue>):<fpage>e10837</fpage>. Published 2020 Oct 7. <comment>doi: </comment><pub-id pub-id-type="doi">10.7759/cureus.10837</pub-id><pub-id pub-id-type="pmid">33173643</pub-id><pub-id pub-id-type="pmcid">PMC7647838</pub-id></mixed-citation></ref><ref id="pone.0304960.ref113"><label>113</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Patanavanich</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Siripoon</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Amponnavarat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Glantz</surname><given-names>SA</given-names></name>. <article-title>Active smokers are at higher risk of COVID-19 death: A systematic review and meta-analysis [published online ahead of print, 2022 Apr 1].</article-title><source><italic toggle="yes">Nicotine Tob Res</italic></source>. <year>2022</year>;<volume>ntac085</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/ntr/ntac085</pub-id><pub-id pub-id-type="pmid">35363877</pub-id></mixed-citation></ref><ref id="pone.0304960.ref114"><label>114</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Patanavanich</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Glantz</surname><given-names>SA</given-names></name>. <article-title>Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis.</article-title><source><italic toggle="yes">BMC Public Health</italic>.</source><year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>1554</fpage>. Published 2021 Aug 16. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12889-021-11579-x</pub-id><pub-id pub-id-type="pmid">34399729</pub-id><pub-id pub-id-type="pmcid">PMC8366155</pub-id></mixed-citation></ref><ref id="pone.0304960.ref115"><label>115</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Alqahtani</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Oyelade</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Aldhahir</surname><given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis.</article-title><source><italic toggle="yes">PLoS One</italic>.</source><year>2020</year>;<volume>15</volume>(<issue>5</issue>):<fpage>e0233147</fpage>. Published 2020 May 11. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0233147</pub-id><pub-id pub-id-type="pmid">32392262</pub-id><pub-id pub-id-type="pmcid">PMC7213702</pub-id></mixed-citation></ref><ref id="pone.0304960.ref116"><label>116</label><mixed-citation publication-type="journal"><name name-style="western"><surname>St&#228;mpfli</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>GP</given-names></name>. <article-title>How cigarette smoke skews immune responses to promote infection, lung disease and cancer</article-title>. <source><italic toggle="yes">Nat Rev Immunol</italic></source>. <year>2009</year>;<volume>9</volume>(<issue>5</issue>):<fpage>377</fpage>&#8211;<lpage>384</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nri2530</pub-id><pub-id pub-id-type="pmid">19330016</pub-id></mixed-citation></ref><ref id="pone.0304960.ref117"><label>117</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Strzelak</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ratajczak</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Adamiec</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Feleszko</surname><given-names>W</given-names></name>. <article-title>Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review.</article-title><source><italic toggle="yes">Int J Environ Res Public Health</italic>.</source><year>2018</year>;<volume>15</volume>(<issue>5</issue>):<fpage>1033</fpage>. Published 2018 May 21. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijerph15051033</pub-id><pub-id pub-id-type="pmid">29883409</pub-id><pub-id pub-id-type="pmcid">PMC5982072</pub-id></mixed-citation></ref><ref id="pone.0304960.ref118"><label>118</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bloom</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Meyerowitz</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Reinus</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Liver Biochemistries in Hospitalized Patients With COVID-19</article-title>. <source><italic toggle="yes">Hepatology</italic></source>. <year>2021</year>;<volume>73</volume>(<issue>3</issue>):<fpage>890</fpage>&#8211;<lpage>900</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/hep.31326</pub-id><pub-id pub-id-type="pmid">32415860</pub-id></mixed-citation></ref><ref id="pone.0304960.ref119"><label>119</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Guan</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>ZY</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2020</year>;<volume>382</volume>(<issue>18</issue>):<fpage>1708</fpage>&#8211;<lpage>1720</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id><pub-id pub-id-type="pmcid">PMC7092819</pub-id></mixed-citation></ref><ref id="pone.0304960.ref120"><label>120</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>ZC</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>CX</given-names></name>, <etal>et al</etal>. <article-title><italic toggle="yes">Zhonghua Gan Zang Bing Za Zhi</italic>.</article-title><year>2020</year>;<volume>28</volume>(<issue>2</issue>):<fpage>107</fpage>&#8211;<lpage>111</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3760/cma.j.issn.1007-3418.2020.02.003</pub-id><pub-id pub-id-type="pmid">32077660</pub-id></mixed-citation></ref><ref id="pone.0304960.ref121"><label>121</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:].</article-title><source><italic toggle="yes">Lancet</italic></source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>497</fpage>&#8211;<lpage>506</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></mixed-citation></ref><ref id="pone.0304960.ref122"><label>122</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Uhl&#233;n</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fagerberg</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hallstr&#246;m</surname><given-names>BM</given-names></name>, <etal>et al</etal>. <article-title>Proteomics. Tissue-based map of the human proteome</article-title>. <source><italic toggle="yes">Science</italic></source>. <year>2015</year>;<volume>347</volume>(<issue>6220</issue>):<fpage>1260419</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><pub-id pub-id-type="pmid">25613900</pub-id></mixed-citation></ref><ref id="pone.0304960.ref123"><label>123</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chai</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection.</article-title><source>bioRxiv</source>; <year>2020</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2020.02.03.931766</pub-id></mixed-citation></ref><ref id="pone.0304960.ref124"><label>124</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Paizis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tikellis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>ME</given-names></name>, <etal>et al</etal>. <article-title>Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2</article-title>. <source><italic toggle="yes">Gut</italic></source>. <year>2005</year>;<volume>54</volume>(<issue>12</issue>):<fpage>1790</fpage>&#8211;<lpage>1796</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/gut.2004.062398</pub-id><pub-id pub-id-type="pmid">16166274</pub-id><pub-id pub-id-type="pmcid">PMC1774784</pub-id></mixed-citation></ref><ref id="pone.0304960.ref125"><label>125</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Herath</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Warner</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Lubel</surname><given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1&#8211;7) levels in experimental biliary fibrosis.</article-title><source><italic toggle="yes">J Hepatol</italic></source>. <year>2007</year>;<volume>47</volume>(<issue>3</issue>):<fpage>387</fpage>&#8211;<lpage>395</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jhep.2007.03.008</pub-id><pub-id pub-id-type="pmid">17532087</pub-id><pub-id pub-id-type="pmcid">PMC7114685</pub-id></mixed-citation></ref><ref id="pone.0304960.ref126"><label>126</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Guan</surname><given-names>GW</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>JW</given-names></name>, <etal>et al</etal>. <article-title><italic toggle="yes">Zhonghua Gan Zang Bing Za Zhi</italic>.</article-title><year>2020</year>;<volume>28</volume>(<issue>2</issue>):<fpage>100</fpage>&#8211;<lpage>106</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3760/cma.j.issn.1007-3418.2020.02.002</pub-id><pub-id pub-id-type="pmid">32077659</pub-id></mixed-citation></ref><ref id="pone.0304960.ref127"><label>127</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Kooyk</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Geijtenbeek</surname><given-names>TB</given-names></name>. <article-title>DC-SIGN: escape mechanism for pathogens</article-title>. <source><italic toggle="yes">Nat Rev Immunol</italic></source>. <year>2003</year>;<volume>3</volume>(<issue>9</issue>):<fpage>697</fpage>&#8211;<lpage>709</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nri1182</pub-id><pub-id pub-id-type="pmid">12949494</pub-id></mixed-citation></ref><ref id="pone.0304960.ref128"><label>128</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name>. <article-title>The Immunobiology of SARS*</article-title>. <source><italic toggle="yes">Annu Rev Immunol</italic></source>. <year>2007</year>;<volume>25</volume>:<fpage>443</fpage>&#8211;<lpage>472</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev.immunol.25.022106.141706</pub-id><pub-id pub-id-type="pmid">17243893</pub-id></mixed-citation></ref><ref id="pone.0304960.ref129"><label>129</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gramberg</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hofmann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>M&#246;ller</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus</article-title>. <source><italic toggle="yes">Virology</italic></source>. <year>2005</year>;<volume>340</volume>(<issue>2</issue>):<fpage>224</fpage>&#8211;<lpage>236</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.virol.2005.06.026</pub-id><pub-id pub-id-type="pmid">16051304</pub-id><pub-id pub-id-type="pmcid">PMC7111772</pub-id></mixed-citation></ref><ref id="pone.0304960.ref130"><label>130</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tisoncik</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Korth</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Simmons</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Farrar</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Katze</surname><given-names>MG</given-names></name>. <article-title>Into the eye of the cytokine storm</article-title>. <source><italic toggle="yes">Microbiol Mol Biol Rev</italic></source>. <year>2012</year>;<volume>76</volume>(<issue>1</issue>):<fpage>16</fpage>&#8211;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/MMBR.05015-11</pub-id><pub-id pub-id-type="pmid">22390970</pub-id><pub-id pub-id-type="pmcid">PMC3294426</pub-id></mixed-citation></ref><ref id="pone.0304960.ref131"><label>131</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Feng</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>KI</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>QQ</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies.</article-title><source><italic toggle="yes">J Clin Transl Hepatol</italic></source>. <year>2020</year>;<volume>8</volume>(<issue>1</issue>):<fpage>18</fpage>&#8211;<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.14218/JCTH.2020.00018</pub-id><pub-id pub-id-type="pmid">32274342</pub-id><pub-id pub-id-type="pmcid">PMC7132016</pub-id></mixed-citation></ref><ref id="pone.0304960.ref132"><label>132</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>JG</given-names></name>. <article-title>Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.</article-title><source><italic toggle="yes">J Clin Transl Hepatol</italic>.</source><year>2020</year>;<volume>8</volume>(<issue>1</issue>):<fpage>13</fpage>&#8211;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.14218/JCTH.2020.00019</pub-id><pub-id pub-id-type="pmid">32274341</pub-id><pub-id pub-id-type="pmcid">PMC7132021</pub-id></mixed-citation></ref><ref id="pone.0304960.ref133"><label>133</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ye</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wysocki</surname><given-names>J</given-names></name>, <name name-style="western"><surname>William</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Soler</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Cokic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Batlle</surname><given-names>D</given-names></name>. <article-title>Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes</article-title>. <source><italic toggle="yes">J Am Soc Nephrol</italic></source>. <year>2006</year>;<volume>17</volume>(<issue>11</issue>):<fpage>3067</fpage>&#8211;<lpage>3075</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1681/ASN.2006050423</pub-id><pub-id pub-id-type="pmid">17021266</pub-id></mixed-citation></ref><ref id="pone.0304960.ref134"><label>134</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Diao</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection.</article-title><source><italic toggle="yes">Nat Commun</italic>.</source><year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>2506</fpage>. Published 2021 May 4. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-22781-1</pub-id><pub-id pub-id-type="pmid">33947851</pub-id><pub-id pub-id-type="pmcid">PMC8096808</pub-id></mixed-citation></ref><ref id="pone.0304960.ref135"><label>135</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Santoriello</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Khairallah</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bomback</surname><given-names>AS</given-names></name>, <etal>et al</etal>. <article-title>Postmortem Kidney Pathology Findings in Patients with COVID-19</article-title>. <source><italic toggle="yes">J Am Soc Nephrol</italic></source>. <year>2020</year>;<volume>31</volume>(<issue>9</issue>):<fpage>2158</fpage>&#8211;<lpage>2167</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1681/ASN.2020050744</pub-id><pub-id pub-id-type="pmid">32727719</pub-id><pub-id pub-id-type="pmcid">PMC7461662</pub-id></mixed-citation></ref><ref id="pone.0304960.ref136"><label>136</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient</article-title>. <source><italic toggle="yes">Emerg Microbes Infect</italic></source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>991</fpage>&#8211;<lpage>993</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/22221751.2020.1760144</pub-id><pub-id pub-id-type="pmid">32342724</pub-id><pub-id pub-id-type="pmcid">PMC7301718</pub-id></mixed-citation></ref><ref id="pone.0304960.ref137"><label>137</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Soleimani</surname><given-names>M.</given-names></name><article-title>Acute Kidney Injury in SARS-CoV-2 Infection: Direct Effect of Virus on Kidney Proximal Tubule Cells.</article-title><source><italic toggle="yes">Int J Mol Sci</italic>.</source><year>2020</year>;<volume>21</volume>(<issue>9</issue>):<fpage>3275</fpage>. Published 2020 May 5. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms21093275</pub-id><pub-id pub-id-type="pmid">32380787</pub-id><pub-id pub-id-type="pmcid">PMC7247357</pub-id></mixed-citation></ref><ref id="pone.0304960.ref138"><label>138</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Su</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.</article-title><source><italic toggle="yes">Kidney Int</italic></source>. <year>2020</year>;<volume>98</volume>(<issue>1</issue>):<fpage>219</fpage>&#8211;<lpage>227</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.kint.2020.04.003</pub-id><pub-id pub-id-type="pmid">32327202</pub-id><pub-id pub-id-type="pmcid">PMC7194105</pub-id></mixed-citation></ref><ref id="pone.0304960.ref139"><label>139</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ahmadian</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hosseiniyan Khatibi</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Razi Soofiyani</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Covid-19 and kidney injury: Pathophysiology and molecular mechanisms.</article-title><source><italic toggle="yes">Rev Med Virol</italic></source>. <year>2021</year>;<volume>31</volume>(<issue>3</issue>):<fpage>e2176</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/rmv.2176</pub-id><pub-id pub-id-type="pmid">33022818</pub-id><pub-id pub-id-type="pmcid">PMC7646060</pub-id></mixed-citation></ref><ref id="pone.0304960.ref140"><label>140</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Verdecchia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cavallini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Spanevello</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>F</given-names></name>. <article-title>The pivotal link between ACE2 deficiency and SARS-CoV-2 infection</article-title>. <source><italic toggle="yes">Eur J Intern Med</italic></source>. <year>2020</year>;<volume>76</volume>:<fpage>14</fpage>&#8211;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejim.2020.04.037</pub-id><pub-id pub-id-type="pmid">32336612</pub-id><pub-id pub-id-type="pmcid">PMC7167588</pub-id></mixed-citation></ref><ref id="pone.0304960.ref141"><label>141</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sodhi</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg<sup>9</sup> bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration</article-title>. <source><italic toggle="yes">Am J Physiol Lung Cell Mol Physiol</italic></source>. <year>2018</year>;<volume>314</volume>(<issue>1</issue>):<fpage>L17</fpage>&#8211;<lpage>L31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1152/ajplung.00498.2016</pub-id><pub-id pub-id-type="pmid">28935640</pub-id><pub-id pub-id-type="pmcid">PMC5866432</pub-id></mixed-citation></ref><ref id="pone.0304960.ref142"><label>142</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tolouian</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zununi Vahed</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ghiyasvand</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tolouian</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ardalan</surname><given-names>MR</given-names></name>. <article-title>COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment.</article-title><source>J Renal Inj Prev.</source><year>2020</year>; <volume>9</volume>(<issue>2</issue>): <fpage>e19</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.34172/jrip.2020.19</pub-id></mixed-citation></ref><ref id="pone.0304960.ref143"><label>143</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vickers</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hales</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kaushik</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase</article-title>. <source><italic toggle="yes">J Biol Chem</italic></source>. <year>2002</year>;<volume>277</volume>(<issue>17</issue>):<fpage>14838</fpage>&#8211;<lpage>14843</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1074/jbc.M200581200</pub-id><pub-id pub-id-type="pmid">11815627</pub-id></mixed-citation></ref><ref id="pone.0304960.ref144"><label>144</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Batah</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Fabro</surname><given-names>AT</given-names></name>. <article-title>Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians.</article-title><source><italic toggle="yes">Respir Med</italic></source>. <year>2021</year>;<volume>176</volume>:<fpage>106239</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.rmed.2020.106239</pub-id><pub-id pub-id-type="pmid">33246294</pub-id><pub-id pub-id-type="pmcid">PMC7674971</pub-id></mixed-citation></ref><ref id="pone.0304960.ref145"><label>145</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Som</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mendoza</surname><given-names>DP</given-names></name>, <etal>et al</etal>. <article-title>Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT</article-title>. <source><italic toggle="yes">Lancet Infect Dis</italic></source>. <year>2020</year>;<volume>20</volume>(<issue>12</issue>):<fpage>1365</fpage>&#8211;<lpage>1366</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30367-4</pub-id><pub-id pub-id-type="pmid">32359410</pub-id><pub-id pub-id-type="pmcid">PMC7252023</pub-id></mixed-citation></ref><ref id="pone.0304960.ref146"><label>146</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Madotto</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rezoagli</surname><given-names>E</given-names></name>, <name name-style="western"><surname>McNicholas</surname><given-names>BA</given-names></name>, <etal>et al</etal>. <article-title>Patterns and Impact of Arterial CO<sub>2</sub> Management in Patients With Acute Respiratory Distress Syndrome: Insights From the LUNG SAFE Study.</article-title><source><italic toggle="yes">Chest</italic></source>. <year>2020</year>;<volume>158</volume>(<issue>5</issue>):<fpage>1967</fpage>&#8211;<lpage>1982</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chest.2020.05.605</pub-id><pub-id pub-id-type="pmid">32589951</pub-id></mixed-citation></ref><ref id="pone.0304960.ref147"><label>147</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tsonas</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Botta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Horn</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Clinical characteristics, physiological features, and outcomes associated with hypercapnia in patients with acute hypoxemic respiratory failure due to COVID-19&#8212;insights from the PRoVENT-COVID study.</article-title><source><italic toggle="yes">J Crit Care</italic></source>. <year>2022</year>;<volume>69</volume>:<fpage>154022</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jcrc.2022.154022</pub-id><pub-id pub-id-type="pmid">35339900</pub-id><pub-id pub-id-type="pmcid">PMC8947815</pub-id></mixed-citation></ref><ref id="pone.0304960.ref148"><label>148</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Morales-Quinteros</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Camprub&#237;-Rimblas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bringu&#233;</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bos</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Schultz</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Artigas</surname><given-names>A</given-names></name>. <article-title>The role of hypercapnia in acute respiratory failure.</article-title><source><italic toggle="yes">Intensive Care Med Exp</italic></source>. <year>2019</year>;<volume>7</volume>(<issue>Suppl 1</issue>):<fpage>39</fpage>. Published 2019 Jul 25. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s40635-019-0239-0</pub-id><pub-id pub-id-type="pmid">31346806</pub-id><pub-id pub-id-type="pmcid">PMC6658637</pub-id></mixed-citation></ref><ref id="pone.0304960.ref149"><label>149</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Muriel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pe&#241;uelas</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome.</article-title><source><italic toggle="yes">Intensive Care Med</italic></source>. <year>2017</year>;<volume>43</volume>(<issue>2</issue>):<fpage>200</fpage>&#8211;<lpage>208</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00134-016-4611-1</pub-id><pub-id pub-id-type="pmid">28108768</pub-id><pub-id pub-id-type="pmcid">PMC5630225</pub-id></mixed-citation></ref><ref id="pone.0304960.ref150"><label>150</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gupta</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Chandrakar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Agarwal</surname><given-names>A</given-names></name>. <article-title>Arterial Blood Gas as a Predictor of Mortality in COVID Pneumonia Patients Initiated on Noninvasive Mechanical Ventilation: A Retrospective Analysis.</article-title><source><italic toggle="yes">Indian J Crit Care Med</italic></source>. <year>2021</year>;<volume>25</volume>(<issue>8</issue>):<fpage>866</fpage>&#8211;<lpage>871</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5005/jp-journals-10071-23917</pub-id><pub-id pub-id-type="pmid">34733025</pub-id><pub-id pub-id-type="pmcid">PMC8559762</pub-id></mixed-citation></ref><ref id="pone.0304960.ref151"><label>151</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kieninger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sinning</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vad&#225;sz</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Lower blood pH as a strong prognostic factor for fatal outcomes in critically ill COVID-19 patients at an intensive care unit: A multivariable analysis.</article-title><source><italic toggle="yes">PLoS One</italic>.</source><year>2021</year>;<volume>16</volume>(<issue>9</issue>):<fpage>e0258018</fpage>. Published 2021 Sep 29. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0258018</pub-id><pub-id pub-id-type="pmid">34587211</pub-id><pub-id pub-id-type="pmcid">PMC8480873</pub-id></mixed-citation></ref><ref id="pone.0304960.ref152"><label>152</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nechipurenko</surname><given-names>YD</given-names></name>, <name name-style="western"><surname>Semyonov</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Lavrinenko</surname><given-names>IA</given-names></name>, <etal>et al</etal>. <article-title>The Role of Acidosis in the Pathogenesis of Severe Forms of COVID-19</article-title>. <source><italic toggle="yes">Biology (Basel)</italic>.</source><year>2021</year>;<volume>10</volume>(<issue>9</issue>):<fpage>852</fpage>. Published 2021 Aug 31. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/biology10090852</pub-id><pub-id pub-id-type="pmid">34571729</pub-id><pub-id pub-id-type="pmcid">PMC8469745</pub-id></mixed-citation></ref><ref id="pone.0304960.ref153"><label>153</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Alharthy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Aletreby</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Faqihi</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study.</article-title><source><italic toggle="yes">J Epidemiol Glob Health</italic>.</source><year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>98</fpage>&#8211;<lpage>104</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2991/jegh.k.200928.001</pub-id><pub-id pub-id-type="pmid">33095982</pub-id><pub-id pub-id-type="pmcid">PMC7958266</pub-id></mixed-citation></ref><ref id="pone.0304960.ref154"><label>154</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mostaza</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Garc&#237;a-Iglesias</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez-Alegre</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population [published online ahead of print, 2020 Jul 27].</article-title><source><italic toggle="yes">Arch Gerontol Geriatr</italic></source>. <year>2020</year>;<volume>91</volume>:<fpage>104204</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.archger.2020.104204</pub-id><pub-id pub-id-type="pmid">32771883</pub-id><pub-id pub-id-type="pmcid">PMC7383171</pub-id></mixed-citation></ref><ref id="pone.0304960.ref155"><label>155</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Skipper</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Pastick</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Engen</surname><given-names>NW</given-names></name>, <etal>et al</etal>. <article-title>Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial [published correction appears in Ann Intern Med. 2021 Mar;174(3):435].</article-title><source><italic toggle="yes">Ann Intern Med</italic></source>. <year>2020</year>;<volume>173</volume>(<issue>8</issue>):<fpage>623</fpage>&#8211;<lpage>631</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7326/M20-4207</pub-id><pub-id pub-id-type="pmid">32673060</pub-id><pub-id pub-id-type="pmcid">PMC7384270</pub-id></mixed-citation></ref><ref id="pone.0304960.ref156"><label>156</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mehra</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Desai</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Ruschitzka</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>AN</given-names></name>. <article-title>RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [published online ahead of print, 2020 May 22] [retracted in: Lancet.</article-title><source>2020 Jun 5;:null]. <italic toggle="yes">Lancet</italic>.</source><year>2020</year>;<fpage>S0140</fpage>&#8211;<lpage>6736</lpage>(20)31180-6. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31180-6</pub-id><pub-id pub-id-type="pmid">32450107</pub-id><pub-id pub-id-type="pmcid">PMC7255293</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC7269709"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC7274621"/></mixed-citation></ref><ref id="pone.0304960.ref157"><label>157</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gautret</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lagier</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Parola</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.</article-title><source><italic toggle="yes">Int J Antimicrob Agents</italic></source>. <year>2020</year>;<volume>56</volume>(<issue>1</issue>):<fpage>105949</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id><pub-id pub-id-type="pmid">32205204</pub-id><pub-id pub-id-type="pmcid">PMC7102549</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11718083"/></mixed-citation></ref><ref id="pone.0304960.ref158"><label>158</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Million</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lagier</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Gautret</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.</article-title><source><italic toggle="yes">Travel Med Infect Dis</italic></source>. <year>2020</year>;<volume>35</volume>:<fpage>101738</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101738</pub-id><pub-id pub-id-type="pmid">32387409</pub-id><pub-id pub-id-type="pmcid">PMC7199729</pub-id></mixed-citation></ref><ref id="pone.0304960.ref159"><label>159</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2020</year>;<volume>369</volume>:<fpage>m1849</fpage>. Published 2020 May 14. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.m1849</pub-id><pub-id pub-id-type="pmid">32409561</pub-id><pub-id pub-id-type="pmcid">PMC7221473</pub-id></mixed-citation></ref><ref id="pone.0304960.ref160"><label>160</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Magagnoli</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Narendran</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pereira</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.</article-title><source><italic toggle="yes">Med (N Y)</italic>.</source><year>2020</year>;<volume>1</volume>(<issue>1</issue>):<fpage>114</fpage>&#8211;<lpage>127</lpage>.e3. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.medj.2020.06.001</pub-id><pub-id pub-id-type="pmid">32838355</pub-id><pub-id pub-id-type="pmcid">PMC7274588</pub-id></mixed-citation></ref><ref id="pone.0304960.ref161"><label>161</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Boulware</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Pullen</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Bangdiwala</surname><given-names>AS</given-names></name>, <etal>et al</etal>. <article-title>A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2020</year>;<volume>383</volume>(<issue>6</issue>):<fpage>517</fpage>&#8211;<lpage>525</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2016638</pub-id><pub-id pub-id-type="pmid">32492293</pub-id><pub-id pub-id-type="pmcid">PMC7289276</pub-id></mixed-citation></ref><ref id="pone.0304960.ref162"><label>162</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cavalcanti</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Zampieri</surname><given-names>FG</given-names></name>, <name name-style="western"><surname>Rosa</surname><given-names>RG</given-names></name>, <etal>et al</etal>. <article-title>Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 [published correction appears in N Engl J Med. 2020 Nov 19;383(21):e119].</article-title><source><italic toggle="yes">N Engl J Med</italic></source>. <year>2020</year>;<volume>383</volume>(<issue>21</issue>):<fpage>2041</fpage>&#8211;<lpage>2052</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2019014</pub-id><pub-id pub-id-type="pmid">32706953</pub-id><pub-id pub-id-type="pmcid">PMC7397242</pub-id></mixed-citation></ref><ref id="pone.0304960.ref163"><label>163</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bansal</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Goyal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cusick</surname><given-names>A</given-names><suffix>4th</suffix></name>, <etal>et al</etal>. <article-title>Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.</article-title><source><italic toggle="yes">Ann Med</italic></source>. <year>2021</year>;<volume>53</volume>(<issue>1</issue>):<fpage>117</fpage>&#8211;<lpage>134</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/07853890.2020.1839959</pub-id><pub-id pub-id-type="pmid">33095083</pub-id><pub-id pub-id-type="pmcid">PMC7880079</pub-id></mixed-citation></ref><ref id="pone.0304960.ref164"><label>164</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Pavel</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture [published correction appears in Commun Biol. 2022 Nov 2;5(1):1164]</article-title>. <source><italic toggle="yes">Commun Biol</italic></source>. <year>2022</year>;<volume>5</volume>(<issue>1</issue>):<fpage>958</fpage>. Published 2022 Sep 14. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s42003-022-03841-8</pub-id><pub-id pub-id-type="pmid">36104427</pub-id><pub-id pub-id-type="pmcid">PMC9472185</pub-id></mixed-citation></ref><ref id="pone.0304960.ref165"><label>165</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yoo</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Baram</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Tocilizumab in the Management of COVID-19: A Preliminary Report</article-title>. <source><italic toggle="yes">Am J Med Sci</italic></source>. <year>2021</year>;<volume>361</volume>(<issue>2</issue>):<fpage>208</fpage>&#8211;<lpage>215</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.amjms.2020.11.005</pub-id><pub-id pub-id-type="pmid">33358502</pub-id><pub-id pub-id-type="pmcid">PMC7649658</pub-id></mixed-citation></ref><ref id="pone.0304960.ref166"><label>166</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mart&#237;nez-Sanz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Muriel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ron</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study</article-title>. <source><italic toggle="yes">Clin Microbiol Infect</italic></source>. <year>2021</year>;<volume>27</volume>(<issue>2</issue>):<fpage>238</fpage>&#8211;<lpage>243</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cmi.2020.09.021</pub-id><pub-id pub-id-type="pmid">32979572</pub-id><pub-id pub-id-type="pmcid">PMC7510451</pub-id></mixed-citation></ref><ref id="pone.0304960.ref167"><label>167</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Capra</surname><given-names>R</given-names></name>, <name name-style="western"><surname>De Rossi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mattioli</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia</article-title>. <source><italic toggle="yes">Eur J Intern Med</italic></source>. <year>2020</year>;<volume>76</volume>:<fpage>31</fpage>&#8211;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejim.2020.05.009</pub-id><pub-id pub-id-type="pmid">32405160</pub-id><pub-id pub-id-type="pmcid">PMC7219361</pub-id></mixed-citation></ref><ref id="pone.0304960.ref168"><label>168</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Boregowda</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Perisetti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nanjappa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gajendran</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kutti Sridharan</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Goyal</surname><given-names>H</given-names></name>. <article-title>Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.</article-title><source><italic toggle="yes">Front Med (Lausanne)</italic>.</source><year>2020</year>;<volume>7</volume>:<fpage>586221</fpage>. Published 2020 Oct 2. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fmed.2020.586221</pub-id><pub-id pub-id-type="pmid">33123544</pub-id><pub-id pub-id-type="pmcid">PMC7566918</pub-id></mixed-citation></ref><ref id="pone.0304960.ref169"><label>169</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lewis</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Adhikari</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tatapudi</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019.</article-title><source><italic toggle="yes">Crit Care Explor</italic>.</source><year>2020</year>;<volume>2</volume>(<issue>11</issue>):<fpage>e0283</fpage>. Published 2020 Nov 16. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/CCE.0000000000000283</pub-id><pub-id pub-id-type="pmid">33225307</pub-id><pub-id pub-id-type="pmcid">PMC7671881</pub-id></mixed-citation></ref><ref id="pone.0304960.ref170"><label>170</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Klopfenstein</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zayet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lohse</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.</article-title><source><italic toggle="yes">Med Mal Infect</italic></source>. <year>2020</year>;<volume>50</volume>(<issue>5</issue>):<fpage>397</fpage>&#8211;<lpage>400</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.medmal.2020.05.001</pub-id><pub-id pub-id-type="pmid">32387320</pub-id><pub-id pub-id-type="pmcid">PMC7202806</pub-id></mixed-citation></ref><ref id="pone.0304960.ref171"><label>171</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Manoharan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ying</surname><given-names>LY</given-names></name>. <article-title>Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials</article-title>. <source><italic toggle="yes">Can J Infect Dis Med Microbiol</italic></source>. <year>2022</year>;<volume>2022</volume>:<fpage>8332819</fpage>. Published 2022 Aug 2. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2022/8332819</pub-id><pub-id pub-id-type="pmid">35938147</pub-id><pub-id pub-id-type="pmcid">PMC9346539</pub-id></mixed-citation></ref><ref id="pone.0304960.ref172"><label>172</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Selvaraj</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Finn</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Dapaah-Afriyie</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Carino</surname><given-names>GP</given-names></name>. <article-title>Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials.</article-title><source><italic toggle="yes">EClinicalMedicine</italic></source>. <year>2022</year>;<volume>49</volume>:<fpage>101489</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101489</pub-id><pub-id pub-id-type="pmid">35677732</pub-id><pub-id pub-id-type="pmcid">PMC9163705</pub-id></mixed-citation></ref><ref id="pone.0304960.ref173"><label>173</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Titanji</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Farley</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Mehta</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2021</year>;<volume>72</volume>(<issue>7</issue>):<fpage>1247</fpage>&#8211;<lpage>1250</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cid/ciaa879</pub-id><pub-id pub-id-type="pmid">32597466</pub-id><pub-id pub-id-type="pmcid">PMC7337637</pub-id></mixed-citation></ref><ref id="pone.0304960.ref174"><label>174</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bronte</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ugel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tinazzi</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Baricitinib restrains the immune dysregulation in patients with severe COVID-19</article-title>. <source><italic toggle="yes">J Clin Invest</italic></source>. <year>2020</year>;<volume>130</volume>(<issue>12</issue>):<fpage>6409</fpage>&#8211;<lpage>6416</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1172/JCI141772</pub-id><pub-id pub-id-type="pmid">32809969</pub-id><pub-id pub-id-type="pmcid">PMC8016181</pub-id></mixed-citation></ref><ref id="pone.0304960.ref175"><label>175</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stebbing</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Phelan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title>. <source><italic toggle="yes">Lancet Infect Dis</italic></source>. <year>2020</year>;<volume>20</volume>(<issue>4</issue>):<fpage>400</fpage>&#8211;<lpage>402</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30132-8</pub-id><pub-id pub-id-type="pmid">32113509</pub-id><pub-id pub-id-type="pmcid">PMC7158903</pub-id></mixed-citation></ref><ref id="pone.0304960.ref176"><label>176</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Banjanac</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Muni&#263; Kos</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Nuji&#263;</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells</article-title>. <source><italic toggle="yes">Pharmacol Res</italic></source>. <year>2012</year>;<volume>66</volume>(<issue>4</issue>):<fpage>357</fpage>&#8211;<lpage>362</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.phrs.2012.06.011</pub-id><pub-id pub-id-type="pmid">22766077</pub-id></mixed-citation></ref><ref id="pone.0304960.ref177"><label>177</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yamauchi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Shibata</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kimura</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages</article-title>. <source><italic toggle="yes">Int J Biol Sci</italic></source>. <year>2009</year>;<volume>5</volume>(<issue>7</issue>):<fpage>667</fpage>&#8211;<lpage>678</lpage>. Published 2009 Oct 23. <comment>doi: </comment><pub-id pub-id-type="doi">10.7150/ijbs.5.667</pub-id><pub-id pub-id-type="pmid">19893639</pub-id><pub-id pub-id-type="pmcid">PMC2773416</pub-id></mixed-citation></ref><ref id="pone.0304960.ref178"><label>178</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gielen</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>MR</given-names></name>. <article-title>Azithromycin induces anti-viral responses in bronchial epithelial cells</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2010</year>;<volume>36</volume>(<issue>3</issue>):<fpage>646</fpage>&#8211;<lpage>654</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/09031936.00095809</pub-id><pub-id pub-id-type="pmid">20150207</pub-id></mixed-citation></ref><ref id="pone.0304960.ref179"><label>179</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sch&#246;gler</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kopf</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>MR</given-names></name>, <etal>et al</etal>. <article-title>Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells</article-title>. <source><italic toggle="yes">Eur Respir J</italic></source>. <year>2015</year>;<volume>45</volume>(<issue>2</issue>):<fpage>428</fpage>&#8211;<lpage>439</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/09031936.00102014</pub-id><pub-id pub-id-type="pmid">25359346</pub-id></mixed-citation></ref><ref id="pone.0304960.ref180"><label>180</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Retallack</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Di Lullo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Arias</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Zika virus cell tropism in the developing human brain and inhibition by azithromycin</article-title>. <source><italic toggle="yes">Proc Natl Acad Sci U S A</italic></source>. <year>2016</year>;<volume>113</volume>(<issue>50</issue>):<fpage>14408</fpage>&#8211;<lpage>14413</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1618029113</pub-id><pub-id pub-id-type="pmid">27911847</pub-id><pub-id pub-id-type="pmcid">PMC5167169</pub-id></mixed-citation></ref><ref id="pone.0304960.ref181"><label>181</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Furtado</surname><given-names>RHM</given-names></name>, <name name-style="western"><surname>Berwanger</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Fonseca</surname><given-names>HA</given-names></name>, <etal>et al</etal>. <article-title>Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.</article-title><source><italic toggle="yes">Lancet</italic></source>. <year>2020</year>;<volume>396</volume>(<issue>10256</issue>):<fpage>959</fpage>&#8211;<lpage>967</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31862-6</pub-id><pub-id pub-id-type="pmid">32896292</pub-id><pub-id pub-id-type="pmcid">PMC7836431</pub-id></mixed-citation></ref><ref id="pone.0304960.ref182"><label>182</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Oldenburg</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Pinsky</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Brogdon</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>2021</year>;<volume>326</volume>(<issue>6</issue>):<fpage>490</fpage>&#8211;<lpage>498</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2021.11517</pub-id><pub-id pub-id-type="pmid">34269813</pub-id><pub-id pub-id-type="pmcid">PMC8285753</pub-id></mixed-citation></ref><ref id="pone.0304960.ref183"><label>183</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gyselinck</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Liesenborghs</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Belmans</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO).</article-title><source><italic toggle="yes">ERJ Open Res</italic>.</source><year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>00610</fpage>&#8211;<lpage>2021</lpage>. Published 2022 Feb 28. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/23120541.00610-2021</pub-id><pub-id pub-id-type="pmid">35233389</pub-id><pub-id pub-id-type="pmcid">PMC8801156</pub-id></mixed-citation></ref><ref id="pone.0304960.ref184"><label>184</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Popp</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stegemann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Riemer</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Antibiotics for the treatment of COVID-19.</article-title><source><italic toggle="yes">Cochrane Database Syst Rev</italic>.</source><year>2021</year>;<volume>10</volume>(<issue>10</issue>):<fpage>CD015025</fpage>. Published 2021 Oct 22. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/14651858.CD015025</pub-id><pub-id pub-id-type="pmid">34679203</pub-id><pub-id pub-id-type="pmcid">PMC8536098</pub-id></mixed-citation></ref><ref id="pone.0304960.ref185"><label>185</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Russell</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Millar</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Baillie</surname><given-names>JK</given-names></name>. <article-title>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>473</fpage>&#8211;<lpage>475</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30317-2</pub-id><pub-id pub-id-type="pmid">32043983</pub-id><pub-id pub-id-type="pmcid">PMC7134694</pub-id></mixed-citation></ref><ref id="pone.0304960.ref186"><label>186</label><mixed-citation publication-type="journal"><collab>RECOVERY Collaborative Group</collab>, <name name-style="western"><surname>Horby</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>WS</given-names></name>, <etal>et al</etal>. <article-title>Dexamethasone in Hospitalized Patients with Covid-19</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2021</year>;<volume>384</volume>(<issue>8</issue>):<fpage>693</fpage>&#8211;<lpage>704</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id><pub-id pub-id-type="pmid">32678530</pub-id><pub-id pub-id-type="pmcid">PMC7383595</pub-id></mixed-citation></ref><ref id="pone.0304960.ref187"><label>187</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fadel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Vahia</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2020</year>;<volume>71</volume>(<issue>16</issue>):<fpage>2114</fpage>&#8211;<lpage>2120</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cid/ciaa601</pub-id><pub-id pub-id-type="pmid">32427279</pub-id><pub-id pub-id-type="pmcid">PMC7314133</pub-id></mixed-citation></ref><ref id="pone.0304960.ref188"><label>188</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tomazini</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Maia</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Cavalcanti</surname><given-names>AB</given-names></name>, <etal>et al</etal>. <article-title>Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>2020</year>;<volume>324</volume>(<issue>13</issue>):<fpage>1307</fpage>&#8211;<lpage>1316</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2020.17021</pub-id><pub-id pub-id-type="pmid">32876695</pub-id><pub-id pub-id-type="pmcid">PMC7489411</pub-id></mixed-citation></ref><ref id="pone.0304960.ref189"><label>189</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Derde</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Al-Beidh</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>2020</year>;<volume>324</volume>(<issue>13</issue>):<fpage>1317</fpage>&#8211;<lpage>1329</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2020.17022</pub-id><pub-id pub-id-type="pmid">32876697</pub-id><pub-id pub-id-type="pmcid">PMC7489418</pub-id></mixed-citation></ref><ref id="pone.0304960.ref190"><label>190</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Corral-Gudino</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bahamonde</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Arnaiz-Revillas</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Methylprednisolone in adults hospitalized with COVID-19 pneumonia: An open-label randomized trial (GLUCOCOVID).</article-title><source><italic toggle="yes">Wien Klin Wochenschr</italic></source>. <year>2021</year>;<volume>133</volume>(<issue>7&#8211;8</issue>):<fpage>303</fpage>&#8211;<lpage>311</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00508-020-01805-8</pub-id><pub-id pub-id-type="pmid">33534047</pub-id><pub-id pub-id-type="pmcid">PMC7854876</pub-id></mixed-citation></ref><ref id="pone.0304960.ref191"><label>191</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hamed</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Belhoul</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Al Maazmi</surname><given-names>NA</given-names></name>, <etal>et al</etal>. <article-title>Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.</article-title><source><italic toggle="yes">J Infect Public Health</italic></source>. <year>2021</year>;<volume>14</volume>(<issue>8</issue>):<fpage>985</fpage>&#8211;<lpage>989</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jiph.2021.06.003</pub-id><pub-id pub-id-type="pmid">34153729</pub-id><pub-id pub-id-type="pmcid">PMC8191304</pub-id></mixed-citation></ref><ref id="pone.0304960.ref192"><label>192</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Effect of corticosteroids in patients with COVID-19: a Bayesian network meta-analysis</article-title>. <source><italic toggle="yes">Int J Infect Dis</italic></source>. <year>2022</year>;<volume>125</volume>:<fpage>84</fpage>&#8211;<lpage>92</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijid.2022.10.021</pub-id><pub-id pub-id-type="pmid">36272700</pub-id><pub-id pub-id-type="pmcid">PMC9581790</pub-id></mixed-citation></ref><ref id="pone.0304960.ref193"><label>193</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chaudhuri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sasaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Karkar</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis.</article-title><source><italic toggle="yes">Intensive Care Med</italic>.</source><year>2021</year>;<volume>47</volume>(<issue>5</issue>):<fpage>521</fpage>&#8211;<lpage>537</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00134-021-06394-2</pub-id><pub-id pub-id-type="pmid">33876268</pub-id><pub-id pub-id-type="pmcid">PMC8054852</pub-id></mixed-citation></ref><ref id="pone.0304960.ref194"><label>194</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Salton</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Confalonieri</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Centanni</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) [published online ahead of print, 2022 Nov 10].</article-title><source><italic toggle="yes">Eur Respir J</italic></source>. <year>2022</year>;<fpage>2201514</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.01514&amp;#x02013;2022</pub-id><pub-id pub-id-type="pmcid">PMC9650195</pub-id><pub-id pub-id-type="pmid">36356972</pub-id></mixed-citation></ref><ref id="pone.0304960.ref195"><label>195</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Steinberg</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Hudson</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>RB</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2006</year>;<volume>354</volume>(<issue>16</issue>):<fpage>1671</fpage>&#8211;<lpage>1684</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa051693</pub-id><pub-id pub-id-type="pmid">16625008</pub-id></mixed-citation></ref><ref id="pone.0304960.ref196"><label>196</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maiese</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Manetti</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>La Russa</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Autopsy findings in COVID-19-related deaths: a literature review.</article-title><source><italic toggle="yes">Forensic Sci Med Pathol</italic></source>. <year>2021</year>;<volume>17</volume>(<issue>2</issue>):<fpage>279</fpage>&#8211;<lpage>296</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s12024-020-00310-8</pub-id><pub-id pub-id-type="pmid">33026628</pub-id><pub-id pub-id-type="pmcid">PMC7538370</pub-id></mixed-citation></ref><ref id="pone.0304960.ref197"><label>197</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brotman</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Girod</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Posch</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers</article-title>. <source><italic toggle="yes">Thromb Res</italic></source>. <year>2006</year>;<volume>118</volume>(<issue>2</issue>):<fpage>247</fpage>&#8211;<lpage>252</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.thromres.2005.06.006</pub-id><pub-id pub-id-type="pmid">16005496</pub-id></mixed-citation></ref><ref id="pone.0304960.ref198"><label>198</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Zaane</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Nur</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Squizzato</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors</article-title>. <source><italic toggle="yes">J Thromb Haemost</italic></source>. <year>2010</year>;<volume>8</volume>(<issue>11</issue>):<fpage>2483</fpage>&#8211;<lpage>2493</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1538-7836.2010.04034.x</pub-id><pub-id pub-id-type="pmid">20735729</pub-id></mixed-citation></ref><ref id="pone.0304960.ref199"><label>199</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mishra</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Mulani</surname><given-names>J</given-names></name>. <article-title>Corticosteroids for COVID-19: the search for an optimum duration of therapy</article-title>. <source><italic toggle="yes">Lancet Respir Med</italic></source>. <year>2021</year>;<volume>9</volume>(<issue>1</issue>):<fpage>e8</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30530-0</pub-id><pub-id pub-id-type="pmid">33248469</pub-id><pub-id pub-id-type="pmcid">PMC7836750</pub-id></mixed-citation></ref><ref id="pone.0304960.ref200"><label>200</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>XC</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhuo</surname><given-names>JL</given-names></name>. <article-title>The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases</article-title>. <source><italic toggle="yes">Pharmacol Res</italic></source>. <year>2017</year>;<volume>125</volume>(<issue>Pt A</issue>):<fpage>21</fpage>&#8211;<lpage>38</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.phrs.2017.06.005</pub-id><pub-id pub-id-type="pmid">28619367</pub-id><pub-id pub-id-type="pmcid">PMC5607101</pub-id></mixed-citation></ref><ref id="pone.0304960.ref201"><label>201</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>YP</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>GH</given-names></name>. <source><italic toggle="yes">Zhonghua Jie He He Hu Xi Za Zhi</italic></source>. <year>2020</year>;<volume>43</volume>(<issue>3</issue>):<fpage>219</fpage>&#8211;<lpage>222</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3760/cma.j.issn.1001-0939.2020.03.016</pub-id><pub-id pub-id-type="pmid">32164092</pub-id></mixed-citation></ref><ref id="pone.0304960.ref202"><label>202</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ling</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Bai</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 with Different Severities: A Multicenter Study of Clinical Features</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med</italic></source>. <year>2020</year>;<volume>201</volume>(<issue>11</issue>):<fpage>1380</fpage>&#8211;<lpage>1388</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1164/rccm.202002-0445OC</pub-id><pub-id pub-id-type="pmid">32275452</pub-id><pub-id pub-id-type="pmcid">PMC7258639</pub-id></mixed-citation></ref><ref id="pone.0304960.ref203"><label>203</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>A</given-names></name>. <article-title>Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China [published correction appears in JAMA Cardiol.</article-title><source>2020 Aug 1;5(8):968]. <italic toggle="yes">JAMA Cardiol</italic>.</source><year>2020</year>;<volume>5</volume>(<issue>7</issue>):<fpage>825</fpage>&#8211;<lpage>830</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1624</pub-id><pub-id pub-id-type="pmid">32324209</pub-id><pub-id pub-id-type="pmcid">PMC7180726</pub-id></mixed-citation></ref><ref id="pone.0304960.ref204"><label>204</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension</article-title>. <source><italic toggle="yes">Emerg Microbes Infect</italic></source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>757</fpage>&#8211;<lpage>760</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/22221751.2020.1746200</pub-id><pub-id pub-id-type="pmid">32228222</pub-id><pub-id pub-id-type="pmcid">PMC7170368</pub-id></mixed-citation></ref><ref id="pone.0304960.ref205"><label>205</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.</article-title><source><italic toggle="yes">Hypertension</italic></source>. <year>2020</year>;<volume>76</volume>(<issue>1</issue>):<fpage>51</fpage>&#8211;<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15143</pub-id><pub-id pub-id-type="pmid">32348166</pub-id></mixed-citation></ref><ref id="pone.0304960.ref206"><label>206</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 [published correction appears in Circ Res. 2020 Aug 28;127(6):e147. Rohit, Loomba [corrected to Loomba, Rohit]].</article-title><source><italic toggle="yes">Circ Res</italic></source>. <year>2020</year>;<volume>126</volume>(<issue>12</issue>):<fpage>1671</fpage>&#8211;<lpage>1681</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.317134</pub-id><pub-id pub-id-type="pmid">32302265</pub-id><pub-id pub-id-type="pmcid">PMC7265882</pub-id></mixed-citation></ref><ref id="pone.0304960.ref207"><label>207</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rathore</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Mortality and Severity in COVID-19 Patients on ACEIs and ARBs-A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.</article-title><source><italic toggle="yes">Front Med (Lausanne)</italic>.</source><year>2022</year>;<volume>8</volume>:<fpage>703661</fpage>. Published 2022 Jan 10. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fmed.2021.703661</pub-id><pub-id pub-id-type="pmid">35083229</pub-id><pub-id pub-id-type="pmcid">PMC8784609</pub-id></mixed-citation></ref></ref-list></back><sub-article article-type="aggregated-review-documents" id="pone.0304960.r001" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0304960.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="RJ">Robert Jeenchen</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2024 Robert Jeenchen Chen</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Robert Jeenchen Chen</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0304960" id="rel-obj001" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">2 Oct 2023</named-content>
</p><p>PONE-D-23-21699Severe COVID-19 Infection: An Institutional Review and Literature ReviewPLOS ONE</p><p>Dear Dr. Akpoviroro,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.&#160;Please revise.</p><p>Please submit your revised manuscript by Nov 16 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#160;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Robert Jeenchen Chen, MD, MPH</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at&#160;</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and&#160;</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
</p><p>2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://journals.plos.org/plosone/s/data-availability" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability</ext-link>.</p><p>Upon re-submitting your revised manuscript, please upload your study&#8217;s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories</ext-link>. Any potentially identifying patient information must be fully anonymized.</p><p>Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions</ext-link>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.</p><p>We will update your Data Availability statement to reflect the information you provide in your cover letter.</p><p>3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.&#160;</p><p>4. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files.&#160;</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>

<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;No</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#160;Congratulations on a work well done.</p><p>Four years after the pandemic, most of the data listed is already known and published everywhere regarding outcomes I different demographics.</p><p>However, the way the results were listed and discussed is very appealing to read. Hence, my suggestion to change the way the paper was written and focus on reformatting the manuscript</p><p>Reviewer #2:&#160;This is an interesting paper by Akpoviroro et al. describing patients with severe COVID-19.</p><p>Some comments for the authors' consideration:</p><p>1) The study would greatly benefit from a flow chart figure that outlines eligibility and inclusion.</p><p>2) The statistical analysis is more descriptive rather than forming associations. Please revise all indications that associations were found. Statistical methods used only describe significant differences between groups.</p><p>3) While the title suggests that it is also a literature review, there is no formal literature search conducted or included in the methods</p><p>4) The discussion is rather long, and perhaps should be a separate paper itself.</p><p>5) Please justify the sample size or include a sample size calculation.</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold>Mahmoud Elfiky</p><p>Reviewer #2:&#160;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#160;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0304960.r002"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0304960.r002</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" id="rel-obj002" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="39163410"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">20 Oct 2023</named-content>
</p><p>1) Thank you for your feedback. We have incorporated a flow chart outlining the inclusion criteria and outcome groups into the manuscript as a figure.</p><p>2) Thank you for your thoughtful comment regarding the use of descriptive statistics in our study. We employed the Chi-squared test, also known as the chi-square test for association or contingency, to analyze our data. The primary purpose of the chi-square test in statistical analyses is to demonstrate associations between categorical data. It is important to note that association does not imply causation, and we have taken great care not to suggest a cause-and-effect relationship in our findings. We believe that the term "association" accurately characterizes the outcomes based on the statistical tests conducted in our study. Nevertheless, we genuinely value your input and in response, we have taken the time to clarify and explicitly state that any associations found in our study results are purely statistical in nature. This precautionary measure is to prevent any potential misunderstandings among our readers and to ensure that our work is accurately represented. If we have erroneously indicated a cause-and-effect relationship in any of our study results, please definitely indicate where these errors are, and we will enthusiastically make the appropriate adjustments. Once again, thank you for your insightful comment; we truly appreciate your engagement with our work and helping to enhance the clarity of our research. </p><p>3) Thank you for bringing this to our attention. We acknowledge that we did not explicitly state in the title or elsewhere in the manuscript that a systematic review was conducted. While we conducted a thorough search for existing literature, it was not done in line with a conventional systematic review process, which was not the primary focus of our manuscript. To ensure transparency and avoid any confusion, we have revised the manuscript's title, replacing the term "review" with "overview." We trust that this modification better communicates the nature of the discussion in our manuscript. </p><p>4) Thank you for your feedback on the manuscript length. We appreciate your perspective on this matter and understand your concerns. We have carefully considered your comments alongside our objectives and have decided to maintain the current length of the manuscript. We believe this length is necessary to comprehensively cover the topic and provide valuable insights to our readers. Your input is valuable, and we hope you understand our reasoning. If you have any further suggestions or specific areas you feel could be condensed, we would be more than happy to hear them. </p><p>5) A post-hoc statistical power analysis was calculated using G*Power Calculator v3.1.9.7 provided by Heinrich Heine University D&#252;sseldorf. This was used to determine the likelihood of detection given our sample size. Of the statistically significant variables, it was found that there was a &gt;80% statistical power on 20/28 tests, or 71.4% of significant tests. The eight tests that were significant but not &gt;80% power all had &gt;60% power with the exception of average bilirubin (mg/dL) and ethnicity. These lower powers are most likely due to the small sample size and the disparity of sizes between groups. A supplemental file has been attached detailing these findings.</p></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0304960.r003" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0304960.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="RJ">Robert Jeenchen</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2024 Robert Jeenchen Chen</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Robert Jeenchen Chen</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" id="rel-obj003" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="39163410"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">1 Dec 2023</named-content>
</p><p>PONE-D-23-21699R1Severe COVID-19 Infection: An Institutional Review and Literature OverviewPLOS ONE</p><p>Dear Dr. Akpoviroro,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please revise.</p><p>Please submit your revised manuscript by Jan 15 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#160;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Robert Jeenchen Chen, MD, MPH</p><p>Academic Editor</p><p>PLOS ONE</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>

<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#8220;Comments to the Author&#8221; section, enter your conflict of interest statement in the &#8220;Confidential to Editor&#8221; section, and submit your "Accept" recommendation.</p><p>Reviewer #1:&#160;All comments have been addressed</p><p>Reviewer #3:&#160;(No Response)</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#160;Congratulations on the work and the paper. It seems everything has been addressed to the slightest detail</p><p>Reviewer #3:&#160;Congratulations to address COVID-19 risk factors and the importance of being vaccinated.</p><p>Your study is well written but there is too much information. Despite being a observational study ,the authors conduct a detailed review of all the variables shown in the results section, giving the impression for the reader that we are reading a narrative review. It is important to adequate the lenght of the writing to not become tiring to the reader. The discussion section should point out the main topics to guide the reader through the authors point of view to support their findings.</p><p>I suggest to reduce the discussion section as the core of the paper is a observational study and their findings.</p><p>I suggest put table 6 ( medication ) in supplemental matherial and point out in the results and discussion section the most relevant points in this section.</p><p>I suggest put the limitations and strenghts section before the conclusion .</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold>Mahmoud Elfiky</p><p>Reviewer #3:&#160;<bold>Yes:&#160;</bold>Marcelo Rodrigues Bacci</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#160;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0304960.r004"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0304960.r004</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0304960" id="rel-obj004" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">23 Dec 2023</named-content>
</p><p>December 23, 2023,</p><p>Editor in Chief</p><p>PLOS ONE</p><p>Subject: Submission of revised manuscript (PONE-D-23-21699) </p><p>Dear Dr. Chen,</p><p>We are pleased to re-submit a revised version of our manuscript titled, &#8220;Severe COVID-19 Infection: An Institutional Review and Literature Overview&#8221;.</p><p>Thank you for the opportunity to revise and resubmit this manuscript. According to the deadline provided, I am submitting this revision before 01/15/2024. We would like to thank you and the reviewers for the time taken to review our manuscript, and the insightful recommendations that were provided. We have incorporated the suggested changes into the manuscript as much as possible. We look forward to working with you and the reviewers to move this manuscript closer to publication in PLOS ONE. </p><p>We have tracked any changes made to the manuscript document. We have specifically responded to each reviewer&#8217;s comments below. We have numbered each reviewer&#8217;s comment, followed with a response detailing how we have addressed the comment. </p><p>Review Comments to the Author</p><p>Reviewer #1: Congratulations on the work and the paper. It seems everything has been addressed to the slightest detail</p><p>Response to review #1</p><p>Thank you for your thoughtful review. We appreciate your time and effort in evaluating our work. We are delighted to hear that you found our paper comprehensive and that we have successfully addressed the details to your satisfaction.</p><p>Reviewer #3: Congratulations to address COVID-19 risk factors and the importance of being vaccinated. </p><p>Your study is well written but there is too much information. Despite being a observational study ,the authors conduct a detailed review of all the variables shown in the results section, giving the impression for the reader that we are reading a narrative review. It is important to adequate the lenght of the writing to not become tiring to the reader. The discussion section should point out the main topics to guide the reader through the authors point of view to support their findings. I suggest to reduce the discussion section as the core of the paper is a observational study and their findings. I suggest put table 6 ( medication ) in supplemental matherial and point out in the results and discussion section the most relevant points in this section. I suggest put the limitations and trengths section before the conclusion .</p><p>Response to reviewer #3</p><p>Thank you for your thoughtful comments. We appreciate your recognition of the detailed overview that all the authors have carefully worked together to collate. </p><p>Our aim is to present an unbiased portrayal of our findings, including both supportive and opposing studies. We have also provided possible explanations for discrepancies and believe our comprehensive approach offers valuable insights in a neutral manner. We value your input and the time dedicated to enhancing our paper. We have significantly condensed the discussion by eliminating less relevant findings, removing over two thousand words and 28 references. Additionally, we have placed Table 6 in the supplemental material file, referencing it appropriately in the main text, and reorganized the limitation and conclusion sections as suggested. We hope that these changes improve the manuscript&#8217;s readability while maintaining a thorough coverage of this topic.</p><p>Sincerely, </p><p>Ogheneyoma Akpoviroro, MD </p><p>Geisinger Northeast/Geisinger Wyoming Valley Medical Center </p><p>1000 East Mountain Boulevard </p><p>Wilkes Barre, Pennsylvania 18711 </p><p>United States </p><p>570-808-3746 </p><p><email>oakpoviroro@geisinger.edu</email>
</p><p>
<email>o.akpoviroro@gmail.com</email>
</p><supplementary-material id="pone.0304960.s002" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to reviewers plos one 12.23.23.docx</named-content></p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0304960.s002.docx" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0304960.r005" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0304960.r005</article-id><title-group><article-title>Decision Letter 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="RJ">Robert Jeenchen</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2024 Robert Jeenchen Chen</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Robert Jeenchen Chen</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0304960" id="rel-obj005" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">22 May 2024</named-content>
</p><p>Severe COVID-19 Infection: An Institutional Review and Literature Overview</p><p>PONE-D-23-21699R2</p><p>Dear Dr. Akpoviroro,</p><p>We&#8217;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#8217;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#8217;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#174;</ext-link>&#160;and clicking the &#8216;Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#8217;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p><p>Kind regards,</p><p>Robert Jeenchen Chen, MD, MPH</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>

<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#8220;Comments to the Author&#8221; section, enter your conflict of interest statement in the &#8220;Confidential to Editor&#8221; section, and submit your "Accept" recommendation.</p><p>Reviewer #1:&#160;All comments have been addressed</p><p>Reviewer #4:&#160;All comments have been addressed</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#160;Excellent manuscript and all comments have been addressed. Thank you for addressing them all and responding to the reviewers</p><p>Reviewer #4:&#160;It seems that all the recommendations made by the reviewers were followed in a detailed and careful manner. Congratulations on the work.</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold>Mahmoud Elfiky</p><p>Reviewer #4:&#160;No</p><p>**********</p></body></sub-article><sub-article article-type="editor-report" id="pone.0304960.r006" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0304960.r006</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="RJ">Robert Jeenchen</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2024 Robert Jeenchen Chen</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Robert Jeenchen Chen</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0304960" id="rel-obj006" related-article-type="reviewed-article"/></front-stub><body><p>
<named-content content-type="letter-date">9 Jul 2024</named-content>
</p><p>PONE-D-23-21699R2 </p><p>PLOS ONE</p><p>Dear Dr. Akpoviroro, </p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. </p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p><p>If we can help with anything else, please email us at <email>customercare@plos.org</email>.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access. </p><p>Kind regards, </p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Robert Jeenchen Chen </p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article></pmc-articleset>